,PageNo,Text
0,page_0,"Protocol Title of trial: A Randomised, Double -blind, Placebo -controlled, Response -adaptive Dose - finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, with Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia due to Nocturnal Polyuria in Adults NCT n umber : NCT03201419 Sponsor trial c ode: 000233 Date: 05 Jul 2018"
1,page_1,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 1 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL CLINICAL TRIAL PROTO COL A Randomised, Double -blind, Placebo -controlled, Response -adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, with Desmopressin Orally Disintegrating Tablet as a Benchmark , During 12 Weeks of Treatment for Nocturia due to Nocturnal Polyuria in Adults 000233 DAWN EudraCT Number: 2016-003851 -31 IND Number: 129355 Investigational Medicinal Product: FE 201836 Indication: Nocturia due to Nocturnal Polyuria Phase: 2 Name and Address of Sponsor: Ferring Pharmaceuticals A/S Global Clinical R&D Kay Fiskers Plads 11 2300 Copenhagen S, Denmark Tel: +45 8833 8834 Version: 5.0 (consolidated protocol; changes introduced with global amendment s #01, #02, and #03 implemented ) GCP Statement: This trial will be performed in compliance with GCP. The information in this document is confidential and is proprietary to Ferring Pharmaceuticals A/S or another company within the Ferring Group. It is understood that information in this document shall not be disclosed to any third party, in any form, without prior written consent of an authorised officer of Ferring Pharmaceuticals A/ S or another company within the Ferring Group."
2,page_2,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 2 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL SYNOPSIS TITLE OF TRIAL A Randomised, Double -blind, Placebo -controlled, Response -adaptive, Dose -finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, with Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia due to Nocturnal Polyuria in Adults SIGNATORY INVESTIGATORS Department of Urology , UZ Gent . Gent, Belgium Consultant in Urology New York, , USA TRIAL SITES Approximately 7 0 sites in Europe and North America. PLANNED TRIAL PERIOD First subjec t first visit : Q3 2017 Last subjec t last visit : Q3 2019 CLINICAL PHASE Phase 2 BACKGROUND AND SCIENTIFIC JUSTIFICATION FOR CONDUCTING THE TRIAL Nocturia is defined by the International Continence Society (ICS) as waking from sleep (during the night) at least once to urinate. This may occur when there is an excessive urine production during the night (noc turnal polyuria [NP]). The anti diuretic hormone arginine vasopressin (AVP) plays a key role in the control of urine production during the night. Desmopressin, a synthetic analogue of AVP developed by Ferring Pharmaceuticals , is approved and used for the treatment of nocturia due to NP in more than 80 countries, including Canada and European countries. However, desmopressin has not yet been approved for this indication in the USA . Low doses of desmopressin (25 Âµg for women and 50 Âµg for men) are approved to date in Canada, Australia and European countries under the trade name NOCDURNA (desmopressin Orally Disintegrating Tablet [ODT]). These gender specific minimum effective low doses are approved for use in all adult ages an d are indicated for treatment of nocturia due to NP in adults, who awaken two or more times each night to void. The global cumulative patient exposure of NOCDURNA by end-2016 is 1,389 patient years based on a dose of 25 Î¼g for women and 50 Î¼g for men (wome n: 779 patient years; men: 610 patient years). Analysis of the combined data from three trials of low-dose desmopressin ODT, comprising >1400 patients with nocturia, shows that desmopressin dose, patient age, baseline serum sodium levels, and kidney functi on according to estimated"
3,page_3,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 3 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL glomerular filtration rate clearance were significant risk factors for hyponatraemia in both sexes. Ferring Pharmceuticals is currently developing FE 201836, another synthetic analogue of AVP and a potent and highly selective shor t-acting vasopressin -2 (V 2)-receptor agonist with an antidiuretic action profile suitable for treating nocturia due to NP in adults. FE 201836 exerts its antidiuretic effect by increasing the water permeability of the luminal membrane of the renal cortical and medullary collecting ducts, and thereby reducing free water excretion. Hyponatraemia may develop over time if excessive drinking occurs during the period of antidiuretic drug effect. Therefore, the ideal V 2-receptor agonist should provide an antidiure tic duration of action not exceeding 6 -8 hours i.e., corresponding to the night -time sleep period when drinking does not occur or is limited to a minimum (to satisfy thirst). The oral half-life should be shorter than that of desmopressin and the key route of metabolism non -renal, since the clinical promise of a short -acting V 2-receptor agonist is based on an improved safety profile without a prolonged duration of action leading to hyponatraemia. A shorter and more predictable duration of antidiuretic action would minimise the risk of hyponatraemia and may reduce the need for serum sodium monitoring. In the present clinical trial, 6 doses of FE 201836 (50-500 Âµg) will be evaluated for estimation of the dose -response curve, where the response is the change in the number of nocturnal voids. The choice of FE 201836 doses is based on the data regarding the antidiuretic effect of FE 201836 in healthy subjects and by the antidiuretic effects of desmopressin in healthy subjects and in patients with NP. In phase 1 trial 000195 in young healthy men and women oral doses of FE 201836 up to 4800 Âµg (i.e., 9.6 times higher than the suggested maximum dose in the present phase 2 trial) were administered and found to be safe and well tolerated. The exposure after intravenous infusion of 0.5 Âµg FE 201836, comparable to the exposure after an oral dose of approximately 900 Âµg FE 201836, resulted in approximately 8 hours of antidiuretic effect. The present trial is powered for detecting differences in treatment effec ts between FE 201836 and placebo. Desmopressin is included as benchmark treatment . There is no prospectively planned power for conclusive inference with regards to differences between desmopressin and placebo (or FE 201836). In order to select trial subjec ts with nocturia primarily due to the underlying condition of NP driven with increased Free Water Clearance (FWC), who will benefit the most from treatment with an antidiuretic agent, a 1 -week active run -in period followed by a 1 -week washout period (refer red to as the â€˜enrichment periodâ€™) will be applied to ensure that drug -responders (defined as a reduction of nocturnal diuresis [mL/min]of 20% or more) are identified. The â‰¥20% dec rease in the nocturnal diuresis rate has been established as a relevant mark er of antidiurectic responsivene ss in previous nocturia trials with an active run -in. The majority of fluid output occurs via the urine, approximately 1 ,500 mL/day, therefore there is no evidence in adult nocturia patients that the"
4,page_4,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 4 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL relative change over the time in nocturnal diuresis rate ( mL/min normalised to time in bed) should be adjusted for body weight and or/body surface area which are both assumed to be constant over a short period of just 1 week. An analysis of individual nocturia subject data found that reducing Nocturnal Urine V olume (NUV) and increasing the duration of antidiuretic action of a V 2-receptor agonist (desmopressin) was a significant predictor for subsequent decrease from baseline in the number of nocturnal voids. The underlying pathophysiologic mechanism of NP can be driven by either increase d FWC, which based on mode of action will be responsive to antidiuretic treatment, or by increased sodium clearance, which differs s ubstantially in mode of action and is governed by Atrial Na triuretic Peptide (ANP) which again is directly and indirectly influenced by the Renin -Angiotensin - Aldosterone System (RAAS). The aim of the active run -in is (after excluding all other medical causes of NP) to identify subjects with increased FWC which is responsive to V 2-receptor agonism. In addition, safety will be assessed in this period with spe cial emphasis on hyponatraemia. OBJECTIVES Primary Objective â€¢ To establish the dose -response of FE 201836 with respect to the number of nocturnal voids in subjects with nocturia due to NP. Secondary Objectives â€¢ To evaluate responder rates with regards to changes in number of nocturnal voids. â€¢ To psychometrically validate the Nocturia Impact DiaryÂ© (NI Diary). â€¢ To evaluate the patient benefit of FE 201836 based on the NI Diary data. â€¢ To evaluate the clinical benefit of FE 201836 based on reduction in nocturnal voiding. â€¢ To evaluate FE 201836 with respect to sleep benefit, i.e., duration of the First Undisturbed Sleep Period ( FUSP) and sleep related Patient Reported Outcomes (PROs). â€¢ To evaluate the pharmacodynamic (PD) effect of FE 201836 with respect to nocturnal diuresis rate and NP. Safety Objective â€¢ To evaluate the safety profile of FE 201836. Exploratory Objectives â€¢ To explore the biomarker c opeptin, an AVP surrogate, to identify low nocturnal vasopressin levels in plasma. â€¢ To explore the dose -response of FE 201836 with respect to total sleep time. â€¢ To explore the association between total sleep time and FUSP. â€¢ To explore the effect of FE 201836 with respect to Nocturnal Polyuria index ( NPi)."
5,page_5,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 5 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL â€¢ To benchmark the efficacy of FE 201836 in relation to desmopressin. ENDPOINTS Primary Endpoint â€¢ Change from b aseline in number of nocturnal voids during 12 weeks of treatment. Secondary Endpoints â€¢ Change from b aseline in number of nocturnal voids at Weeks 1, 4, 8 and 12. â€¢ Responder rate defined as 50% reduction in nocturnal voids from baseline at Weeks 1, 4, 8 and 12 and during 12 weeks of treatment. â€¢ Change from b aseline in NI Diary Total Score at Weeks 1, 4, 8 and 12 and d uring 12 weeks of treatment. â€¢ Percentage of nights during the treatment period with at most one nocturnal void. â€¢ Percentage of nights during the treatment period with complete response, i.e. , with no nocturnal voids. â€¢ Change from b aseline in NI Diary Overall Impact Score at Weeks 1, 4, 8 and 12 and during 12 weeks of treatment. â€¢ Patient Global Impression of Improvement (PGI -I) urinary symptoms scores at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in Patient Global Impression of Severity (PGI -S) scores at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in Bother as measured by the Hsu 5 -point Likert Bother scale at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in Insomnia Severity Index (ISI) at Weeks 4, 8 and 12. â€¢ Change from b aseline in FUSP at 1, 4, 8 and 12 weeks of tr eatment and during 12 weeks. â€¢ Change from b aseline in nocturnal diuresis rate (hourly) profiles at Week 1 and Week 12. â€¢ Change from b aseline in NUV at Week 1 and Week 12. Safety Endpoints â€¢ Incidence and severity of adverse events. â€¢ Incidence of hyponatraemia as measured by serum sodium level throughout the trial. â€¢ Change from baseline in mean 24 -hour urine volume at Week 1 and Week 12. â€¢ Clinically significant changes in vital signs and laboratory values. Exploratory Endpoints â€¢ Responder rates defined as 33%, 60%, 70%, 80%, 90% and 100% reduction from baseline in number of nocturnal voids at Weeks 1, 4, 8 and 12. â€¢ Responder rates defined as 1, 2, and 3 voids reduction from baseline in number of nocturnal voids at Weeks 1, 4, 8 and 12."
6,page_6,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 6 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL â€¢ The correlation of c opeptin levels to NPi at Visit 2. â€¢ Change from b aseline in c opeptin levels at Week 12. â€¢ Change from b aseline in total sleep time per night at Weeks 1, 4, 8 and 12 and during 12 weeks of treatment. â€¢ Correlation between change from b aseline in tot al sleep time and FU SP at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in NP i at Week 1 and Week 12 . METHODOLOGY This is a randomised, double -blind, placebo -controlled, response -adaptive, dose -finding trial investigating the efficacy, safety and tolerability of 6 different oral doses ( 50-500 Âµg) of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to NP in adults. The trial will comprise 8 visits to the clinic and will consist of a 2 -week screening/lifestyle changes period where no Investigational Medicinal Product ( IMP) will be given, an enrichment period consisting of a 1-week single -blind (to subjects) active run -in period and a 1 -week washout period , and a 12 -week double -blind randomised treatment period for each subject . During th e active run -in period the trial subjects will receive 500 Âµg FE 201836 and placebo to assess safety and establish that subjects who respond to treatment with FE 201836 are included in the trial (i.e., an enrichment design). The 12 -week double -blind random ised treatment period of the trial will follow a response -adaptive Bayesian top -down design. Initially subjects will be randomised to: placebo, 500 Âµg FE 201836 or desmopressin (for benchmarking only). When approximately 125 subjects have been randomised t o the trial, an interim analysis will be conducted to investigate the efficacy of 500 Âµg FE 201836. If 500 Âµg FE 201836 is not sufficiently efficacious compared to placebo the trial will be stopped for futility. If 500 Âµg FE 201836 is efficacious additiona l doses of FE 201836 (doses 50 -350 Âµg) will be opened up for randomisation of new sub jects in order to identify the Minimum Effective Dose (MED) and near maximal Effective D ose (ED 85). The ED 85 is the lowest dose that achieves at least 85% of the effect of the maximum dose (500 Âµg). After the first interim analysis, subsequent interim analyses will take place every 8 weeks to reassess the randomisation allocation probabilities to 50 -500 Âµg FE 201836, based on observed responses at the respective interim loc ks. After the first interim analysis eligible subjects will be randomised to one of 8 treatment groups (Table S -1). Each subject will be instructed to take the IMP every night at bedtime with the intention to sleep. In order to keep the treatment blinded each subject will receive two medications throughout th e trial; an oral solution and an Orally Disintegrating Tablet (ODT), i.e., a double - dummy design will be applied because desmopressin is available in an ODT formulation and FE 201836 is an oral solution. Subjects will be asked to follow lifestyle changes ( e.g., limiting fluid intake) throughout the entire"
7,page_7,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 7 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL duration of the trial. In addition, subjects will be asked to complete electronic diary (e -Diary) assessments and Patient Reported Outcome (PRO) questionnaires before and after randomisation. One objectiv e of the present trial is to further validate the NI Diary. Therefore, a sample of subjects (from trial sites in the US A) who have completed the trial will be invited to participate in an exit interview within 14 days of attending the end -of-trial visit (V isit 8), to record the subjectsâ€™ perception of what constitutes a meaningful change in the NI Diary Total Score . Safety, including serum sodium levels, adverse events and clinically significant changes in vital signs and laboratory values will be monitored throughout the trial and reviewed on an ongoing basis by a Safety Review Committee (SRC) . Furthermore, the risk for subjec ts developing hyponatraemia will be mitigated by a serum sodium monitoring plan , including a 1-week active run -in period to identify subjects at increased risk for developing acute hyponatraemia prior to randomisation . If the incidence of serum sodium levels <130 mmol/L is statistically significantly >10% during the active run -in, the Data Monitoring Committee (DMC) will be notified and further action will be discussed, e.g., the DMC may recommend that the highest dose of FE 201836 ma y be replaced by a lower dose. T he trial is designed so the dose may be lowered from 500 Âµg to 3 50 Âµg, if recommended by the DMC . NUMBER OF SUBJECTS A maximum of 300 subjects (males and females) will be randomised into the trial. At least 50% of subjects should be randomised at trial sites in the USA. CRITERIA FOR INCLUSION / EXCLUSION Inclusion Criteria Each subject must meet the following inclusion criteria between Visit 1 (screening) throu gh Visit 4 (randomisation) : 1. Written informed consent prior to performance of any trial -related activity 2. Adults â‰¥18 years of age (at the time of written consent) 3. Female subjects of child-bearing potential must be wi lling and able to use adequate contraception throughout the trial. Documentation of an acceptable effective method of contraception must be available . All pre - and perimenopausal subjects have to perform pregnancy tests. Amenorrhea of more than 12 months d uration based on the reported date of the last menstrual period is sufficient documentation of post -menopausal status and does not require a pregnancy test 4. Medical history of, or subject reported nocturia symptoms during the 6 months prior to Visit 1 5. â‰¥2 nocturnal voids (an average over 3 days) as documented in the 3 -day e -Diary prior to Visit 2 6. The largest single voided volume must be â‰¥200 mL (at least 1 void â‰¥200 mL) as documented in the 3 -day e -Diary prior to Visit 2"
8,page_8,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 8 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 7. Nocturnal polyuria, defined as NPi >33%, a ratio of NUV in excess of 33% of total daily (24 - hour) urine volume as documented in the 3 -day e -Diary prior to Visit 2 8. b 9. â‰¥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2) as documented in the 3 -day e -Diary prior to Visit 3 10. Additionally to be randomised into the trial at Visit 4 subjects must have â‰¥2 nocturnal voids (an average over 3 days) as documented in the 3 -day e -Diary prior to Visit 4 Exclusion Criteria Any subject meeting one or more of the following exclu sion criteria between Visit 1 (screening) through Visit 4 (randomisation) will be considered as a screening failure : 1. Current diagnosis of Obstructive Sleep Apnoea (OSA) 2. Restless Legs Syndrome (RLS) 3. Suspicion of Bladder O utlet Obstruction (BOO) or urine flow <5 mL/s , as confirmed by uroflowmetry during screening prior to Visit 2 4. Urinary incontinence defined as an average of >1 episode/day in the 3 -day e-Diary prior to Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not necessarily exclusionary) 5. c 6. Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation within the past 6 months prior to Visit 1. Includ ing e.g., transurethral resection for BOO or Benign Prostatic Hyperplasia (BPH ), hysterectomy or female incontinence procedures 7. Genito -urinary tract pathology that can in the investigatorâ€™s opinion be responsible for urgency or urinary incontinence e.g., s ymptomatic or recurrent urinary tract infections, interstitial cystitis, bladder -related pain, chronic pelvic pain syndrome, or stone in the bladder or urethra causing symptoms 8. A history of cancer with the last date of disease activity/prescence of maligna ncy within the last 12 months prior to Visit 1, except for adequately treated basal cell carcinoma of the skin 9. History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple Sclerosis, Parkinsonâ€™s, spinal cord injury, spi na bifida) 10. Habitual (fluid intake >3L per day) or psychogenic polydipsia 11. Uncontrolled hypertension , as judged by the investigator b Original inclusion criterion omitted as per Clinical Trial Protocol Amendment 02 (applicable for all trial sites). c Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all trial sites)."
9,page_9,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 9 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 12. a 13. Uncontrolled diabetes mellitus , as judged by the investigator 14. Central or nephrogenic diabetes insipidus 15. Known history of Syn drome of Inappropriate Antidiuretic Hormone ( SIADH) secretion 16. History of g astric retention 17. Suspicion or evidence of congestive heart failure, (New York Heart Association [NYHA] class II, III, IV) 18. Hyponatraemia: â€¢ Serum sodium level <135 mmol/L at Visit 1(re-tested, with results available within 7 days) â€¢ Serum sodium level <130 mmol/L at Visit 3 (re-tested, with results available within 7 days) 19. Hepatic and/or biliary diseases: â€¢ Child -Pugh Class A, B, or C or â€¢ Aspartate aminotransferase and/or al anine aminotransferase levels >3 x the upper limit of normal range as well as total bilirubin level >2x the upper limit of normal range 20. Known history of hypersensitivity to desmopressin ODT 21. Pregnancy, breastfeeding, or a planning to become pregnant during the per iod of the trial 22. Known alcohol or substance abuse 23. Work or lifestyle that may interfere with regular night -time sleep e.g. , shift workers 24. Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrie r that, in the judgment of the i nvestigator, would impair participation in the trial 25. d 26. Previous participation in a nocturia, B enign Prostatic Obstruction (BPO), or OAB clinical trial within the past 6 months prior to Visit 1 27. The subject is in a state of dependence of the sponsor, or is directly or indirectly involved in the conduct of this trial as an investigator, sub -investigator, trial coordinator or other trial staff member, or the subject is a first degree family member, significant other or relative residing with one of the above persons involved directly or indirectly with the trial a Original exclusion criterion omitted as per Clinical Trial Protocol Amendment 01 (applicable for all trial sites). d Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all t rial sites)."
10,page_10,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 10 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 28. Use of any restricted therapy not in accordance with the protoco l 29. Use of any prohibited therapy listed below: â€¢ Current or former (within 3 months prior to screening) trea tment with any other IMP â€¢ Unstable electrostimulation or behavioural bladder training program less than 3 months prior to screening (stable electrostimulation or behavioural bladder training program started at least 3 months before screening are acceptable) â€¢ Thiazide diuretics â€¢ Antiarrhythmic agents â€¢ V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin) â€¢ Loperamide â€¢ Botulinum toxin (cosmetic non -urological use is acceptable) â€¢ Valproate INVESTIGATIONAL MEDICINAL PRODUCTS In order to maintain the treatment blinding each subject will receive 2 medications ( a double -dummy design), an oral solution and an ODT formulation, during every treatment period of the trial, as outlined in Table S -1. Table S -1 Treatment During the Trial Treatment Investigational Medicinal Product Active Substance Placebo Active Run -in 500 Âµg FE 201836 500 Âµg FE 201836 oral solution Placebo ODT Washout - - - Randomised Trial Period Up to First Interim Analysis 500 Âµg FE 201836 500 Âµg FE 201836 oral solution Placebo ODT Desmopressin Desmopressin ODT (25Âµg for females and 50 Âµg for males) Placebo oral solution Placebo - Placebo oral solution and Placebo ODT After First Interim Analysis 50 Âµg FE 201836 50 Âµg FE 201836 oral solution Placebo ODT 100 Âµg FE 201836 100 Âµg FE 201836 oral solution Placebo ODT 150 Âµg FE 201836 150 Âµg FE 201836 oral solution Placebo ODT 250 Âµg FE 201836 250 Âµg FE 201836 oral solution Placebo ODT 350 Âµg FE 201836 350 Âµg FE 201836 oral solution Placebo ODT 500 Âµg FE 201836 500 Âµg FE 201836 oral solution Placebo ODT Desmopressin Desmopressin ODT (25Âµg for females and 50 Âµg for males) Placebo oral solution Placebo - Placebo oral solution and Placebo ODT"
11,page_11,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 11 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL DURATION OF TREATMENT The duration of the trial is approximately 16 weeks . Subjects will be screened, enter a 2 -week lifestyle changes period followed by a 1-week single -blind ac tive run -in and 1 -week washout prior to randomisation. Following randomisation , the first 125 subjects will be treated daily with placebo, 500 Âµg FE 201836 or desmopressin (25 Âµg for females and 50 Âµg for males ) for up to 12 weeks . When the first 125 subjects have been randomised an interim analysis will be conducted and a decision taken on whether to continue the trial as planned or stop the trial for futility. If the decision is to continue the trial as planned, subjects may be randomised to one of 8 treatment groups for 12 weeks : placebo, 50 Âµg FE 201836, 100 Âµg FE 201836, 150 Âµg FE 201836, 2 50 Âµg FE 201836, 350 Âµg FE 201836, 500 Âµg FE 201836 , or desmopressin (25 Âµg for females and 50 Âµg for males) . STATISTICAL METHODS Primary Analysis Model used in the Response -adaptive Trial Design The primary an alysis is based on a time -course hierarchical longitudinal model, i.e., ğ‘Œğ‘¡,ğ‘–=ğ‘’ğ›¾ğ‘¡(ğœ‡ğ‘‘,ğ‘–+ğ›¿ğ‘–)+ ğœ€ğ‘¡ where Y t,i is the change from baseline in number of nocturnal voids at visit t for subject i, d is the dose, ğ‘’ğ›¾ğ‘¡ the fraction of the effect at Visit t (Week 1, Week 4 or Week 8) as compared to the Month 3 visit ( ğ›¾t=0 at Month 3), Î´ i the random subject effect and Îµ t the independent N(0, ğœ†ğ‘¡2) distributed error term. The dose -response for subject ğ‘–, ğœ‡ğ‘‘,ğ‘–, is adjusted for the number of baseline voids ( ğ‘¥0,ğ‘–) and modelled using the sigmoidal E -max model, i.e., ğœ‡ğ‘‘,ğ‘–=ğ›½ğ‘¥0,ğ‘–+ğ›¼1+(ğ›¼2âˆ’ğ›¼1) ğ‘‘ğ›¼4 ğ‘‘ğ›¼4+ğ›¼3ğ›¼4=ğ›½ğ‘¥0,ğ‘–+ğœ‡ğ‘‘ Inference will be based on a Bayesian analysis using sufficiently non -informative priors on respective parameters. The trial will be considered successful if the maximum dose has a greater than 97.5% posterior probability of being better than placebo, i.e. , if Pr( Î¼MAX < Î¼ Plb) > 97.5%. Response -adaptive Decision Rules The double -blind treatment period is based on a response -adaptive Bayesian top -down design. After an initial 125 subjects have been randomised to placebo, 500 Âµg FE 201836 (the highest dose) or desmopressin in a 2:2:1 ratio an interim analysis will take place to stop for futility if the Pr ( Î¼MAX â€“ Î¼Plb < -0.3) <10%, where Pr (.) denotes posterior probability (under the assumed mon otonic dose - response relation, i.e. smaller doses will be less e ffective). If not stopped for futility, all treatment arms will be opened up for randomisation, subjects can be randomised to placebo, desmopressin or to any FE 201836 dose (50 -500 Âµg) in a 2:1:7 ratio. When allocated to a FE 201836 dose (7/10), unrestrict ed randomisation will be used to allocate a subject"
12,page_12,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 12 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL to a specific FE 201836 dose using an allocation probability that is the average of I(dose is MED) and I(dose is ED 85), where I(target) is the probability that â€œdose is targetâ€ scaled by the squared stand ard error at that dose. The MED is the lowest dose that has at least a âˆ†=0.3 larger reduction in mean nocturnal voids as compared to placebo and the ED 85 is the lowest dose that achieves at least 85% of the effect of the maximum dose ( 500 Âµg). After the first interim analysis, subsequent interims will take place every 8 weeks where the randomisation allocation probabilities to FE 201836 doses are being updated. Futility stopping will remain to take place if Pr ( Î¼MAX â€“ Î¼Plb < -0.3) < 5. Operating Character istics Under the assumptions (based on previous desmopressin trials and feasibility) that: â€¢ Response fractions of 0.8142, 0. 9328 and 0.9874 at Weeks 1, 4 and 8, respectively , as compared to the averaged dose -response at Week 12 â€¢ Varian ce fractions of 0.8481 , 0.8329 and 0.8900 at Weeks 1, 4 and 8, respectively, as compared to the averaged dose -response at Week 12 â€¢ A constant drop -out rate of 15% during the randomised treatment period â€¢ A between to total variance (Ïƒ2) ratio of 0.90 and a true underlying Ïƒ of 0.9 5 â€¢ During the initial 17 weeks the recruitment rate will increase line arly from 0 to 8.2 subjec ts per week â€¢ After 17 weeks, when all trial sites have been initiated, the recruitment rate is assumed to remain constant at 8.2 subjects per week and â€¢ Considering six dose-response scenarios for the mean change from baseline to a large extent is characterised by the response of the maximum dose ( 500 Âµg FE 201836 ) Given these assumptions the operating characteristics presented in Table S -2 apply: Table S -2 Operating Characterisitics Dose -Response Scenario Maximum response (ğ›¼2) ED 50 (ğ›¼3) Average Number of Subjects Futility Stopping at First Interim Total Futility stopping Power (Total Success) Null 0 0 Âµg 200 75.8% 97.0% 3.0% I -0.3 150 Âµg 277 15.7% 47.9% 52.1% II -0.4 200 Âµg 288 7.9% 25.1% 74.9% III -0.5 200 Âµg 296 2.8% 9.6% 90.4% IV -0.5 350 Âµg 295 3.4% 15.4% 84.6% V -0.6 300 Âµg 298 1.4% 2.7% 97.3% For each dose -response scenario, 1 ,000 trials were simulated in order to estimate the operating characteristics presented in Table S -2. Assuming a maximum re duction versus placebo of 0.5 voids"
13,page_13,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 13 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL the power (probability o f success ) reaches approximately 85 to 90%, while the probability of making a false positive conclusion is 3.0%. Randomisation if the Maximum Dose is Lowered The trial has been designed with the option to decrease the maximum dose of FE 201836 from 500 Âµg to 350 Âµg if recommended by the DMC. If this decision is made, randomisation to the 500 Âµg FE 201836 treatment group will be closed, the trial will continue w ith 350 Âµg FE 201836 as the highest dose for the active run -in and the highest dose of FE 201836 that any sub ject can be randomised to. In the case where subjects have already been randomised to 500 Âµg FE 201836 and have not completed the trial the DMC will recommend whether or not, these subjects may be permitted to remain on 500 Âµg FE 201836 treatment for the remainder of the trial. In case subjects randomised to treatment with 500 Âµg FE 201836 prematurely discontinue the trial due to DMC decision they may be replaced by subjects randomised to treatment with a lower dose of FE 201836. No other prematurely discontinued subjects will be replaced. If the decision to close randomisation to 500 Âµg FE 201836 occurs prior to the first interim analysis (when the first 125 subjects are randomised) the remaining subjects will be randomised to the following treatment groups: placebo, desmopressin (25 Âµg for females and 50 Âµg for males) or 350 Âµg FE 201836. After the first interim analysis the dose -response adaptive randomisation will allocate subjects to the remaining open doses, i.e., one of 7 treatment groups: placebo, 50 Âµg FE 201836, 100 Âµg FE 201836, 150 Âµg FE 201836, 250 Âµg FE 201836, 350 Âµg FE 201836, or desmopressin (25 Âµg fo r females and 50 Âµg for males). The dose -response model will be fitted across all doses, i.e., 0 -500 Âµg, but inference will be made only on the doses th at remain open to randomisation e.g., 0 -350 Âµg. That is, the MED and ED 85 doses and the inferences with regards to proof -of-concept and fu tility are limited to the dose range (i.e, with a maximum dose of 350 Âµg FE 201836)."
14,page_14,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 14 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL TABLE OF CONTENTS SYNOPSIS ................................ ................................ ................................ ................................ .. 2 LIST OF TABLES ................................ ................................ ................................ ...................... 18 LIST OF FIGURES ................................ ................................ ................................ ..................... 18 LIST OF ABBR EVIATIONS AND DEFINITION OF TERMS ................................ ...................... 19 1 INTRODUCTION ................................ ................................ ................................ ............. 22 1.1 Background ................................ ................................ ................................ ............. 22 1.2 Scientific Justification for Conducting the Trial ................................ ............................ 24 1.3 Benefit / Risk Aspects ................................ ................................ ............................... 24 2 TRIAL OBJECTIVES AND ENDPOINTS ................................ ................................ .......... 26 2.1 Objectives ................................ ................................ ................................ ............... 26 2.2 Endpoints ................................ ................................ ................................ ............... 26 3 INVESTIGATIONAL PLAN ................................ ................................ .............................. 28 3.1 Overall Trial Design ................................ ................................ ................................ .28 3.1.1 Trial Design Diagrams ................................ ................................ ................... 28 3.1.2 Overall Design and Control Methods ................................ ............................... 31 3.1.3 Trial Schedule ................................ ................................ .............................. 32 3.2 Planned Number of Trial Sites and Subjects ................................ ................................ .32 3.3 Interim Analyses ................................ ................................ ................................ ......32 3.4 Safety Review and Data Monitoring Committees ................................ .......................... 32 3.5 Discussion of Overall Trial Design and Choice of Control Groups ................................ ...33 3.5.1 Trial Design ................................ ................................ ................................ .33 3.5.2 Selection of Endpoints ................................ ................................ ................... 34 4 SELECTION OF TRIAL POPULATION ................................ ................................ ........... 36 4.1 Trial Population ................................ ................................ ................................ ....... 36 4.1.1 Inclusion Criteria ................................ ................................ .......................... 36 4.1.2 Exclusion Criteria ................................ ................................ ......................... 37 4.2 Method of Assigning Subjects to Treatment Groups ................................ ...................... 39 4.2.1 Recruitment ................................ ................................ ................................ .39 4.2.2 Randomisation ................................ ................................ ............................. 40 4.2.2.1 Randomisation if Maximum Dose is Lowered ................................ .....40 4.3 Restrictions ................................ ................................ ................................ ............. 41 4.3.1 Prior and Concomitant Therapies ................................ ................................ ....41 4.3.2 Prohibited Therapy ................................ ................................ ....................... 42 4.3.3 Lifest yle Changes and Other Restrictions ................................ ......................... 43 4.3.4 Contraception ................................ ................................ ............................... 43 4.4 With drawal Criteria ................................ ................................ ................................ ..44 5 TREATMENTS ................................ ................................ ................................ ................. 45 5.1 Treatments Administered ................................ ................................ .......................... 45 5.2 Characteristics and Source of Supply ................................ ................................ .......... 46 5.2.1 Investigational Medicinal Products ................................ ................................ ..46 5.3 Packaging and Labelling ................................ ................................ ........................... 46 5.4 Conditions for Storage and Use ................................ ................................ .................. 46 5.5 Blinding/Unblinding ................................ ................................ ................................ .47
15,page_15,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 15 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 5.5.1 Blinding ................................ ................................ ................................ ......47 5.5.2 Unblinding of Individual Subject Treatment ................................ ...................... 47 5.6 Treatment Compliance ................................ ................................ .............................. 48 5.6.1 Dispensing and Accountability ................................ ................................ ........ 48 5.6.2 Assessment of Compliance ................................ ................................ ............. 48 5.7 Return and Destruction of Investigational Medicinal Products ................................ ......... 48 6 TRIAL PROCEDURES ................................ ................................ ................................ .....49 6.1 Trial Flow Chart ................................ ................................ ................................ ......49 6.2 Visit 1 Screening ................................ ................................ ................................ ......51 6.3 Visit 2 Active Run -in Period ................................ ................................ ...................... 52 6.4 Visit 3 Washout Period ................................ ................................ ............................. 52 6.5 Visit 4 ................................ ................................ ................................ .................... 53 6.6 Visit 5 to V isit 7 ................................ ................................ ................................ ......53 6.7 Visit 8 â€“ End-of-Trial Visit ................................ ................................ ........................ 54 6.8 Unscheduled Visits ................................ ................................ ................................ ...54 7 TRIAL ASSESSMENTS ................................ ................................ ................................ ....56 7.1 Asse ssments Related to Endpoints ................................ ................................ .............. 56 7.1.1 e-Diary ................................ ................................ ................................ ........ 56 7.1.1.1 3-Day Voiding Diary ................................ ................................ ....... 56 7.1.1.2 Nocturia Impact Diary ................................ ................................ .....58 7.1.1.3 Patient Reported Outcomes ................................ .............................. 59 7.1.1.3.1 Patient Global Impression of Severity and Patient Global Impression of Disease Improvement ...................... 59 7.1.1.3.2 Insomnia Severity Index ................................ ................. 59 7.1.1.3.3 Bother ................................ ................................ ......... 60 7.1.2 Adverse Events ................................ ................................ ............................ 61 7.1.3 Clinical Laboratory Variables ................................ ................................ ......... 61 7.1.3.1 Serum Sodium ................................ ................................ ................ 62 7.1.3.2 von Willebrand Factor and Factor VIII ................................ ............... 63 7.1.3.3 Copeptin ................................ ................................ ........................ 64 7.1.4 Vital Signs ................................ ................................ ................................ ...64 7.1.5 24-Hour Urine Volume and Nocturnal Urine Volume ................................ ......... 64 7.2 Other Assessments ................................ ................................ ................................ ...64 7.2.1 Demographics ................................ ................................ .............................. 64 7.2.2 Medical History ................................ ................................ ............................ 64 7.2.3 Concomitant Medication ................................ ................................ ................ 64 7.2.4 Body Weight and Height ................................ ................................ ................ 64 7.2.5 Physical Examination ................................ ................................ .................... 65 7.2.6 Pregnancy Test ................................ ................................ ............................. 65 7.2.7 Electrocardiogram ................................ ................................ ......................... 65 7.3 Handling of Biological Samples ................................ ................................ ................. 65 8 ADVERSE EVENTS ................................ ................................ ................................ .......... 66 8.1 Adverse Event Definition ................................ ................................ .......................... 66 8.2 Collection and Recording of Adverse Events ................................ ................................ 66 8.2.1 Collection of Adverse Events ................................ ................................ .......... 66 8.2.2 Recording of Adverse Events ................................ ................................ .......... 66
16,page_16,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 16 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 8.3 Adverse Events of Special Interest ................................ ................................ .............. 69 8.4 Pregnancy and Pregnancy Outcome ................................ ................................ ............ 69 8.5 Serious Adverse Events ................................ ................................ ............................. 70 8.5.1 Serious Adverse Event Definition ................................ ................................ ....70 8.5.2 Collection, Recording and Reporting of Serious Adverse Events .......................... 71 8.6 Follow -up of Adverse Events and Serious Adverse Events ................................ ............. 72 8.6.1 Follow -up of Adverse Events with Onset during the Trial ................................ ...72 8.6.2 Collection of Serious Adverse Events with Onset after Last Visit in the Trial ......... 72 9 STATISTICAL METHODS ................................ ................................ ............................... 73 9.1 Operating Characteristics ................................ ................................ .......................... 73 9.2 Protocol Deviations ................................ ................................ ................................ ..75 9.3 Analysis Sets ................................ ................................ ................................ ........... 76 9.3.1 Intention -to-Treat Analysis Set for the Enrichment (ITT -ENR) Period .................. 76 9.3.2 Safety Analysis Set for the Enrichment Period ................................ ................... 76 9.3.3 Intention -to-Treat ( ITT) Analysis Set for the Randomised Treatment Period .......... 76 9.3.4 Full Analysis Set (FAS) ................................ ................................ ................. 76 9.3.5 Per Protocol (PP) Analysis Set ................................ ................................ ........ 76 9.3.6 Safety Analysis Set for the Randomised Treatment Period ................................ ..76 9.4 Subject Disposition ................................ ................................ ................................ ..76 9.5 Enrichment Period Assessments and Analysis Sets ................................ ........................ 77 9.6 Trial Population ................................ ................................ ................................ ....... 77 9.6.1 Medical History, Concomitant Medication and Other Safety Evaluations .............. 77 9.7 Endpoint Assessments ................................ ................................ .............................. 77 9.7.1 General Considerations ................................ ................................ .................. 77 9.7.2 Primary Analysis ................................ ................................ .......................... 78 9.7.2.1 Statistical Dose -Response Model ................................ ...................... 78 9.7.2.2 Overall Trial Outcome ................................ ................................ .....80 9.7.2.3 Dose -Response ................................ ................................ ............... 80 9.7.2.4 Sensitivity Analyses ................................ ................................ ........ 80 9.7.2.5 Descriptive Analysis ................................ ................................ ....... 80 9.7.3 Secondary and Explorative Analyses ................................ ............................... 81 9.7.3.1 Therapeutic Window ................................ ................................ ....... 83 9.8 Explorative Benchmarking Analysis ................................ ................................ ........... 83 9.9 Extent of Exposure and Treatment Compliance ................................ ............................. 83 9.10 Safety ................................ ................................ ................................ ..................... 83 9.10.1 General C onsiderations ................................ ................................ .................. 83 9.10.2 Adverse Events ................................ ................................ ............................ 84 9.10.3 Adverse Events of Special Interest: Hyponatraemia Episodes .............................. 84 9.10.3.1 Hyponatraemia during the Randomised Treatment Period ..................... 85 9.10.4 Safety Laboratory Variables ................................ ................................ ........... 85 9.11 Interim Analyses ................................ ................................ ................................ ......85 9.11.1 Serum Sodium Monitoring during the Active Run -In Period ................................ 86 9.11.2 Interim Efficacy Analyses ................................ ................................ .............. 87 10 DATA HANDLING ................................ ................................ ................................ ........... 89 10.1 Source Data and Source Documents ................................ ................................ ............ 89 10.2 Electronic Case Report Form ................................ ................................ ..................... 90"
17,page_17,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 17 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 10.3 Use of Patient Reported Outcomes ................................ ................................ .............. 90 10.3.1 Validation of the Nocturia Impact Diary ................................ ........................... 91 10.3.1.1 Psychometric Validation ................................ ................................ ..91 10.3.1.2 Validation through Exit Interviews ................................ .................... 91 10.4 Data Management ................................ ................................ ................................ ....92 10.5 Provision of Additional Information ................................ ................................ ............ 92 11 MONITORING PROCEDURES ................................ ................................ ........................ 93 11.1 Periodic Monitoring ................................ ................................ ................................ .93 11.2 Audit and Inspection ................................ ................................ ................................ .93 11.3 Confidentiality of Subject Data ................................ ................................ .................. 94 11.4 Centralised Statistical Monitoring ................................ ................................ ............... 94 12 CHANGES IN THE CONDUCT OF THE TRIAL ................................ ............................... 95 12.1 Protocol Amendments ................................ ................................ ............................... 95 12.2 Deviations from the Protocol ................................ ................................ ..................... 95 12.3 Premature Trial Termination ................................ ................................ ...................... 95 13 REPORTING AND PUBLICATION ................................ ................................ .................. 96 13.1 Clinical Trial Report ................................ ................................ ................................ .96 13.2 Confidentiality and Ownership of Trial Data ................................ ................................ 96 13.3 Publications and Public Disclosure ................................ ................................ ............. 96 13.3.1 Publication Policy ................................ ................................ ......................... 96 13.3.2 Public Disclosure Policy ................................ ................................ ................ 97 14 ETHICAL AND REGULATORY ASPECTS ................................ ................................ ....... 98 14.1 Independent Ethics Committee / Institutional Review Board / Research Ethics Board ......... 98 14.2 Regulatory Authorities Approval ................................ ................................ ................ 98 14.3 End-of-Trial and End-of-Trial Notification ................................ ................................ ..98 14.4 Ethical Conduct of the Trial ................................ ................................ ....................... 98 14.5 Subject Information and Consent ................................ ................................ ................ 98 14.6 Subject Participation Card ................................ ................................ ......................... 99 14.7 Compliance Reference Documents ................................ ................................ ............. 99 15 LIABILITIES AND INSURANCE ................................ ................................ .................... 100 15.1 ICH-GCP Responsibilities ................................ ................................ ....................... 100 15.2 Liabilities and Insurance ................................ ................................ ......................... 100 16 ARCHIVING ................................ ................................ ................................ .................. 101 16.1 Investigator File ................................ ................................ ................................ ..... 101 16.2 Trial Master File ................................ ................................ ................................ .... 101 17 REFERENCES ................................ ................................ ................................ ................ 102 18 APPENDICES ................................ ................................ ................................ ................. 105 Appendix 1 ................................ ................................ ................................ ...................... 105 Appendix 2 ................................ ................................ ................................ ...................... 140
18,page_18,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 18 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL LIST OF TABLES Table 5-1 Treatment during the Trial ................................ ................................ .......................... 45 Table 6-1 Trial Flow Chart ................................ ................................ ................................ ........ 50 Table 7-1 Timing of Voiding Diary Assessments ................................ ................................ .......... 57 Table 7-2 Example of Voiding Diary Completion When Visit Planned for Friday .............................. 57 Table 7-3 Safety Laboratory Var iables ................................ ................................ ........................ 61 Table 8-1 Serious Adverse Events during the Trial ................................ ................................ ....... 70 Table 9-1 Operating Characteristics ................................ ................................ ............................ 75 Table 9-2 Quantities of Interest ................................ ................................ ................................ ..79 Table 9-3 Overall Trial Criteria ................................ ................................ ................................ .80 Table 9-4 Analysis of Endpoints ................................ ................................ ................................ 82 Table 9-5 Tabulations of Adverse Events ................................ ................................ .................... 84 Table 9-6 Definition of Hyponatraemic Episodes by Serum Sodium Range during the Randomised Treatment Period ................................ ................................ ................................ ....... 85 Table 9-7 Examples of Incidence Rates that are Statistically Significantly >10% ............................... 86 LIST OF FIGURES Figure 3-1 Trial Overview ................................ ................................ ................................ .......... 28 Figure 3-2 e-Diary Assessments and Questionnaires to be Completed by the Subject Prior to Randomisation ................................ ................................ ................................ .......... 29 Figure 3-3 e-Diary Assessments and Questionnaires to be Completed by the Subject During the Randomised Treatment Period ................................ ................................ ..................... 30 Figure 9-1 Dose -Response Scenarios ................................ ................................ ........................... 73 Figure 9-2 Interim Analysis Decision Tree (2nd Interim Analysis and Onwards) ................................ 88
19,page_19,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 19 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL LIST OF ABBREVIATIONS AND DEFINITION OF TERMS List of Abbreviations ADR Adverse Drug Reaction ANCOVA Analysis of Covariance ANP Atrial Natriuretic Peptide ATC Anatomical Therapeutic Chemical Classification System AUA American Urology Association BOO Bladder Outlet Obstruction BPO Benign Prostatic Obstruction BPH Benign Pro static Hyperplasia CRO Contract Research Organisation DMC Data Monitoring Committee ECG Electrocardiogram eCRF Electronic Case Report Form e-Diary Electronic Diary ED 85 The near (â‰¥85%) m aximal Effective Dose EU European Union FACTS Fixed and Adaptive Clinical Trial Simulator FAS Full Analysis Set FDA Food and Drug Administration FWC Free Water Clearan ce FUSP First Undisturbed Sleep Period GCP Good Clinical Practice GEE Generalized Estimating Equation GMP Good Manufacturing Practice ICF Informed Consent Form ICH International Conference on Harmonisation ICMJE International Committee of Medical Journal Editors IEC Independent Ethics Committee IMP Investigational Medicinal Product IRB Institutional Review Board ISI Insomnia Severity Index ITT Intention -to-Treat analysis set for the randomised treatment period ITT-ENR Intention -to-Treat analysis set for the enrichment period
20,page_20,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 20 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL IUD Intrauterine Device IUS Intrauterine System KM Kaplan -Meier LAM Lactational Amenorrhoea Method LUTS Lower Urinary Tract Symptoms MED Minimum Effective Dose MedDRA Medical Dictionary for Regulatory Activities MNAR Missing Not At Random NLM National Library of Medicine NP Nocturnal Polyuria NPi Nocturnal Polyuria i ndex NYHA New York Heart Association NI Diary Nocturia Impact DiaryÂ© NUV Nocturnal Urine Volume OAB Overactive Bladder ODT Orally Disintegrating Tablet OSA Obstructive Sleep Apnoea PAP Psychometric Analysis Plan PD Pharmacodynamic PGI-I Patient Global Impression of Improvement PGI-S Patient Global Impression of Severity PK Pharmacokinetic PP Per Protocol PRO Patient Reported Outcome RAAS Renin -Angiotensin -Aldosterone System REB Research Ethics Board RLS Restless Legs Syndrome SAE Serious Adverse Event SAP Statistical Analysis Plan SIADH Syndrome of Ina ppropriate Antidiuretic Hormone SOC System Organ Class SRC Safety Review Committee SSRI Selective Serotonin Reuptake Inhibitors SUSAR Suspected Unexpected Serious Adverse Reaction
21,page_21,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 21 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Definition of Terms Hyponatraemia Hyponatraemia is categoris ed by severity based on serum sodium concentrations: â€¢ Normal lower limit of serum sodium >135 mmol/L â€¢ Mild hyponatraemia : serum sodium 134 -130 mmol/L â€¢ Moderate* hyponatraemia : serum sodium <130 mmol/L â€¢ Severe hyponatraemia : serum sodium <125 mmol/L * Moderate hyponatraemia is equivalent to the term â€˜clinically significant hyponatraemia â€˜ (Verbalis, 2013) Nocturnal diuresis The nocturnal diuresis rate is calculated from the mean of 3 days Nocturnal Urine Volume ( NUV) and total time in bed: ğ‘ğ‘œğ‘ğ‘¡ğ‘¢ğ‘Ÿğ‘›ğ‘ğ‘™ ğ‘‘ğ‘–ğ‘¢ğ‘Ÿğ‘’ğ‘ ğ‘–ğ‘  ğ‘Ÿğ‘ğ‘¡ğ‘’ (ğ‘šğ¿/ğ‘šğ‘–ğ‘› )=NUV (mL) Total Time in Bed (min) FUSP First Undisturbed Sleep Period (FUSP) is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occurred. MED The lowest dose that has at least a âˆ†=0.3 larger reduction in mean nocturnal voids as compared to placebo. ED 85 The lowest dose that achieves at least 85% of the effect of the maximum dose. NPi Nocturnal Polyuria i ndex (NP i) is calculated by dividing the nocturnal urine volume (NUV) by the 24 -hour urine volume ( van Kerrebroeck, 2002; Gormley , 2014). In this clinical trial the NPi definition >33% is used for all ages to define presence of Noctur nal P olyuria (NP) . NUV Nocturnal Urine Volume (NUV) is t he total urine volume from 5 minutes after bedtime with the intention to sleep until the first void within 30 minutes of rising (in the morning) . Enrichment period The enrichment period consists of 1 week active run -in followed by 1 week washout. The enrichment ensures that subjects respond to the drug (reduction in nocturna diureis by â‰¥20% from Visit 2 to Visit 3) and have a stable condition of â‰¥2 voids at Visit 2 and Visit 4."
22,page_22,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 22 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 1 INTRODUCTION 1.1 Background Nocturia is defined by the International Continence Society (ICS) as waking from sleep (during the night) at least once to urinate. Nocturia is a symptom complex associated with several underlying medical and urological causes and pathologies ( van Kerrebroeck, 2002 ; Wein , 2002). It is common in the elderly, occurring in up to 50% of men and women older than 75 years ( Bosch, 2010). Nocturia is associated with a variety of clinical syndromes and disorders, which may result from (van Kerrebroeck, 2002 ): â€¢ Disorders that cause frequent low volume vo ids (e.g., Overactive Bladder [ OAB ], Bladder Outlet Obstruction [ BOO ], stiffer/less -compliant/functionally -smaller bladder associated with aging) or â€¢ frequent high volume voids (e.g., Nocturnal Polyuria [NP] , global polyuria [d iabetes insipidus or mellitus] ) or â€¢ a combin ation of both, which is common. As described above , NP is a subset of nocturia defined as excessive volume of urine produced at night. The human body typically produces less urine while asleep. People with NP produce larger volumes of urine when asleep, causing them to awaken multiple times in the night to void. Thus, the diagnosis nocturia may be applied when there is an excessive urine production during the night . Nocturnal polyuria has been attributed to: â€¢ Abnormalities in diurnal variation in vasopressin secretion (a condition also coined as NP syndrome ) (Asplund, 1991) â€¢ Abnormalities in the diuresis of solutes (e.g., urea, sodium, potassium) â€¢ Night time mobilisation of oedematous fluid in conditions such as congestive heart failure, nephrotic sy ndrome, or venous insufficiency However, as described abo ve, patients often have more than one symptom presenting as nocturia (or NP); e.g., high volume of urine at night in combination with low volume bladder (perhaps associated with ageing) and BOO . Taken together, these facts make the clinical situation compl icated since patients may have NP overlaid symptoms associated with frequent, low -volume voids, including OAB and Benign Prostatic Hyperplasia (BPH) . The anti diuretic hormone arginine vasopressin (AVP) plays a key role in the control of urine production during the night. Desmopressin, a synthetic analogue of AVP developed by Ferring Pharmaceuticals , is approved and used for the treatment of noc turia due to NP in more than"
23,page_23,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 23 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 80 countries, including Canada and European countries. However, desmopressin has not yet been approved for this indication in the USA . Low doses of desmopressin (25 Âµg for women and 50 Âµg for men ) are approved to date in Canada, Australia and Europe an countries under the trade name NOCDURNA (desmopr essin Orally Disintegrating Tablet [ODT]) . These gender specific minimum effective low doses are approved for use in all adult ages and are indicated for treatment of nocturia due to NP in adults, who awaken two or more times each night to void. The global cumulative patient exposure of NOCDURNA by end-2016 is 1 ,389 patient years based on a dose of 25 Î¼g for women and 50 Î¼g for men (women: 779 patient years; men : 610 patient years). Analysis of the combined data from three trials of low-dose desmopressin OD T, comprising >1400 patients with nocturia, shows that desmopressin dose, patient age, baseline serum sodium levels, and kidney function according to estimated glomerular filtration rate clearance were significant risk factors for hyponatraemia in both sex es (Juul, 2016). Ferring Pharm aceuticals is currently developing FE 201836, another synthetic analogue of AVP and a potent and highly selective short -acting vasopressin -2 (V 2)-receptor agonist with an antidiuretic action profile suitable for treating nocturia due to NP in adults. FE 201836 exerts its antidiuretic effect by increasing the water permeability of the luminal membrane of the renal cortical and medullary collecting du cts, and thereby reducing free water excretion. Hyponatraemia may develop over time if drinking occurs during the period of antidiuretic drug effect. Therefore, the ideal V2-receptor agonist should provide an antidiuretic duration of action not exceeding 6 -8 hours i.e., corresponding to the night -time sleep period when drinking does not occur or is limi ted to a minimum (to satisfy thirst only). The oral half -life should be shorter than that of desmopressin and the key route of metabolism non -renal, since th e clinical promise of a short - acting V 2-receptor agonist is based on an improved safety profile without a prolonged duration of action potentially leading to hyponatraemia. A shorter and more predictable duration of antidiuretic action would minimise the r isk of hyponatraemia and may reduce the need for serum sodium monitoring. In the present clinical trial, 6 doses of FE 201836 (50-500 Âµg) will be evaluated for estimation of the dose -response curve, where the response is the change in the number of nocturnal voids. The selection of FE 201836 doses in the trial is based on data regarding the antidiuretic effect of FE 201836 in healthy subjects and by the antidiuretic effects of desmopre ssin in healthy subjects and in patients with NP. In a phase 1 trial (000195 ) in young healthy men and women , oral doses of FE 201836 of up to 4 ,800 Âµg were administered and found to be safe and well tolerated. The exposure after in travenous infusion of 0. 5 Âµg FE 201836, comparable to the exposure after an oral dose of approximately 900 Âµg FE 201836, resulted in approximately 8 hours of antidiuretic effect. The present trial is powered for detecting differences in treatment effects between FE 201836 and placebo. Desmopressin is inc luded as benchmark treatment. There is no prospectively planned power for conclusive inference with regards to differences between desmopressin and placebo (or FE 201836)."
24,page_24,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 24 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 1.2 Scientific Justification for Conducting the Trial Concer n over hyponatraemia and the risk -benefit ratio has limited the use of desmopressin to younger patient s and recently allowing treatment in elderly nocturia patients only under serum sodium monitoring. Renal impairment has also limited the use due to a risk of prolonging duration of action. FE 201836 , a novel short -acting V 2-receptor agonist , now under development , is designed to preserve potency at the V 2-receptor at the same level as desmopressin, with a shorter half-life, increased selectivity, faster clearance and greater extra -renal clearance compared to desmopressin . The present phase 2 trial will establish the dose -response of FE 201836 with respect to the number of nocturnal voids in subjects with nocturia due to NP, allowing the development to pro ceed for a novel agonist at the V 2-receptor for treatment of nocturia due to NP. 1.3 Benefit / Risk Aspects Benefits Subjects enrolled in the present trial will be closely monitored and they will have the same or more frequent visits to the hospital compared t o routine treatment, depending on local practice. During these visits the subjects will be given instructions regarding lifestyle changes (including limiting fluid intake ). For some subjects the implementation of lifestyle changes might be enough to reduce bothersome nocturia, defined as 2 or more nocturnal voids . Risks Treatment of nocturia due to NP with desmopressin implies a prolonged antidiuretic effect that may be associated with an increased risk of developing hyponatraemia, especially in elderly patients. FE 201836 is designed to preserve potency at the V 2-receptor at the same level as desmopressin, with a shorter half -life, increased selectivity, faster clearanc e and greater extra -renal clearance compared to desmopressin. Based on the low degree of unchanged renal excretion of FE 201836 , renal impairment is not expected to have any clinically relevant impact on the duration of the antidiuretic effect . An improved safety profile is expected to result from this combination of characteristics. The short half-life of FE 201836 (approximately 2 hours) and low degree of unchanged renal excretion (approximately 5%) are designed to limit the antidiuretic effect to the night -time sleep period, when subjec ts do not drink or their fluid intake is limited to a minimum (to satisfy thirst only). Therefore, the risk for dilutional hyponatraemia that may occur after the subjec t starts drinking in the morning is expected to be l ow. Subjects in the phase 1 clinical trial 000195 were dosed with up to 48 00 Âµg (i.e. , 9.6 times higher than the suggested maximum dose in the present phase 2 trial ) orally without any subject being hyponatr aemic. Pharmacokinetic/pharmacodynamic (PK/PD ) modelling suggests that the duration of antidiuretic effect at 500 Âµg will be approximately 6 hours, limiting the potential for daytime antidiuresis."
25,page_25,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 25 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL In the present trial, the risk of subjects developing hyponatraemia will be mitigated by a serum sodium monitoring plan , as described in Section 7.1.3.1 . The plan includes a 1 -week active run -in period to identify subjects at increased risk for developing acute hyponatraemia prior to randomisation , as well as serum sodium sampling at Week 1, Week 4, Week 8 and Week 12, to identify any subject developing hyponatraemia while on treatment with Investigational Medicinal Product ( IMP). Moreover, safety including the occur rence of adverse events and clinically significant changes in laboratory value s (including serum sodium values) will be monitored throughout the trial."
26,page_26,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 26 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 2 TRIAL OBJECTIVES AND ENDPOINTS 2.1 Objectives Primary Objective â€¢ To establish th e dose -response of FE 201836 with respect to the number of nocturnal voids in subjects wi th nocturia due to NP. Secondary Objectives â€¢ To evaluate responder rates with regards to changes in number of nocturnal voids. â€¢ To psychometrically validate the Nocturia Impact DiaryÂ© (NI Diary). â€¢ To evaluate the patient benefit of FE 201836 based on the NI Diary data. â€¢ To evaluate the clinical benefit of FE 201836 based on reduction in nocturnal voiding. â€¢ To evaluate FE 201836 with respect to sleep benefit, i.e., duration of the First Undisturbed Sleep Period ( FUSP) and sleep related Patient Reported Outcomes (PROs). â€¢ To evaluate the PD effect of FE 201836 with respect to nocturnal diuresis rate and NP. Safety Objective â€¢ To evaluate the safety profile of FE 201836. Exploratory Objectives â€¢ To explore the biomarker c opeptin, an AVP surrogate, to identify low nocturnal vasopress in levels in plasma. â€¢ To explore the dose -response of FE 201836 with respect to total sleep time. â€¢ To explore the association between total sleep time and FUSP. â€¢ To explore the effect of FE 201836 with respect to Nocturnal Polyuria i ndex ( NPi). â€¢ To benchmark t he efficacy of FE 201836 in relation to desmopressin. 2.2 Endpoints Primary Endpoint â€¢ Change from b aseline in number of nocturnal voids during 12 weeks of treatment. Secondary Endpoints â€¢ Change from b aseline in number of nocturnal voids at Weeks 1, 4, 8 and 12. â€¢ Responder rate defined as 50% reduction in nocturnal voids from baseline at Weeks 1, 4, 8 and 12 during 12 weeks of treatment. â€¢ Change from b aseline in NI Diary Total Score at Weeks 1, 4, 8 and 12 and during 12 weeks of treatment. â€¢ Percentage of nights durin g the treatment period with at most one nocturnal void. â€¢ Percentage of nights during the treatment period with complete response, i.e. , with no nocturnal voids."
27,page_27,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 27 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL â€¢ Change from b aseline in NI Diary Overall Impact Score at Weeks 1, 4, 8 and 12 and during 12 weeks of treatment. â€¢ Patient Global Impression of Improvement (PGI -I) urinary symptoms scores at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in Patient Global Impression of Severity (PGI -S) scores at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in Bother as measured by the Hsu 5 -point Likert Bother scale (Hsu, 2015) at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in Insomnia Severity Index (ISI) at We eks 4, 8 and 12. â€¢ Change from b aseline in FUSP at 1, 4, 8 and 12 weeks of treatment and during 12 weeks. â€¢ Change from b aseline in nocturnal diuresis rate (hourly) profiles at Week 1 and Week 12. â€¢ Change from b aseline in Nocturnal Urine Volume (NUV) at Week 1 and Week 12. Safety Endpoints â€¢ Incidence and severity of adverse events. â€¢ Incidence of hyponatraemia as measured by serum sodium level throughout the trial. â€¢ Change from baseline in mean 24 -hour urine volume at Week 1 and Week 12. â€¢ Clinically significant changes in vital signs and laborato ry values. Exploratory Endpoints â€¢ Responder rates defined as 33%, 60%, 70%, 80%, 90% and 100% reduction from baseline in number of nocturnal voids at Weeks 1, 4, 8 and 12. â€¢ Responder rates defined as 1, 2, and 3 voids reduction from baseline in number of noc turnal voids at Weeks 1, 4, 8 and 12. â€¢ The c orrelation of c opeptin levels to NPi at Visit 2. â€¢ Change from b aseline in c opeptin levels at Week 12. â€¢ Change from b aseline in total sleep time per night at Weeks 1, 4, 8 and 12 and during 12 weeks of treatment. â€¢ Correlation between change from b aseline in total sleep time and FUSP at Weeks 1, 4, 8 and 12. â€¢ Change from b aseline in NPi at Week 1 and Week 12."
28,page_28,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 28 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 3 INVESTIGATIONAL PLAN 3.1 Overall Trial Design 3.1.1 Trial Design Diagram s A trial overview is presented in Figure 3-1. Overviews of trial visits and electronic diary ( e-Diary ) assessments and questionnaires to be completed by the subjects before and after randomisation are presented in Figure 3-2 and Figure 3-3. a A sample of subjects (f rom trial sites in the US A) who have completed the trial will participate, by telephone, in an exit interview within 14 days of attending Visit 8. Figure 3-1 Trial Overview Screening (1 Day) Lifestyle Changes 2 weeksVisit 1 Active Run -in 1 weekVisit 2 Washout 1 weekVisit 3 Randomised Treatment 12 weeksVisits 4-7 End-of-Trial Exit InterviewaVisit 8"
29,page_29,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 29 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Figure 3-2 e-Diary Assessments and Questionnaires to be Completed by the Subject Prior to Randomisation V1 Reminder CallDiary Training 5 DaysMinimum 2 weeks Lifestyle ChangesScreening 7 Days Active Run- in 7 Days Washout V:Visit *R*: Randomisation ISI: Insomnia Severity Index PGI-S: Patient Global Impression ofDisease Severity IMP: Investigational Medicinal Product NI Diary : Nocturia Impact DiaryÂ© Bother: Hsu 5-point Likert Bother ScaleEnrichment Period Void Diary V2-3 Days to V2-2 Days to V2-1 Days to V2 NI DiaryNI DiaryNI DiaryIMP IMP ISI IMP-4 Days to V2 PGI-S V3 -3 Days to V3-2 Days to V3-1 Days to V3 IMP IMP IMP IMP-4 Days to V3 V4 -3 Days to V4-2 Days to V4-1 Days to V4 Day 1 PGI-S*R* IMPISI-4 Days to V4 NI DiaryNI DiaryNI Diary BotherVoid DiaryVoid DiaryVoid Diary Void DiaryVoid DiaryVoid DiaryVoid DiaryVoid DiaryVoid DiaryVoid DiaryVoid DiaryVoid Diary
30,page_30,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 30 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Figure 3-3 e-Diary Assessments and Questionnaires to be Completed by the Subject During the Randomised T reatment Period
31,page_31,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 31 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 3.1.2 Overall Design and Control Methods This is a randomised, double -blind, placebo -controlled, response -adaptive, dose -finding trial investigating the efficacy, safety and tolerability of 6 different oral doses ( 50-500 Âµg) of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to NP in adults. The trial will comprise 8 visits (Section 3.1.1 ) to the clinic and will consist of a 2 -week screening/lifestyle changes period where no IMP will be given, an enrichment period consisting of a 1-week single -blind (to subjects) active run -in period and a 1 -week washout period, and a 12-week double -blind randomised treatment period for each subject (Figure 3-1). During the active run-in period the trial subjects will receive 500 Âµg FE 201836 and placebo to assess safety and establish that subjects who respond to treatment with FE 201836 are included in the trial (i.e., an enrichment design). The 12 -week double -blind randomised treatment period of the trial will follow a response -adaptive Bayesian top -down design. Initially subjects will be randomised to: placebo, 500 Âµg FE 201836 or desmopressin (for benchmarking only). When approximately 125 subjects have been ran domised to the trial, an interim analysis will be conducted to investigate the efficacy of 500 Âµg FE 201836 . If 500 Âµg FE 201836 is not sufficiently efficacious compared to placebo the trial will be stopped for futility. If 500 Âµg FE 201836 is efficacious additional doses of FE 201836 (doses 50 -350 Âµg) will be opened up for randomisation of new subjects in order to identify the Minimum Effective Dose (MED) and near maximal Effective D ose (ED 85). The ED 85 is the lowest dose that achieves at least 85% of the effect of the maximum dose (500 Âµg). After the first interim analysis, subsequent interim analyses will take place every 8 weeks to reassess the randomisation allocation probabilities to 50 -500 Âµg FE 201836, based on observed responses at the respective in terim locks . For more information regarding the interim analyses, please refer to Section 3.3 and Section 9.11.2 . After the first interim analysis eligible subjects will be randomised to one of 8 treatment groups (Table 5-1). Each subject will be instructed to take the IMP every night at bedtime with the intention to sleep. In order to keep the treatment blinded each subject will receive two medications throughout the trial; an oral solution and an ODT , i.e., a double -dummy design will be applied because desmopressin is available in an ODT formulation and FE 201836 is an oral solution (Table 5-1). Subjects will be asked to follow lifestyle changes (e.g. , limiting fluid intake) througho ut the entire duration of the trial. In addition, subjects will be asked to complete e-Diary assessments (Section 7.1.1 ) and PRO questionnaires (Section 7.1.1.3 ) before and after randomisation (Figure 3-2 and Figure 3-3). One objective of the present trial is to further validate the NI Diary. Therefore, a sample of subjects (from trial sites in the US A) who have completed the trial will be invited to participate in an exit interview within 14 days of attending the end -of-trial visit (Visit 8), to record the subjectsâ€™ perception of what constitutes a meaningful change in the NI Diary Total Score (Section 10.3.1 )."
32,page_32,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 32 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Safety, including serum s odium levels (Section 7.1.3.1 ), adverse events and clinically significant changes in vital signs and laboratory values will be monitored throughout the trial and reviewed on an ongoing basis by a Safety Review Committee (SRC) (Section 3.4). Furthermore, the risk for subject s developing hypona traemia will be mitigated by a serum sodium monitoring plan (Section 7.1.3.1 ), including a 1-week active run -in to identify subjects at increased risk for developing acute hyponatraemia prior to randomisation . If the incidence of serum sodium levels <130 mmol/L is statistically significantly >10% during the active run -in, the Data Monitoring Committee ( DMC) established for the trial (Section 3.4) will be notified and further action will be discussed, e.g., the DMC may recommend that the highest dose of FE 201836 ma y be replaced by a lower dos e. The trial is designed so the dose may be lowered from 500 Âµg to 3 50 Âµg if recommended by the DMC, as described in Section 9.11.1 . 3.1.3 Trial Schedule The first trial visit ( Visit 1, screening) for the first subject is expected in Q 3 2017 and the last trial visit for the last subject is expected in Q3 2019. The total duration of the trial (for a subject) is expected to be approximately 1 8 weeks (includi ng the exit interview) . Trial completion is defined as when the last subjec t has completed the last visit in the randomised trial period (Visit 8). 3.2 Planned Number of Trial Sites and Subjects The trial will be conducted at approximately 70 sites in Europe and North America . A maximum of 300 subjects will be included (Section 9.1). 3.3 Interim Analyse s Interim analyses will be performed by an internal DMC established for the trial. The first interim analysis will be conducted after an initial 125 subjects have been randomised in a 2:2:1 ratio to placebo , 500 Âµg FE 201836 or desmopressin . After the first 125 randomised subject s, the allocation ratio is 2:7:1 for placebo, active treatment and desmopressin, respectively. Subsequent interim analyse s will be performed every 8 weeks , where the randomisation allocation probabilities to FE 201836 doses will be adjusted . The interim a nalyses are detailed in Section 9.11. 3.4 Safety Review and Data Monitoring Committee s Trial data will be reviewed on an ongoing basis by the sponsor SRC. In addition , an internal DMC will be established for the trial. The main purpose of the DMC i s to perform pre -planned interim analyses (Section 3.3) and make recommendations based on review of the efficacy and safety data . An additional purpose of the DMC is to address any potential safety concerns raised by the SRC. The responsibilities and the composition of the DMC are provided in a separate charter document."
33,page_33,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 33 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 3.5 Discussion of Overall Trial Design and Choice of Control Groups 3.5.1 Trial Design The present clinical trial includes a 2 -week period of lifestyle changes. Lifestyle changes (e.g., limiting fluid intake ) are recommended as an initial treatment in most clinical guidelines , e.g., the updated American Urology Association ( AUA ) guideline on the management of BPH (McVary, 2011), despite the relative paucity of supporting data ( Weiss, 2013). Excluding pel vic floor exercises for bladder -related Lower Urinary Tract Symptoms ( LUTS ), which are not part of the present trial, there seems to be no evidence that prolonged lifestyle changes, versus the proposed 2 weeks in the present trial, will result in additional benefit on NP related to excessive nocturnal fluid intake. From a practical point of view, the total of 4 weeks during the pre-randomisation period in the present trial is consider ed adequate for subjec t compliance. In order to select subjec ts with nocturia primarily due to the underlying condition of NP driven with increased Free Water Clearance (FWC), who will benefit the most from treatment with an antidiuretic agent, a 1 -week ac tive run -in period followed by a 1 -week washout period will be applied to ensure that drug -responders (defined as subjects with a reduction of nocturnal diuresis rate [mL/min] of 20% or more) are identified. The â‰¥20% decrease in the nocturnal diuresis rate has been established as a relevant marker of antidiurectic responsivenes in previous nocturia trials with an active run -in (Lose, 2003; Mattiasson, 2002 ). The NUV is defined as the total urin e volume from 5 minutes after bedtime with the intention to sleep until the first void within 30 minutes of rising in the morning. Total time in bed is a proxy for the time the subject is in nocturnal diuresis. The nocturnal diuresis rate is calculated fro m the mean of 3 days NUV and total time in bed: ğ‘ğ‘œğ‘ğ‘¡ğ‘¢ğ‘Ÿğ‘›ğ‘ğ‘™ ğ‘‘ğ‘–ğ‘¢ğ‘Ÿğ‘’ğ‘ ğ‘–ğ‘  ğ‘Ÿğ‘ğ‘¡ğ‘’ (ğ‘šğ¿/ğ‘šğ‘–ğ‘› )=NUV (mL) Total Time in Bed (min) The majority of fluid output occurs via the urine, approximately 1500 mL/day, therefore threre is no evidence in adult nocturia subjects that the relative change over the time in nocturnal diuresis rate ( mL/min normalised to time in bed ) should be adjusted for body weight and or/body surface area which are both assumed to be constant over a short period of 1 week only. An analysis of individual nocturia subject data found that reducing NUV and increasing the duration of antidiuretic action of a V 2-receptor agonist (desmopressin) was a significant predictor for subsequent decrease from baseline in the number of nocturn al voids (Yamaguchi, 2013 ). The underlying pathophysiologic mechanism of NP can be driven by either increased FWC, which based on mode of action will be responsive to antidiuretic treatment, or by increased sodium clearanc e, which differs substantially in mode of action and is governed by Atrial Natriuretic Peptide (ANP) which is directly and indirectly influenced by the Renin -Angiotensin -Aldosterone System (RAAS). The aim of the active run -in is (after excluding all other medical causes of NP) to identify subjects with increased FWC , which is responsive to V 2-receptor agonism. In addition, safety will be assessed in this period with special emphasis on hyponatraemia."
34,page_34,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 34 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Treatment group allocation will be determined by central randomisation to eliminate selection bias and ensure that any dif ference in treatment groups at b aseline is a result of random chance . Following randomisation at Visit 4, a double -blind design has been chosen to minimise both investigator and subject ascertainment bias. In order to keep the treatment blinded each subject will receive two medications throughout the trial; an oral solution and an ODT , i.e., a double -dummy design will be applied because desmopressin is available i n an ODT formulation and FE 201836 is an oral solution. The blinding is further described in S ection 5.5. Interim analyses will be conducted throu ghout the trial in order to investigate the efficacy of FE 201836 and to reassess the randomisation probabilities for each dose of FE 201836 based on observed responses at the respective interim locks. In addition, serum sodium will be monitored during the active run -in in order to identify subjects at increased risk of developing acute hyponatraemia. The interim analyses are further described in Section 3.3 and Section 9.11. 3.5.2 Selection of Endpoints The change in mean number of nocturnal voids has become a standard primary clinical trial endpoint in nocturia trials since the first overseas trials (with desmopressi n) in early 2000 (Lose, 2003; Mattiasson, 2002 ; van Kerrebroeck, 2007 ). It is therefore reasonable and appropriate to use reduction in number of nocturn al voids from baseline as the primary endpoint in this trial. Nocturia is one of the primary causes of sleep disturbance and has been shown to impair functioning, quality of life, health and productivity, with those experiencing 2 or more voids per night reporting significant bother ( Ancoli -Israel, 2011 ). Awakening during the first 3 -4 hours of the night during the deep and slow -wave restorative sleep is more likely to contribute to daytime fatigue ( Chartier -Kastler, 2006 ). The clinically relevant benefit (for the subject) of desmopressin treatment may be demonstrated further by measuring the time to first awakening to void ( FUSP ), which reduces the time spent in slow wave (deep) sleep ( Bliwise, 2015 ). Therefore it is reasonable to include FUSP as an endp oint in the present trial . To further evaluate the clinical benefit of FE 201836 endpoints relating to percentag e of nights with at most one nocturnal void or with complete response are included for analysis. The significant impact of nocturia and its treatment on subjectsâ€™ quality of life and daily lives will be documented by the use of a n e-Diary which contains a 3-day voiding diary, NI Diary and PRO questionnaires. Voiding diaries are standard tools use d within the urology area (Holm -Larsen, 2009) and are among the best possible means of obtaining objective data on subjective symptoms ( Abrams, 1983 ). A voiding diary therefore represents a self -monitoring daily record of the individualâ€™s voiding behaviour. The ICS recommends inclusion of voiding diaries in clinical assessment of subjec ts with LUTS (Abrams, 2002). The subjects will be asked to complete voiding diaries over 3 consecutive 24 -hour periods just prior to scheduled visits throughout the trial. Three -day voiding diaries have been shown to be as effective as 7 -day diaries with the potential for better accuracy ( Dmochowski, 2005). The NI Diary, is a 12-item PRO measure assessing t he impact burden associated with nocturia (Holm -Larsen, 2014 ). The NI Diary has been developed and psychometrically evaluated in patients with nocturia, in line with published International Society for Quality of Life Research (ISOQOL)"
35,page_35,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 35 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL and International Society for Pharmacoeconomic and Outcomes Research (ISPOR) gui dance (Patrick, 2011 ; Reeve, 2013 ), as well as the Food and Drug Administration (FDA ) Guidance for Industry, Patient -Reported Outcome Measures, 2009 (FDA, 2009 ). The PGI -S and PGI-I questionnaires , developed for use in populations with urinary tract conditions (Viktrup, 2012 ; Yalcin, 2003), are included to support anchor -based analysis of the NI Diary , as described in Section 10.3.1 . To further assess the change in subjective bothersomeness of nocturia, trial participants will be asked, â€œHow much has this frequency of night -time urination bothered you?â€ with response options including â€œnot at all,â€ â€œslightly,â€ â€œmoderately,â€ â€œquite a bit,â€ and â€œextremely.â€ This 5 point Likert scale has previo usly been used i n a large epidemiological study (Hsu, 2015). The ISI is a PRO instrument to quantify the subject's perception of his/her insomnia severity, it is included as a measure of sleep quality. The ISI targets the subjec tive symptoms and consequences of insomnia as well as the degree of concern or distress caused by those difficulties ( Bastien, 2001 )."
36,page_36,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 36 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 4 SELECTION OF TRIAL POPULATION 4.1 Trial Population The tria l population will be adult male and female subjects with nocturia due to NP , approximately 50% of each gender, who fulfil the eligibility criteria listed below. 4.1.1 Inclusion Criteria Each subject must meet the following inclusion criteria between Visit 1 (screening) through Visit 4 (randomisat ion): 1. Written informed consent prior to performance of any trial -related activity 2. Adults â‰¥18 years of age (at the time of written consent) 3. Female subjects of child-bearing potential must be willing and able to use adequate contraception throughout the trial. D ocumentation of an acceptable effective method of contraception must be available . All pre - and perimenopausal subjects have to perform pregnancy tests. Amenorrhea of more than 12 months duration based on the reported date of the last menstrua l period is sufficient documentation of post -menopausal status and does not require a pregnancy test 4. Medical history of, or subject reported nocturia symptoms during the 6 months prior to Visit 1 5. â‰¥2 nocturnal voids (an average over 3 days) as documented in the 3 -day e-Diary prior to Visit 2 6. The largest single voided volume must be â‰¥200 mL (at least 1 void â‰¥200 mL) as documented in the 3-day e -Diary prior to Visit 2 7. Nocturnal polyuria, defined as NPi >33%, a ratio of NUV in excess of 33% of total daily (24-hour) urine volume as documented in the 3-day e -Diary prior to Visit 2 8. b 9. â‰¥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2) as documented in the 3 -day e -Diary prior to Visit 3 10. Additionally to be randomised into the trial a t Visit 4 subjects must have â‰¥2 nocturnal voids (an average over 3 days) as documented in the 3-day e -Diary prior to Visit 4 b Original inclusion criterion omitted as per Clinical Trial Protocol Amendment 02 (applicable for all trial sites)."
37,page_37,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 37 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 4.1.2 Exclusion Criteria Any subject meeting one or more of the following exclusion criteria between Visit 1 (screening) through Visit 4 (randomisation) will be considered as a screening failure : 1. Current diagnosis of Obstructive Sleep Apnoea (OSA) 2. Restless Legs Syndrome (RLS) 3. Bladder Outlet O bstruction (BOO) or urine flow <5 mL/s , as confirmed by uroflowmetry upon suspicion during screening prior to Visit 2 4. Urinary incontinence defined as an average of >1 episode/day in the 3 -day e-Diary prior to Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not necessarily exclusionary) 5. c 6. Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation within t he past 6 months prior to Visit 1. Including e.g., transurethral resection for BOO or BPH, hysterectomy or female incontinence procedures 7. Genito -urinary t ract pathology that can in the i nvestigatorâ€™s opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder -related pain, chronic pelvic pain syndrome, or stone in the bladder or urethra causing symptoms 8. A history of cancer with the last date of disease activity/prescence of malignancy within the last 12 months prior to Visit 1, except for adequately treated basal cell carcino ma of the skin 9. History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple Sclerosis, Parkinsonâ€™s, spinal cord injury, spina bifida) 10. Habitual (fluid intake >3L per day) or psychogenic polydipsia 11. Uncontrolled hypertensi on, as judged by the investigator 12. a 13. Uncontrolled diabetes mellitus , as judged by the investigator 14. Central or nephrogenic diabetes insipidus 15. Known history of Syndrome of Inappropriate Antidiuretic H ormone (SIADH) secretion 16. History of g astric retention 17. Suspicion or evidence of congestive heart failure, (New York Heart Association [NYHA] class II, III, IV) c Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all trial sites). a Origina l exclusion criterion omitted as per Clinical Trial Protocol Amendment 01 (applicable for all trial sites)."
38,page_38,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 38 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 18. Hyponatraemia: â€¢ Serum sodium level <1 35 mmol/L at Visit 1(re-tested, with results available within 7 days) â€¢ Serum so dium level <130 mmol/L at Visit 3 (re-tested, with results available within 7 days) 19. Hepatic and/or biliary diseases: â€¢ Child -Pugh Class A, B, or C or â€¢ Aspartate aminotransferase and/or al anine aminotransferase levels >3 x the upper limit of normal range as well as total bilirubin level >2x the u pper limit of normal range 20. Known history of hypersensitivity to desmopressin ODT 21. Pregnancy, breastfeeding, or a planning to become pregnant during t he period of the trial 22. Known alcohol or substance abuse 23. Work or lifestyle that may interfere with regular n ight-time sleep e.g. , shift workers 24. Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrie r that, in the judgment of the i nvestigator, would impair participation in the trial 25. d 26. Previous participation in a nocturia, Benign Prostatic Obstruction (BPO ), or OAB clinical trial within the past 6 months prior to Visit 1 27. The subject is in a state of dependence of the sponsor, or is directly or indirectly involved in t he conduct of this t rial as an i nvestigator, sub-investigator, trial coordinator or other trial staff member, or the subject is a first degree family member, significant other or relative residing with one of the above persons involved direct ly or indirectly with the trial 28. Use of any restricted therapy not in accordance with the protoco l 29. Use of any prohibited therapy listed below: â€¢ Current or former (within 3 months prior to screening) treatment with any other IMP â€¢ Unstable electrostimulation or behavioural bladder training program less than 3 months prior to screening (stable electrostimulation or behavioural bladder training program started at least 3 months before screening are acceptable) â€¢ Thiazide diuretics â€¢ Antiarrhythmi c agents â€¢ V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin) â€¢ Loperamide d Original ex clusion criterion omitted as per Clinical Trial Protocol Amendment 0 3 (applicable for all trial sites)."
39,page_39,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 39 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL â€¢ Botulinum toxin (cosmetic non -urological use is acceptable) â€¢ Valproate 4.2 Method of Assigning Subjects to Treatment Groups 4.2.1 Recruitment Subjects who have given written informed consent will receive a unique (site -specific) screening number and be invited to perform a screening visit (Visit 1) . All screening assessments must be completed and evaluated to confirm that all eligibility criteria are met by the subject . A site-specific Screening L og, for record ing of details of all subjects screened and confirmation of eligibility or record ing of reasons for s creening failure , as applicable , must be maintained at the trial site. The screening number , whic h will be allocated sequentially in the order in which the subjects are screened , must be entered into the Screening L og. It is permitted to re -screen a subject in this trial in case a subject has been considered a screening failure due to one or more of the following reasons: â€¢ not fulfilling the inclusion criterion number 6 as defined in Clinical Trial Protocol versions 2.0 (>250 mL) , 3.0 (>250 mL) , or 4.0 (â‰¥250 mL) but had at least 1 single voided volume â‰¥200 mL prior to Visit 2 â€¢ not fulfilling the inclusion criterion of an NI Diary Total Score of â‰¥10 points (raw score) prior to Visit 2 (inclusion criterion number 8) as defined in Clinical Trial Protocol versions 2.0 and 3.0 â€¢ fulfilling the exclusion criterion of a serum triglyceride level >400 mg/dL (exclusion criterion number 12) as defined in Clinical Trial Protocol version 2.0 â€¢ fulfilling the exclusion criterion of aspartate aminotransferase and/or alanine aminotransferase levels >2x the upper limit of normal range and a total bilirubin level >1.5 mg/dL (second part of exclusion criterion number 19) as defined in Clinical Trial Protocol version 2.0 â€¢ fulfilling exclusion criterion number 3 as defined in Clinical Trial Protocol version s 2.0, 3.0, and 4.0 â€¢ fulfilling exclusion criterion number 5 as define d in Clinical Trial Protocol version s 2.0, 3.0, and 4.0 â€¢ fulfilling exclusion criterion number 25 as defined in Clinical Trial Protocol version s 2.0, 3.0, and 4 .0 â€¢ technical issues with the e -Diary device prior to Visit 2 If a subject has failed screening du e to any other reason the subject must not be re -screened for participation in the trial at a later time."
40,page_40,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 40 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 4.2.2 Randomisation A computer -generated randomisation list will be prepared prior to enrolment of the first subject into the trial . The randomisation list will be adjusted during the course of the trial via a response - adaptive randomisation procedure. At least 50% of subjects should be randomised at trial sites in the USA to allow for an optimised validation of the NI Diary. Therefore, a cap of maximum 150 subjects will need to be set for countries other than the USA. Subject -specific randomisation number s will be allocated in the order at which the subject s are being rand omised into the trial. The subject randomisation number will be recorded in the Screening L og. It is not permitted for a subject to be randomised in the trial twice . The first 125 subject s will be randomised to treatment in a fixed manner. The allocation r atio is 2:2:1 for placebo, 500 Âµg FE 201836 and desmopressin. At the first interim analysis, after 125 subjects being randomised , the allocation ratio is 2:7:1 for placebo, active treatment and desmopressin, respectively. Subject s will be randomised to the active treatment groups of FE 201836 in a response -adaptive randomisation manner. A pre -defined algorithm will be used to determine the relative randomisation to each of the FE 201836 groups . Subsequent i nterim analyses will be conducted every 8 weeks to adjust the adaptive randomisation probabilities . The enrolment of subject s will continue without any stop at the interim analyses. For more information regarding the interim analyses, please refer t o Section 3.3 and Section 9.11. The screening rate will be monitored such that the a ccrual of randomised subjects does not overshoot the operating characteristics described in Section 9.1, which could potentially result in a loss of statistical power. 4.2.2.1 Randomisation i f Maxim um Dose is Lowered The trial has been designed with the option to decrease the maximum dose of FE 201836 from 500 Âµg to 350 Âµg if recommended by the DMC (Section 9.11.1 ). If this decision is made, randomisation to the 500 Âµg FE 201836 treatment group will be closed, the trial will continue with 350 Âµg FE 201836 as the highest dose for the active run -in and the highest dose of FE 201836 that any sub ject can be randomised to. In case subjects have already been randomised to the 500 Âµg FE 201836 treatment group and have not completed the trial , the DMC will recommend whether or not these subjects may be permitted to remain on treatment with 500 Âµg FE 201836 for the remainder of the trial. Subjects randomised to treatment with 500 Âµg FE 201836 who prematurely discontinue the trial due to DMC decision (Section 4.4) may be replaced by subject s randomised to treatment with a lower dose of FE 201836. If the decision to close randomisation to 500 Âµg FE 201836 is taken prior to the first interim analysis, i.e., when the first 125 subjects have been randomised, the remaining subjects will be randomised to the following treatment groups: placebo, desmopressin (25 Âµg for females and 50 Âµg for males) or 350 Âµg FE 201836. After the first interim analysis the do se-response adaptive randomisation will allocate sub jects to the remaining 7 open treatment groups : placebo, 50 Âµg FE 201836, 100 Âµg FE 201836, 150 Âµg FE 201836, 250 Âµg FE 201836, 350 Âµg FE 201836 , or desmopressin (25 Âµg fo r females and 50 Âµg for males)."
41,page_41,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 41 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 4.3 Restrictions 4.3.1 Prior and Concomitant Therapies Details of all concomitant medications/therapies and the main reason for the prescription must be recorded in the medical source record and in the Electronic Case Report Form (eCRF ) at screening (Visit 1). Any c hanges (including new therapies) must be recorded at each subsequent visit. Any therapy for treat ment of nocturia or sleep disorders (e.g., guidance for lifestyle changes, pelvic floor muscle training, electrostimulation, biofeedback treatment) that a subject received before trial initiation should be continued without any change throughout the trial period. All subjects must have normal serum sodium (â‰¥135 mmol/L) at screening and serum sodium levels will be monitored throughout the trial as described in Se ction 6.1 (Table 6-1) and Section 7.1.3.1 . The following medications will be permitted, provided that t he subject has been on a stable dose for the 3 months prior to the screening visit (Visit 1) (i.e., treatment has not been initiated or discontinued and there has been no change in dose): â€¢ Sedative/hypnotic medications for sleep disorders â€¢ Selective Serotoni n Reuptake Inhibitors (SSRIs): citalopram, duloxetine, venlafaxine, escitalopram, paroxetine, fluoxetine, sertraline â€¢ Chronic use of Non -steroidal Anti -inflammatory Drugs (NSAIDs) â€¢ Chlorpromazine â€¢ Medicines used for treatment of BPH such as alpha -blockers (d oxazosin, tamsulosin, terazosin and alfuzosin) and 5 -alpha -reductase inhibitors (e.g., dutasteride and finasteride) and phosphodiesterase -5 inhibitors (e.g., tadalafil) â€¢ Medicines used for treatment of OAB such as antimuscarinic therapy (tolterodine, fesoterodine, oxybutynin, darifenacin, hyoscyamine, trospium, solifenacin) and beta-3 adrenergic receptor agonist s (mirabegron) â€¢ Sulfonylurea, including chlorpropamide â€¢ Loop diuretics (furosemide, torsemide, ethacrynic acid) and other classes of diuretics (triamterene, chlorthalidone, amiloride, indapamide) are permitted, either as monotherapy or combination therapy if the subject takes the loop diuretic prior to 4 pm (the timing of this treatment regimen must have been in place for at least 1 week prior to the screening visit [Visit 1]) â€¢ Systemic corticosteroids â€¢ Carbamazepine â€¢ Lithium â€¢ Opioids â€¢ Lamotrigine â€¢ Tricyclic antidepressants"
42,page_42,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 42 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Additional serum sodium monitoring should be performed as described in Section 7.1.3.1 if treatment with the following medications is initiated or dosing is increased during the trial: â€¢ SSRIs: citalopram, duloxetine, venlafaxine, escitalopram, paroxetine, fluoxetine, sertraline â€¢ Chronic use of NSAIDs â€¢ Chlorpromazine â€¢ Sulfonylurea, including chlorpropamide â€¢ Loop diuretics (furosemide, torsemide, ethacrynic acid) and other classes of diuret ics (triamterene, chlorthalidone, amiloride, indapamide) â€¢ Systemic corticosteroids â€¢ Carbamazepine â€¢ Lithium â€¢ Opioids â€¢ Lamotrigine â€¢ Tricyclic antidepressants â€¢ Any other drug that increases the risk of hyponatraemia 4.3.2 Prohibited Therapy The following medications a re prohibited throughout the duration of the trial (exclusion criterion number 29, Section 4.1.2 ): â€¢ Current or former (within 3 months prior to the screening visit [Visit 1]) treatment with any other IMP â€¢ Unstable electrostimulation or behavioural bladder training program less than 3 months prior to the screening visit (Visit 1) (stable electrostimulation or behavioural bladder training program started at least 3 months prior to the screening visit are acceptable) â€¢ Thiazide diuretics â€¢ Antiarrhythmic agents â€¢ V2-receptor antagonists/agonists â€¢ Loperamide â€¢ Botulinum toxin (non -urological use is a cceptable) â€¢ Valporate Any new therapy for treat ment of nocturia or sleep disorders must not be initiated throughout the duration of the trial."
43,page_43,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 43 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 4.3.3 Lifestyle Changes and Other Restrictions In order to prevent hyponatraem ia and to avoid interference with efficacy assessment of the treatment : â€¢ The fluid intake must be limited to a minimum (to satisfy thirst only) during the time interval of 1 hour before , until 8 hours after administration of IMP â€¢ The subject should empty the bladder before going to bed with the intention to sleep â€¢ The treatment should be interrupted during acute intercurrent illnesses characterised by fluid and/or electrolyte imbalance (such as systemic infections, fever, gastroenteritis) until the subject has fully recovered. The treatment can be re-started at the discretion of the investigator once the condition of the subject is stabilised Subjects will be reminded to follow instructions regarding lifestyle changes throughout the duration of the trial. Subjects participating in the present trial should refrain from donating blood or sperm throughout the trial period. 4.3.4 Contraception Female subjects of child -bearing potential must be willing and able to use an acceptable effective contraceptive method throughout the trial. Documentation of the method used must be available. A female subject is considered to be of child -bearing potential following menarche and until becoming post -menopauseal, unless permanently sterile. Post-menopausal is defined as amenorrhea of >12 months d uration based on the reported date of the last menstrual period. In the context of this trial, acceptable effective method s include: â€¢ Transdermal patch â€¢ Established use of oral, injected or implanted hormonal methods of contraception â€¢ Placement of an intraute rine device (IUD) or intrauterine system (IUS) â€¢ Barrier methods of contraception: condom or o cclusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository â€¢ Male sterilisation (with the appropriate post -vasectomy documentati on of the absence of sperm in the ejaculate) â€¢ True abstinence: When this is in line with the preferred and usual lifestyle of the subject Periodic abstinence (cale ndar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. Femal e condom and male condom should not be used together. Contraceptive measures will not be required for male subjects participating in the trial based on genotoxici ty data obtained in animal studies with FE 201836, as detailed in the Investigatorâ€™s Brochure."
44,page_44,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 44 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 4.4 Withdrawal Criteria A subject must be withdrawn from the trial in case of: â€¢ Serum sodium level is â‰¤125 mmol/L at any time point during the trial â€¢ Significant non -compliance with the trial protocol, as judged by the i nvestigator and/or the sponsor â€¢ Other medical or sa fety reasons, as judged by the i nvestigator and/or the sponsor â€¢ The subject wishe s to discontinue for any reason A subject has the right to withdraw from the trial at any time for any reason, without the need to justify his/her decision. However, the i nvestigator should record the reason for the subjectâ€™s withdrawal, if possible. The investigator also has the right to withdraw a subject . Since an excessive rate of withdrawals can render the trial devoid of meaning, unnecessary withdrawal of subjects should be avoided. Every effort should be made to invite subjects withdrawn/discontinued from the trial to an end -of- trial v isit (Visit 8) as so on as possible after a decision of withdrawal/ discontinuation has been taken. For any discontinuation, the investigator should obtain the required information and document the date and reason for the premature discontinuation in the eCRF. In case the subje ct has withdrawn consent, no new data can be recorded in the eCRF. Correction of previous data and/or recording data related to visits/procedures done prior to but made available after withdrawal of consent (e.g. , laboratory results) will be allowed unless the subject disapproves it. If the reason for withdrawal is an adverse event, the specific event or the main laboratory abnormality must be recorded in the eCRF. The investigator should make thorough efforts to document the outcome. Subjects discontinued from the trial will not be replaced , except for subjects randomised to treatment with 500 Âµg FE 201836 in case a decision is taken to decrease the maximum dose of FE 201836 from 500 Âµg to 350 Âµg (Section 4.2.2.1 )."
45,page_45,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 45 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 5 TREATMENTS 5.1 Treatments Administered In order to maintain the treatment blinding each subject will receive 2 medications (double -dummy design) , an oral solution and an ODT formulation, during every treatment period of the trial, as outlined in Table 5-1. During the a ctive run -in period all subjects will receive 500 Âµg FE 201836 oral solution (and placebo ODT ) for 1 week. After the lifestyle changes/screening, active run -in and w ashout periods, eligible subjects will be randomised to a treatment group as follows: â€¢ Prior to the first interim analysis, the first 125 subjects will be randomised to the following treatment groups : placebo , desmopressin or 500 Âµg FE 201836. â€¢ After the first interim analysis , subjects may be randomised to one of 8 treatment groups: placebo, 50 Âµg FE 201836, 100 Âµg FE 201836, 150 Âµg FE 2 01836, 250 Âµg FE 201836, 350 Âµg FE 201836, 500 Âµg FE 201836 or desmopressin (25 Âµg for females and 50 Âµg for males) . After randomisation, the duration of treatment is 12 weeks. Table 5-1 Treatment during the Trial Treatment Investigational Medicinal Product Active Substance Placebo Active Run -in 500 Âµg FE 201836 500 Âµg FE 201836 oral solution Placebo ODT Washout - - - Randomised Treatment Period Up to First Interim Analysis 500 Âµg FE 201836 500 Âµg FE 201836 oral solution Placebo ODT Desmopressin Desmopressin ODT (25Âµg for females and 50 Âµg for males) Placebo oral solution Placebo - Placebo oral solution and Placebo ODT After First Interim Analysis 50 Âµg FE 201836 50 Âµg FE 201836 oral solution Placebo ODT 100 Âµg FE 201836 100 Âµg FE 201836 oral solution Placebo ODT 150 Âµg FE 201836 150 Âµg FE 201836 oral solution Placebo ODT 250 Âµg FE 201836 250 Âµg FE 201836 oral solution Placebo ODT 350 Âµg FE 201836 350 Âµg FE 201836 oral solution Placebo ODT 500 Âµg FE 201836 500 Âµg FE 201836 oral solution Placebo ODT Desmopressin Desmopressin ODT (25Âµg for females and 50 Âµg for males) Placebo oral solution Placebo - Placebo oral solution and Placebo ODT Each subject will be instructed to take the IMP every night at bedtime with the intention to sleep . In addition, as potential food interaction cannot be ruled out at this point in the development of"
46,page_46,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 46 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL FE 201836 , subjects participating in the present trial wi ll be instructed to wait for a minimum of 2 hours after eating the main evening meal before taking the IMP. 5.2 Characteristics and Source of Supply All IMP is provided by Ferring Pharmaceuticals A/S and will be handled according to the principles of G ood Manufacturing Practice (GMP). Ferring Pharmaceuticals A/S will provide the trial sites with IMP in amounts sufficient for the trial. 5.2.1 Investigational Medicinal Product s The following IMP will be used in the trial: IMP : FE 201836 Strength: 50, 100, 150, 250, 350 and 500 Âµg Formulation: Oral solution, bottle of 5 mL Administration method For oral use IMP: Desmopressin Strength: 25 Âµg and 50 Âµg Formulation: ODT Administration method: To be placed under the subjectâ€™s tongue, without water IMP: Placebo Strength: - Formulation: Oral solution , bottle of 5 mL Administration method: For oral use IMP: Placebo Strength: - Formulation: ODT Administration method: To be placed under the subjectâ€™s tongue, without water 5.3 Packaging and Labelling Packaging and labelling of the IMP will be performed under the responsibility of the IMP department at Ferring Pharmaceuticals A/S in accordance with GMP and na tional regulatory requirements. The IMP will be labelled in a manner that ensures the treatment blinding of the trial is maintained . The active drug and placebo are visually identical. The label of the IMP will contain one self -adhesive tear -off portion to be affixed to the Drug Dispensing Log maintained at the trial site. 5.4 Conditions for Storage and Use The investigator will ensure that the IMP is stored under appropriate conditions in a secure location with controlled access . The storage compartment shall be monitored regularly and the temperature shall be documented."
47,page_47,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 47 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL FE 201836 and placebo oral solut ion must be stored at 2 -8Â°C (36-46Â°F) before dispensing. After dispensing, the products should be stored at room temperature. Desmopressin and placebo ODT should be stored at 25Â°C (77ÂºF); excursions permitted to 15 -30Â°C (59-86Â°F). The product should be kept in the original package to be protect ed from moisture and light. The product should be used immediately upon opening of the individual tablet blister. The investigator will ensure that the IMP is stored under appropriate conditio ns in a secure location with controlled access. The storage temperature shall be monitored regularly and documented in accordance with the instructions provided by the sponsor. Deviations in storage temperature must be reported to the sponsor as instructed in the IMP handling instruction. Returned IMP from the subjects (used/partly used o r unused , including empty packag ing material) must be stored separately from non -allocated IMP. The subjects will be instructed to store the IMP in accordance with the abov e-mentioned conditions. 5.5 Blinding/Unblinding 5.5.1 Blinding The IMP will be supplied by the sponsor in individually packed containers. The IMP for the randomised treatment period will be packaged according to a computer -generated randomisation list prepared for all trial sites. The randomisation list will not be available to any person involved in the conduct and evaluation of the trial until the trial database is declared clean and is released to the trial statistician. 5.5.2 Unblinding of Individual Subject Treatment An emergency unblinding procedure will be available for the investigator a nd designated personnel at the s ponsor through the eCRF . It is the investigatorâ€™s responsibility to decide whether it is medically necessary to know which IMP the subject receives (i.e., unblinding) to ensure the subjectâ€™s welfare and safety. Breaking of the blind for individual subjects in emergency situations is only permitted in case of a S uspected Unexpected Serious Adverse R eaction (SUSAR) , or in case of an adverse event where the knowledge of the IMP administered is required for medical management of the subject. As far as the emergency permits, the need to break the blind will be agreed by the investigator and the sponsor. The investigator who unblinds a treatment will use the eCRF and is required to enter a password and must record the reason for unblinding before the treatment code can be broken. It must also be recorded in the eCRF when , and by whom , the code was broken. The investigator must record the event of unblinding i n the subjectâ€™s medical record , including the r eason for unblinding. If the s ponsor needs to unblind a treatment, the eCRF will be used for unblinding . It is a requirement to enter a password and the reason for unblinding before the treatment code can be broken. It must also be recorded in the eCRF when and by whom the code was broken."
48,page_48,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 48 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL It may be necessary to unblind an individual subjectâ€™s treatment sche dule for the purposes of expedited reporting to the authorities and/or Independent Ethics Committees (IECs)/ Institutional Review Boards ( IRBs )/Research Ethics Boards (REBs) . In that situation, every effort should be made to m aintain blinding of the sponsor personnel involved in data analysis and interpretation. Other personnel may be unblinded for SUSARs, including trial site personnel as well as personnel acting on behalf of the sponsor. Information on whether the blind has been broken for any subjects is available in the eCRF and must be collected before the database is declared clean and is released to the trial statistician. In case the eCRF cannot be accessed , and hence the emergency unblinding cannot be performed within the eCRF system, the investigato r should contact Ferring Global Pharmacovigilance using the contact details below: Global Pharmacovigilance, Ferring Pharmaceuticals A/S Tel: 5.6 Treatment Compliance 5.6.1 Dispensing and Accountability The IMP will be handled by authorised personnel at the trial site according to instructions provided by the sponsor. The IMP for the active run-in will only be dispensed to subjects wh o meet the eligibility criteria at Visit 2. The IMP for the randomised treatment period will only be dispensed to subjec ts wh o meet the eligibility criteria at Visit 4 and are randomised into the trial . The investigator (or his/her design ee) will maintain a Drug Dispensing Log detailing the dates and quantities of IMP dispensed to, and used by each subject, as well as the batch number (s). Each subject should return all unused and used IMP bottles and ODT blister sheets (empty foils) to the trial site. The delegated designee at each trial site will reconcile all used and unused IMP and maintain all IMP (including empty bottles and ODT blister/foils) for drug accountability. The monitor will verify the drug accountability during the trial. 5.6.2 Assessment of Compliance Treatment compliance will be verified at Visits 3, 5, 6, 7 and 8, by reviewing the used, partly used and unused IMP and/or subjectâ€™s statements documented in the source documents in case the IMP is lost. 5.7 Return and Destruction of Investigational Medicinal Products Subjects will be asked to return unused and used IMP bottles and ODT blist er sheets. Used and partly used IMP bottles and blisters (foils) will be destroyed at the trial site according to local regulations and standard procedures at the site, after the drug accountability has been verified by"
49,page_49,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 49 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL the monitor. Any unused IMP will be returned for destruction, as instructed by the IMP department at Ferring Pharmaceuticals A/S and in accordance with local requirements . Documentation on destruction will be forwarded to the s ponsor. 6 TRIAL PROCEDURES The i nvestigator is obliged to keep logs of all screened and randomised subjects. Each subject will receive a unique screening number available at each t rial site. Prior to , or at Visit 1, all subjects must receive a detailed explanation (verbal and written information) of the trial and must sig n an Informed Consent Form (ICF) after having had sufficient time to consider the participation in the trial. No trial -related procedures must be performed on the subject prior to signing the ICF. 6.1 Trial Flow Chart The overall tr ial design is shown in Secti on 3.1. The assessments scheduled for each visit are presented in the flow chart in Section 6.1, listed in Section s 6.2 to 6.7 and further described in Section 7."
50,page_50,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 50 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Table 6-1 Trial Flow Chart Assessment Screening/ Lifestyle Changes Active Run -in Period Washout Period Randomised Trial Period Visit (V) V1 Reminder V2 Telephone Follow -up V3 V4 L V5 V6 V7 V8 O Week 1 4 8 12 Day/Visit window S1 -14 -10Â±1 m -7 n 1 8Â±2 28Â±3 56Â±3 84Â±7 Inform ed consent X Inclusion and exclusion criteria X X X X Lifestyle Changes a X X X X X X X X X Randomisation X Dispense e -Diary X e-Diary Training X b e-Diary Compliance X X X X X X X Dispense IMP X X X X X Accountability of IMP X X X X X Demographics X Medical history X Physical examination X X X Body weight X X X X X X X X Height X Vital Signs c X X X X X X X X Electrocardiogram (ECG) X X Pregnancy test - serum d X X X Pregnancy test - urine d X Clinical chemistry, haematology, urinalysis X X X X X X Coagulation factors X X X X Copeptin X X X OSA assessment e X Serum sodium p X j X k, n X X X X Voiding Diary f X X X X X X X NI Diary f X X X X X X PGI-S g X X X X X X PGI-I g X X X X ISI h X X X X X Bother h X X X X X Exit Interview i X Adverse events X X X X X X X X Concomitant medication X X X X X X X X a. Subjec ts will be reminded about lif estyle c hanges throughout the trial. b. Original f ootnote omitted as per Clinical Trial Protocol Amendment 0 3 (applicable f or all trial sites). c. Vital signs ( blood pressure and heart rate ) measured af ter resting f or 5 minutes in a sitting position. d. Applicable to all pre - and perimenopausal f emale subjects. e. Original f ootnote omitted as per Clinical Trial Protocol Amendment 0 3 (applicable f or all trial sites). f. Completed by the subjects at home over 3 consecutive days just prior to scheduled visits. g. Completed at home 1 day prior to scheduled visits . h. Completed at the site visit bef ore any consultation with the trial site personnel takes place . i. A sample of subjects (at trial sites in the USA ) who completed the trial will be invited to participate, by telephone, in an exit interview wi thin 14 days of attending Visit 8. j. If serum sodium is <135mmol/L the test should be repeated within 7 days, if the second result is <1 35mmol/L the subject must be discontinued f rom the trial as a â€˜screening f ailureâ€™. If more than 21 days elapse between the serum sodium measurement at Visit 1 and Visit 2, the serum sodium measurement must be re -tested, with results available prior to Visit 2. k. If serum sodium is <130mmol/L the investigator must immediately contact the subject and schedule visits f or f urther evaluatio n , if the serum sodium is <130mmol/L (results conf irmed within 7 days) the subject will not be randomised to the trial an d must be discontinued f rom the trial as a â€˜screening f ailureâ€™. l. Baseline ef f icacy. m. During the 1 week active run in period, 4 days (Â±1 day) af ter the planned start of IMP treatment , the subject will be telephoned to f ollow up on saf ety. n. If the subject canno t attend Visit 3 as planned, arrangements must be made to test the serum sodium level at Day 6-8 f rom the IMP start date. o. The end -of-trial v isit (Visit 8) shoul d be perf ormed if the subj ect discontinues the trial prior to Visit 8. p. Sample to be taken pref erably in the morning ."
51,page_51,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 51 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 6.2 Visit 1 Screening Potential participants will be scheduled to come to the clinic for the screening assessments. The following must take place during the screening period: â€¢ Signing of informed consent â€¢ Allocation of a screening number â€¢ Inclusion and exclusion criteria will be evaluated . â€¢ Demographic data will be recorded. â€¢ Information on medical history will be recorded based on review of the medical records and interview of the subject. â€¢ Information on concomitant medication will be recorded. â€¢ Physical examination , including body weight and height , will be performed. â€¢ Vital signs (blood pressure and heart rate) will be measured. â€¢ Blood samples will be drawn for analysis of haematology , clinical chemistry (including serum sodium ) and coa gulation factors . â€¢ Urine samples will be collected for urinalysis. â€¢ Serum and urine pregnancy test s will be performed in all pre - and perimenopausal female subjects. â€¢ Assessment of OSA. â€¢ 12-lead electrocardiogram (ECG) will be measured. â€¢ The e-Diary will be dispensed. Subjects will be trained to complete the e -Diary and will be encouraged to complete the diary at home during 5 days for training purposes . â€¢ The subject will be given instructions about lifestyle changes and will be requested to maintain t hese lifestyle changes throughout the trial (Section 4.3.3 ). The e -Diary training will be followed by the trial site personnel (via the web -portal) . Prior to Visit 2 the subject will be reminded to complete the e-Diary ( Section 7.1.1 ) for 3 consecutive days just prior to the visit."
52,page_52,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 52 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 6.3 Visit 2 Active Run -in Period All assessments and procedures to be performed at Visit 2 are listed below. â€¢ The subject will complete the questionnaire (ISI), in the e-Diary (Section 7.1.1.3.2 ), at the trial site before any consultation with the trial site personnel takes place. â€¢ Inclusion and exclusion criteria will be evaluated. â€¢ Body weight will be measured. â€¢ Vital signs (blood pressure and heart rate) will be measured. â€¢ The subject will be interviewed about any changes in concomitant medication and about any adverse events since the last visit. â€¢ Blood samples w ill be drawn for assessment of c opeptin . â€¢ The subject will be reminded about lifestyle changes (Section 4.3.3 ). â€¢ Instructions for start and use of IMP will be given . â€¢ IMP will be dispensed to eligible subjects for the 1 -week active run -in (Table 5-1). Prior to Visit 3 the subject will be reminded to complete the e -Diary (Section 7.1.1 ) for 3 consecutive days prior to the visit. The e -Diary will be reviewed for completeness (via the web-portal) by the trial site personnel . Four days after the planned start of IMP treatment the subject will be telephone d to follow -up on safety . 6.4 Visit 3 Washout Period All assessments and proce dures to be performed at Visit 3 are listed below. â€¢ Inclusion and exclusion criteria will be evaluated (specifically inclusion criterion number 9, Section 4.1.1 ). â€¢ Eligible subjects will enter the 1 -week Washout -period. â€¢ The subject will be interviewed about any changes in concomitant medication and about any adverse events since the last visit. â€¢ Body weight will be measured. â€¢ Vital signs (blood pressure and heart rate) will be measured. â€¢ A blood sample will be collected for analysis of serum sodium. â€¢ Used IMP bottles, ODT blister sheet s and unused IMP will be collected for drug accountability. â€¢ The subject will be reminded about lifestyle changes (Section 4.3.3 ). If the subject cannot attend Visit 3 as planned, arrangements must be made to test the serum sodium level at Day 6 -8 from the IMP start date."
53,page_53,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 53 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Prior to Visit 4 the subject will be reminded to complete the e -Diary ( Section 7.1.1 ) for 3 consecutive days prior to the visit. The e -Diary will be reviewed for completeness (via the web-portal ) by the trial site personnel . 6.5 Visit 4 All assessments/proce dures to be performed at Visit 4 are listed below. â€¢ The subject will complete the questionnaires (ISI and Bother), in the e-Diary (Section 7.1.1 ), at the trial, site before any consultation with the trial site personnel takes place. â€¢ Inclusion and exclusion criteria will be evaluated (specifically inclusion criterion number 10, Section 4.1.1 ). â€¢ The subject will be interviewed about any changes in concomitant medication and about any adverse events since the last visit. â€¢ A ph ysical examination including body weight, will be performed . â€¢ Vital signs (b lood pressure and heart rate ) will be measured. â€¢ Blood samples will be drawn for analysis of haematology , clinical chemistry , coagulation factors and c opeptin . â€¢ Urine samples will be collected for urinalysis. â€¢ Serum pregnancy test will be performed in all pre - and perimenopausal female subjects. â€¢ Eligible subjects will be randomised to a treatment group ( placebo , 500 Âµg FE 201836 or desmopressin up until the first interim analysis and pl acebo , 50-500 Âµg FE 201836 or desmopressin after the first interim analysis) . â€¢ The subject will be reminded about lifestyle changes (Section 4.3.3 ) and to wait for a minimum of 2 hours after eating their evening meal before taking the IMP . â€¢ IMP will be dispensed (Table 5-1). Prior to Visit 5 the subject will be reminded to complete the e -Diary (Section 7.1.1 ) for 3 consecutive days prior to the visit. The e -Diary will be reviewed for completeness (via the web-portal) by the trial site personnel . 6.6 Visit 5 to Visit 7 All assessments/proce dures to be performed at Visits 5 to 7 are listed below. â€¢ The subject will complete the questionnaires ( Bother [Visits 5, 6 and 7] and ISI [Visit 6 and 7]), in the e -Diary (Section 7.1.1 ), at the trial site before any consultation with the trial site personnel takes place. â€¢ The subject will be interviewed about any changes in concomitant medication and about any adverse events since the last visit. â€¢ Body weight will be measured. â€¢ Vital signs (blood pressure a nd heart rate) will be measured."
54,page_54,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 54 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL â€¢ Blood samples will be drawn for analysis of haematology, clinical chemistry (including serum sodium) and coagulation factors (Visit 6). â€¢ Urine samples will be collected for urinalysis. â€¢ Used IMP bottles, blister sheet s and un used IMP will be collected for drug accountability. â€¢ IMP will be dispensed. â€¢ The subject will be reminded about lifestyle changes (Section 4.3.3 ) and to wait for a minimum of 2 hours after eating their evening meal before taking the IMP. Prior to the next visit (Visits 6, 7 and 8) the subject will be reminded to complete the e -Diary (Section 7.1.1 ) for 3 consecutive days prior to the visit. The e -Diary will be reviewed for completeness (via the web -portal) by the trial site personnel . 6.7 Visit 8 â€“ End-of-Trial Visit All assessments/proce dures to be performed at Visit 8 are listed below. â€¢ The subject will complete the questionnaires (ISI and Bother), in the e -Diary (Section 7.1.1 ), at the trial, site before any consultation with the trial site personnel takes place. â€¢ The subject will be interviewed about any changes in concomitant medication and about any adverse events since the last visit. â€¢ Physical examination including body weight will be performed. â€¢ 12-lead ECG will be measured. â€¢ Vital signs (b lood pressure and heart rate) will be measured. â€¢ Blood samples will be drawn for analysis of haematology , clinical chemistry (including serum sodium ), coagulation factors and copeptin. â€¢ Urine samples will be collected for urinalysis. â€¢ Serum pregnancy test will be performed in all p re- and perimenopausal female subjects. â€¢ Used IMP bottles, blister sheets and unused IMP will be collected for drug accountability. In addition to the above, a sample of subjects (from trial sites in the USA) who have completed the trial, will be invited to participate in an exit interview (Section 10.3.1.2 ), by telephone, within 14 days of attending the end -of-trial visit (Visit 8) to record the subjectsâ€™ perception of what constitutes a meaningful change in the NI Diary Total Score. 6.8 Unschedule d Visits The subject may be called in for additional unscheduled visits due to safety reason s at the discretion of the investigator or the sponsor, unless the subject has withdrawn his/her consent. The subject may also contact the trial site due to safety reason s for an unscheduled visit. The unscheduled visit may include additional collection of blood samples for safety reasons. The unscheduled visit may also include additional assessments deemed necessary by the investigator such as laboratory samples, EC Gs, or other procedures which were missed at a previous visit. All unscheduled visits"
55,page_55,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 55 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL should be described (including the reason for the visit) and documented in the medical/source record, and in the eCRF."
56,page_56,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 56 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 7 TRIAL ASSESSMENTS 7.1 Assessments Related to Endpoints 7.1.1 e-Diary Subjects will receive an e-Diary for completion containing : a 3-day voiding diary (Section 7.1.1.1 ), the N I Diary and PRO questionnaires as described in Section 7.1.1.2 . The followin g items are included in the e -Diary: â€¢ Time of daily IMP administration â€¢ 3-Day Voiding Diary â€¢ Nocturia Impact (NI) DiaryÂ© â€¢ PRO questionnaires o Patient Global Impression of Severity (PGI -S) o Patient Global Impression of Improvement (PGI -I) o Insomnia Severity Index (ISI) o Hsu 5-point Likert Bother Scale At Visit 1, the subjects will be trained to complete the e -Diary, which they will be encouraged to complete at home for 5 days (Figure 3-2). If the subject is not able to complete the e -Diary assessments, due to technical issues, prior to Visit 2 (only), it is permitted that the subject r epeats the e -Diary assessments. The e-Diary will be reviewed for completeness by the trial site personnel, via the web portal, throughout the trial . 7.1.1.1 3-Day Voiding Diary A 3-day voiding diar y (included in the e -Diary , Section 7.1.1 ) will be used to collect information regarding: time of voiding episodes, urine volume, wit h or without urgency, with or without incontinence and other related information, including time of going to bed and time of awakening in the morning . The subjects will be asked to complete voiding diaries over 3 consecutive 24 -hour periods just prior to scheduled visits , as outlined in Table 7-1 and shown in Figure 3-2 and Figure 3-3."
57,page_57,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 57 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Table 7-1 Timing of Voiding Diary Assessments Voiding Diary Assessment 3 Consecutive Days Prior to Visit(s) Time of Going to Bed with the Intenti on to S leep 2, 3, 4, 5, 6, 7, 8 Time of Awakening in the Morning 2, 3, 4, 5, 6, 7, 8 Assessment of U rgency and Incontinence Episodes 2 Number and Timing of Nocturnal Voids 6, 7 Number and Timing of Voids during 24 -hours 2, 3, 4, 5, 8 Nocturnal Urine Volume 3* 24-hour Urine Volume 2, 4, 5, 8 * Includes collection of total urine volume within 30 minutes of rising (in the morning) Effort should be made to ensure that the subject fills out the voiding diary (in the e -Diary) on the same weekdays throughout the trial for consistency , e.g., if the first voiding d iary (in the e -Diary) is started on a Monday, the subsequent e-Diary should al so be started on a Monday (Table 7-2). During the night (the sleep period) before the visit no measurements will be recorded. Table 7-2 Example of Voiding Diary Completion When Vis it Planned for Friday Monday Day-4 Tuesday Day -3 Wednesday Day-2 Thursday Day-1 Friday Visit Day Saturday Sunday Morning X X X Afternoon/ E vening X X Finish voiding diary (in e-Diary ) X Night Start voiding diary (in e-Diary ) X X X During the screening peri od, each subject must complete the 3-day voiding diary to document the severity of nocturia and to confirm the eligibility for the active run -in period. The voiding diary should be completed over 3 consecutive 24 -hour periods just prior t o Visit 2. During the 1 -week active run -in period, each subject must complete a 3 -day voiding diary to document treatment response of â‰¥20% decrease in the nocturnal diuresis (mL/min) that was recorded at Visit 2 and confirm the eligibility . The voiding diary should be completed over 3 consecutive 24 -hour periods just prior to Visit 3."
58,page_58,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 58 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL During the 1 -week washout period, each subject must complete a 3 -day voiding diary to confirm the eligibility for the trial. The voiding diary should be completed over 3 consecutive 24 -hour periods just prior to Visit 4. After randomisation (Visit 4) each subject has to complete four 3-day voiding diaries prior to the scheduled trial visits. Nocturnal voids are defined as the voids occurring from 5 minute s after bedtime, with the intention to sleep at night, until rising in the morning. The first morning void will not be counted as a nocturnal void even though its volume is included as part of the NUV . The time to first void is defined as the time from bed time with the intention to sleep until first nocturnal void. The s ponsor will provide the subjects with cups for measuring the urine volume. Prior to each visit the subjects will receive reminders to complete the e -Diary. 7.1.1.2 Nocturia Impact Diary Nocturia has wide -ranging implications for patientsâ€™ quality of life, mainly through persistent, repeated sleep interruptions. Valid patient self -reported assessments of disease burden and benefit of therapy are essential to evaluate the full clinical value of treatment for the patient. The NI Diary is a validated, nocturia -specific tool available in multiple languages and consists of a 12-item questionnaire with 11 core items (Q1 -Q11) and an ove rall QoL impact question (Q12) (Holm -Larsen, 2014 ). It is used in conjunction with a v oiding diary to capture patient reported consequences of nocturia and its treatment. It has a recall period of one night and day. Responses are scored from 0 to 4 (lowest to highest impact). For Question 12, response options range from 0 (not at all) to 4 (a great deal). The NI Diary total scores are calculated by summing the 11 core items . The NI Diary total and overall impact scores are standardised from 0 to 100 (lowest to highest impact). The NI Diary will be included in t he e-Diary (Section 7.1.1 ), which will be completed by the subjects at home, for the 3 conse cutive days just prior to scheduled visit s as outlined in Figure 3-2 and Figure 3-3. The NI D iary should be completed in the evening and before completing the PGI-S and PGI -I questionnaires . One objective of this trial is to further validate the NI Diary, as well as to establish what constitutes a meaningful change in the NI Diary Total Score. Thus, the disease -specific NI Diary will be further tested and validated in connection with this trial. This will be done through pshychometric validation, as described in Section 10.3.1.1 , and through exit interviews, as described in Section 10.3.1.2 ."
59,page_59,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 59 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 7.1.1.3 Patien t Reported Outcome s The PRO instrument s (questionnaires) that will be used in the trial are listed below. They should be completed in the following order : â€¢ At home in the evening (after completion of the NI Diary) : o Patient Global Impression of Severity (PGI -S) o Patient Global Impression of Improvement (PGI -I) â€¢ At the trial site: o Insomnia Severity Index (ISI) o Bother ( Hsu 5-point Likert Bother Scale) The two PRO questionnaires that will be completed at the trial site (ISI and Hsu 5 -point Likert Bother Scale) are recommended to be completed before any other assessments are performed, by the subject in a quiet place without influence from the trial personnel or accompanying family or friends. It is not permitted to help the subject cho ose an answer or interpret or rephrase questions which the subject do es not understand. The subjects should be informed that there are no right or wrong answers and that all of the subjectsâ€™ responses will remain confidential. 7.1.1.3.1 Patient Global Impression of Severity and Patient Global Impression of Disease Improvement Patient Global Impression of Disease scales are commonly used measures of symptom severity, treatment response and the efficacy of treatments ( Yalcin, 2003). The P GI-I and PGI -S will be included in the trial to indicate change or stability in global health status for anchor -based analyses to identify thresholds for clinically important change s in, e.g., NI Diary scores and number of nocturnal voids, as described in a separate Psychometric Analysis Plan (PAP) . Moreover, b oth scales will be analysed for treatment effect , as described in Section 9.7.3 . To better reflect the current condition, the revised and patient -tested versions of PGI -I and PGI -S will refer to â€˜night - time voidingâ€™, as compared to â€˜LUTSâ€™ ( Viktrup, 2012 ). The PGI -S is a prospective measure that measures a patientâ€™ s current severity reported as â€œNone,â€ â€œMild,â€ â€œModerate,â€ or â€œSevereâ€ ( coded as 1 -4). Scores on this measure will provide a patient -rated summary of the severity of the patientâ€™s nocturia symptoms . The PGI -I is a retrospective measure. It will provide a p atient -rated summary of change in nocturia since the start of trial treatment , reported as â€œVery much better,â€ â€œMuch better,â€ â€œA little better,â€ â€œNo change,â€ â€œA little worse,â€ â€œMuch worse,â€ or â€œVery much worse,â€ (coded as 1 -7). PGI-S followed by PGI-I will be completed by the subjects at home in the evening immediately after completing the NI Diary , as outlined in Figure 3-2 and Figure 3-3. 7.1.1.3.2 Insomnia Severity Index Chronic disruptions of sleep will have consequences for daytime performance and well -being. Nocturia patients often report excessive daytime sleepiness, with some experiencing more severe symptoms, including increased rates of mood disorders and decrease of physical health. Fatigue is a"
60,page_60,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 60 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL commonly reported symptom by individuals and causes a great amount of interferences with daily life. Sleepin ess has also been linked to increased risks for accidents, such as falling asleep while driving or work -related accidents ( Asplund, 2005 ; Ancoli -Israel, 2011 ). Nocturia is characteris ed by shortening the FUSP . The first sleep period is of high importance due to that deepest stages of sleep (most restorative sleep) typically occur within the first few hours of the sleeping and once these stages are interrupted by wakening (e.g. , to void ) patients are not able to make up for this during the rest of the night ( Bliwise, 2015 ). FUSP will be a secondary endpoint in the trial. Sleep quality will be measure d through the ISI, which is an instrument to quantify the subject's perception of his/her insomnia severity. The ISI targets the subjective symptoms and consequences of insomnia as well as the degree of concern or distress caused by those difficulties ( Bastien, 2001 ). The ISI comp rises of four `sleep -related' items and three `wake -related' items assessing the severity of sleep -onset and sleep maintenance difficulties (both nocturnal and early morning awakenings), satisfaction with current sleep pattern, interference with daily func tioning, noticeability of impairment attributed to the sleep problem and degree of distress or concern caused by the sleep problem. Each item is rated on a 0 -4 scale and the total score ranges from 0 to 28. A higher score suggests more severe insomnia. The self -administered ISI questionnaire will be completed at the trial site by the subj ect before active run -in period (Visit 2), at the randomisation visit (Visit 4), after 4 weeks (Visit 6), after 8 weeks (Visit 7) and at the last trial visit after 12 we eks of treatment (Visit 8) as illustrated in Figure 3-2 and Figure 3-3. Since the ISI has a two -week recall, a reminder to think back two weeks will appear on the screen upon start of completion , in order to improve on quality of the information captured . The ISI will be completed at Visit 2 in order to compare insomnia severity to other diseases presenting with insomnia, as recorded by the ISI. The ISI completed at the remaining visits (Visits 4, 6, 7 and 8) will be used to measure treatment effect. 7.1.1.3.3 Bother Patient bother is a broad concept covering as pects such as impact on sleep, daily life, social life, mental health, fatigue, etc. ( Tikkinen, 2010 ). It has been shown that most nocturia patients are not very bothered by one nightly void, but that there is clearly a bot her threshold at two voids or more. Moreover, comparing two adjacent voiding categories at a time, the increase was statistically significant with each increment in number of nightly voids. To further assess the change in subjective bothersomeness of noctu ria, trial participants will be asked, â€œHow much has this frequency of night -time urination bothered you?â€ with response options including â€œnot at all,â€ â€œslightly,â€ â€œmoderately,â€ â€œquite a bit,â€ and â€œextremely.â€ This 5 -point Likert scale has previously been used in a large epidemiological study (Hsu, 2015). The Hsu 5-point Likert Bother Scale will be completed by the subject at the trial site at randomisation (Visit 4), after 1 week (Visit 5), after 4 weeks (Visit 6), after 8 weeks (Visit 7) and at the last trial visit after 1 2 weeks of treatment (Visit 8), as illustrated in Figure 3-2 and Figure 3-3."
61,page_61,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 61 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 7.1.2 Adverse Events The procedures for collection and recording of adverse events are described in Section s 8 (Adverse Events) and 8.5 (Serious A dverse Events). 7.1.3 Clinical Laboratory Variables Urine and blood samples for assessment of safety laboratory values (urinalysis, haematology , coagulation factors and clinical chemistry parameters including serum sodium) will be collected as presented in Table 6-1. A central laboratory will be used for the analyses (Section 7.3). Evaluation of the laboratory -based eligibility criteria will be determined by the central laboratory results. The analytical parameters are listed in Table 7-3. Deta ils for handling of serum sodium samples are given in Section 7.1.3.1 . Laboratory values will be reported to the investigator. Laboratory reports from the screening visit (Visit 1) must be available for evaluating the inclusion and exclusion criteria prior to t he active run - in period (Visit 2) and before randomisation (Visit 4). Measurements outside normal ranges will be assessed by the investigator as â€˜abnormal, not clinically significantâ€™ or â€˜abnormal, clinically significantâ€™. Any abnormal, clinically signific ant changes should be reported as adverse events (Section 8.2). The laboratory reports will be signed and dated by the investigator. Table 7-3 Safety Laboratory Variables Clinical Chemistry Haematology Coagulation Urinalysis Alanine aminotransferase Haemoglobin von Willebrand Factor Blood Albumin Haematocrit Factor VIII Glucose Albumin/Globulin ratio Platelet count Ketones Alkaline phosphatase Red blood cell count Urinary sediment (erythrocyte s, leukocytes) Aspartate aminotransferase White blood cell count with differential count (eosinophil s, monocyte s, basophil s, neutrophil s, lymphocyte s) Calcium pH Chloride Protein Creatinine Urobilinogen Creatine phosphokinase Gamma -glutamyl transferase Dipstick assessment and microscopic examination will be performed. A culture will be performed in case of abnormal values. Glucose HbA 1c Potassium Sodium Total bilirubin Direct bilirubin Total protein Blood urea nitrogen Uric acid Triglycerides"
62,page_62,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 62 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 7.1.3.1 Serum Sodium Serum sodium levels will be monitored throughout the trial as hyponatraemia is a potentially serious adverse drug reaction (ADR) associated with desmopressin treatment and may potentially be asso ciated with FE 201836 treatment . A central laboratory will be used . However, a local laboratory may be used in addition to the central laboratory if a quick turn -around time of the result is needed . In such case a sample must also be sent to the central laboratory. Evaluation of the laboratory -based eligibility criteria will be determined by the central laboratory results. All serum sodium values must be reviewed as soon as possible after the results are available . Any unexpected low serum sodium value must be re -tested. Any significant changes in serum sodium, judged by the investigator as clinically significant must be rep orted as adverse events , as described in Section 8.2. Blood samples for analysis of serum sodium will be collected , preferably in the morning, at Visits 1, 3, 5, 6, 7 and 8, as presented in Table 6-1. The risk for subjects developing hyponatraemia during the trial period will be mitigated as follows (serum monitoring plan) : Screening (Visit 1) All subjects must have normal serum sodium (â‰¥13 5 mmol/L) at screening (Visit 1). If the serum sodium value is <135 mmol/ L (re-tested and confirmed , with results available within 7 days) the subject must be discontinued from the trial as a â€˜screening failureâ€™. Active Run -in Period During the 1 -week active run -in period, 4 days (Â±1 day) after the planned start of IMP treatment, the subject will be telephoned to follow -up on safety . Visit 3 At Visit 3 (after the active run -in), if the serum sodium value is <130 mmol/L the investigator must immediately contact the subject and schedule visits for further evaluation. If the serum sodium value is <130 mmol/L (re-tested and confirmed , with results available within 7 days) the sub ject will not be randomised to the trial and must be discontinued from the trial as a â€˜ screening failureâ€™. The subject will be followed (by the investigator) for safety until the serum sodium level is stable and not clinically significant, preferably until at least â‰¥135 mmol/L. If the subject cannot attend Visit 3 as planned, arrangements must be made to test the serum sodium level at Day 6 -8 from the IMP start date to ensure the serum sodium level is measured while the subject is taking IMP . 12-week Random ised Treatment Period During the 12 weeks randomised treatment period, any unexpected low serum sodium value (<135 mmol/L or a drop in serum sodium level >10 mmol/L) must be re -tested with at least 2 additional consecutive tests to identify the nadir and d uration of the hyponatraemic episode. The serum sodium level should be re -tested within 5 (Â±2 days) since the previous test. The subject will be followed (by the investigator) for safety until the serum sodium level is stable and not clinically significant , preferably until at least â‰¥135 mmol/L."
63,page_63,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 63 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Any Time Point during the Trial If the serum sodium value is â‰¤125 mmol/L at any time point during the trial, the treatment with the IMP must be stopped immediately and the subject must be withdrawn from the trial. All cases of serum sodium values â‰¤125 mmol/L will be reported a s Serious Adverse Event (SAEs ) (Section 8.5). The subject will be followed (by the investigator) for safety until the serum sodium level is stable and not clinically significant, preferably until at least â‰¥135 mmol/L. Acute Intercurrent Illness In case of acute intercurrent illnesses characterised by fluid and/or electrolyte imbalance (s uch as systemic infections, fever, gastroenteritis), the treatment with IMP should be interrupted until the subject has fully recovered. The treatment can be re -started at the discretion of the investigator once the condition of the subject is stabilised. In addition, subjects may be called in for additional unscheduled visits due to safety reason, as described in Section 6.8. Additional Serum Sodiu m Testing Events that will trigger additional serum sodium testing include, but are not limited to, the following: â€¢ If more than 21 days elapse from the serum sodium measurement at Visit 1 and the visit date of Visit 2, the serum sodium measurement must be re-tested, with results available prior to Visit 2. â€¢ A subject is presenting with signs or symptoms of hyponatraemia (e.g., headache, dizziness) â€¢ A subject has gained more than 2 kilograms in body weight between visits (Section 7.2.4 ) â€¢ If concomitant treatment with therapy that may induce hyponatraemia (Section 4.3.1 ) is initiated or dosing of an existing therapy is increased during the trial, additional serum sodium monitoring should be performed in the first week (4 -8 days) after initiation and again wi th follow -up as judged by the investigator, at least at 4 weeks . 7.1.3.2 von Willebrand Factor and Factor VIII Blood samples for assessment of coagulation factors will be collected at Visits 1, 4, 6 and 8 . The concentration s of the coagulation factors von Willebra nd Facto r (vWF) and Factor VIII (FVIII) were assessed in the phase 1 clinical trial , 000195 , after both oral and intravenous administration of FE 201836. The results indicated that both v WF and F VIII were increased at high plasma concentration s of FE 201836. vWF started to increase at a plasma concentration of ap proximately 150 pg/mL FE 201836 and FVIII at a plasma concentration of approximately 200 pg/mL . Such high plasma concentrations are unlikely to be reached in the urological doses proposed for t he present trial, however, vWF and FVIII will be measured as a safety precaution, and to ensure that these coagulation factors are not released in clinically significant amounts."
64,page_64,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 64 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 7.1.3.3 Copeptin Blood samples for exploratory analysis of copeptin levels in plasma will be collected at Visit 2, Visit 4 and Visit 8. The biomarker copeptin can be easily tested for , and is therefore used as an AVP surrogate to potentially identify low nocturnal vasopressin levels in plasma . In patients with NP, an inverse circadian rhythm of vasopressin is suspected , resulting in low nocturnal concentrations, which may be the root cause of NP. Copeptin may be a useful biomarker to diagnose NP due to low levels of endogenous AVP , thereby identifying the ideal candidate for antidiuretic therapy (Brunell, 2016) and consequently treatment with FE 201836. 7.1.4 Vital Signs Diastolic and systolic blood pressure (mm Hg) and heart rate (beats per minute) will be measured after resting for 5 minutes in a sitting position , according to usual clinical practice at all trial visits . Measurements outside normal ranges will be assessed by the investigator as â€˜abnormal, not clinically significantâ€™ or â€˜abnormal, clinically signific antâ€™. Any abnormal, clinically significant changes should be reported as adverse events. 7.1.5 24-Hour Urine Volume and Nocturnal Urine Volume Data on 24 -hour urine volume, i.e., including NUV, will be obtained from the 3 -day voiding diary (Section 7.1.1.1 ) completed prior to Visits 2, 4, 5 and 8. In addition, NUV data will be obtained from the 3 -day voiding diary completed prior to Visit 3 (Table 7-1). 7.2 Other Assessments 7.2.1 Demographics Demographic data , including date of birth and race , will be collected at screening (Visit 1). 7.2.2 Medical History Information on clinically significant previous a nd concomitant illnesses, signs or findings from assessments and examinations during the screening, including surgical history, will be recorded as medical history at the screening visit (Visit 1). 7.2.3 Concomitant Medication Information on concomitant medicati ons will be collected at each visit throughout the trial , as described in Section 4.3.1 . Concomitant medications are defined as any medication , other than the IMP, taken by the subject at entry and during the trial. Prohibited medications/therapies are listed in Section 4.3.2 . 7.2.4 Body Weight and Height Body weight and height will be measured to calculate the body mass index (BMI). The eCRF will be configured to automatically calculate the BMI . Height (without shoes) will be measured at screening (Visit 1)."
65,page_65,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 65 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Body weight (without overcoat and shoes) will be measured at all visits . The same scale should preferably be used on the subject during the course of the trial for consisten cy in readings. If the subject has gained more than 2 kilograms between trial visits , the serum sodium level must be measured , as described in Section 7.1.3.1 . 7.2.5 Physical Examination Physical examinations will be performed at Visits 1, 4 and 8 by the investigator or a delegated sub-investigator (MD, Medical Doctor; DO, Doctor of Osteopathic Medicine; PA, Physician Assistant; NP, Nurse Practitioner) and must not be delegated to any other trial site personnel. The same individual should preferably perform the physical examinations for a subject for consistency in evaluation. A complete physical examina tion will include , at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, urological and neurological systems . Any abnormal, clinically significant changes should be reported as adverse events. 7.2.6 Pregnancy Test A serum pregnanc y test will be performed in all pre - and peri -menopausal female subjects at screening ( Visit 1), Visit 4 and at the end -of-trial visit (Visit 8). A urine pregnancy test will also be performed at screening (Visit 1). Female s ubjects of childbearing potential must have documentation of an acceptable effective method of contraception , as described in Section 4.3.4 . Amenorrhea of >12 months duration based on the reported date of the last menstrual period is sufficient documentation of post -menopausal status and does not require a pregnancy test. 7.2.7 Electrocardiogram A 12 -lead ECG will be performed by the investigator or appropriate design ee at the screening visit (Visit 1) and at the end -of-trial visit (Visit 8). The ECG should be taken after resting for 5 minutes. The ECG print -out should be reviewed, signed and dated by the investigator. Any abnormal, clinically significant changes shoul d be reported as adverse events. 7.3 Handling of Biological Samples A trial -specific laboratory manual will be provided to the participating sites, describing in detail how to handle, store and transport the biological samples in this trial. All biological sam ples will be analysed at central laboratories and will be destroyed after the results are available . For all biological samples collected in the trial, analyses beyond those described in the protocol can only be performed after obtaining the required appro vals. The processes related to handling biological samples will be described in the informed consent docu ments and data protection legislation including local legislation will be adhered to. In addition to the central laboratory, a local laboratory may be used for analysis of serum sodium if a quick turn -around time of the result is needed (Section 7.1.3.1 )."
66,page_66,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 66 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 8 ADVERSE EVENTS 8.1 Adverse Event Definition An adverse event is any untoward medical occurrence in a subject participating in a clinical trial. It includes: â€¢ Any unfavourable and unintended sign, symptom or disease temporally associated with the use of the IMP, whether or not considered to be caused by the IMP. â€¢ Adverse events commonly observed and adverse events anticipated based on the pharmacological effect of the IMP. â€¢ Any laboratory abnormality, vita l sign or finding from physical examination assessed as clinically significant by the i nvestigator (note: pre-existing conditions diagnosed through assessments and examinations at the screening visit or during the screening period are not adverse events, but are recorded as medical history ). â€¢ Accidental injuries, reasons for any change in medication (drug and/or dose), reasons for any medical, nursing or pharmacy consultation, or reasons for admission to hospital or surgical procedures. â€¢ Overdoses and medication errors with and without clinical consequences. 8.2 Collection and Recording of Adverse Events 8.2.1 Collec tion of Adverse Events The investigator must monitor the condition of the subject throughout the trial from the time of obtaining informed consent until the last visit. The sources of adverse events cover : â€¢ The subjectâ€™s response to questions about his/her health (a standard non -leading question such as â€œHow have you been feeling since your last visit?â€ is asked at each visit). â€¢ Symptoms spontaneously reported by the subject. â€¢ Investigations and examinations where the findings are assessed by the investigator to be clinically significant changes or abnormalities. â€¢ Other information relating to the subjectâ€™s health becoming known to the investigator (e.g. , hospitalisation). 8.2.2 Recording of Adverse Events The investigator must record all adverse events in the Adverse Event Log provide d in each subjectâ€™s eCRF with information about: â€¢ Adverse event â€¢ Date and time of onset (time can be omitted, if applicable) â€¢ Intensity â€¢ Causal relationship to IMP"
67,page_67,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 67 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL â€¢ Action taken to IMP â€¢ Other action taken â€¢ Date and time of outcome (time can be o mitted, if applicable) â€¢ Outcome â€¢ Seriousness. Each of the items in the Adverse Event Log is described in detail in the following sections. Adverse Event Adverse events should be recorded as diagnoses, if available. If not, separate signs and symptoms should be recorded. One diagnosis/symptom should be entered per record. If a subject suffers from the same adverse event more than once and the subject recovers in between the events, the adverse events should be re corded separately. If an adverse event changes i n intensity, a worst -case approach should be used when re cording the event, i.e. the highest intensity and the longest duration of the event.a Note the following: A procedure is not an adverse event; the reason for conducting the procedure is. Hospitalisat ion is not an adverse event; the reason for hospitalisation is. Death is not an adverse event, but the cause of death is (an exception is sudden death of unknown cause, which is an adverse event). Date and Time of Onset The date of onset is the date when t he first sign(s) or symptom(s) were first noted . If the adverse event is an abnormal clinically significant laboratory test or outcome of an examination , the onset date is the date the sample was taken or the examination was performed . Intensity The intensity of an adverse event must be classified using the following 3-point scale: Mild: Awareness of signs or symptoms, but no disruption of usual activity. Moderate: Event sufficient to affect usual activity (disturbing). Severe: Inability to work or pe rform usual activiti es (unacceptable). a Exception: if an adverse event with onset before the first IMP administration (i.e., a pre -treatment adverse event) worsens in intensity, this must be recorded as two separate events. The initial adverse event should be recorded with outcome â€œnot recovered â€ and the date and time of outcome is when the intensity changed. The second adverse event should be recorded with date and time of onset when the intensity changed."
68,page_68,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 68 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Causal Relationship to IMP The possibility of whether the IMP caused the adverse event must be classified as one of the following: Reasonable possibility: There is evidence or argument to suggest a causal relationshi p between the IMP and the adverse event , i.e., it is an ADR . The ADR may occur as part of the pharmacological action of the IMP or may be unpredictable in its occurrence. No reasonable possibility: There is no reasonable evidence or argument to suggest a c ausal relationship between the IMP and the adverse event. Action Taken to IMP The action taken to the IMP in response to an adverse event must be classified as one of the following: â€¢ No change (medication schedule maintained or no action taken) â€¢ Withdrawn â€¢ Interrupted Other Action Taken Adverse events requiring therapy must be treated with recognised standards of medical care to protect the health and well -being of the subject. Appropriate resuscitation equipment and medicines must be available to ensure the best possible treatment of an emergency situation. If medication is administered to treat the adverse event, this medication should be entered in the Concomitant Medication Log . Date and Time of Outcome The date and time the subject recovered or died. Outcome The outcome of an adverse event must be classified as one of the following: â€¢ Recovered (fully recovered or the condition has returned to the level observed at initiation of trial treatment) â€¢ Recovered with sequelae (resulted in persistent or significant disability/incapacity) â€¢ Recover ing (the event is improving) â€¢ Not recovered â€¢ Fatal"
69,page_69,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 69 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 8.3 Adverse Events of Special Interest Hyponatraemia Serum sodium levels will be monitored throughout the trial as hyponatraemia is a well-known ADR associated with desmopressin treatment ( Section 7.1.3.1 ) and may potentially be associated with FE 201836 treatment . Serum sodium levels should be tested in subjects presenting with signs or symptoms of hyponatraemia . Any significant changes in serum sodium, judged by the investigator as clinically significant must be reported as adverse events , as described in Section 8.2. All cases of serum sodium values â‰¤125 mmol/L are considered important medical events and must be reported as SAEs , as described in Section 8.5.2 . 8.4 Pregnancy and Pregnancy Outcome If a pregnancy occurs, the IMP should be immediately stopped for the pregnant subject and Global Pharmacovigilance at Ferring Pharmaceuticals A/S must be informed. The pregnancy should be reported via the pregnancy Report Form included in the eCRF system. In case the eCRF cannot be accessed and hence the Pregnancy Report Form cannot be fill ed in within the eCRF system, a paper Pregnancy Report Form available in the investigatorâ€™s file should be used and sent to Ferring Global Pharmacovigilance. Contact details to Ferring Global Pharmacovigilance are provided in Section 8.5.2 . A pregnant participant or the partner of a male participant should be followed until termination or until term to ensure absence of congenital anomaly or birth de fect that may have resulted from maternal exposure or transmission of the study drug via semen following paternal exposure. The pregnancy should be followed -up at least until the birth of the infant and 4 -6 weeks after the birth of the infant. In general, the follow -up will include the course; duration and the outcome of the pregna ncy as well as neonatal health. If a pregnancy results in an abnormal outcome (birth defect/congenital anomaly) this must be reported as a n SAE to Global Pharmacovigilance at Ferr ing Pharmaceuticals A/S."
70,page_70,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 70 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 8.5 Serious Adverse Events 8.5.1 Serious Adverse Event Definition Table 8-1 Serious Adverse Events during the Trial An event is defined a serious adverse event if it: Guidance results in death Any event resulting in a fatal outcome must be fully documented and reported, including deaths occurring within 4 weeks after the treatment ends and irrespective of the causal relationship to the IMP. The death of a subject enrolled in a trial is per se not an event, but an outcome. is life-threatening The term life -threatening refers to an adverse event in which the subject was at immediate risk of death at the time of the event. It does not refer to an event, which may have caused death if it were more severe. requires in -patient hospitalisation or prolongation of existing hospitalisation The term hosp italisation means that the subject was admitted to hospital or that existing hospitalisation was extended as a result of an event. Hospitalisation describes a period of at least 24 hours. Over -night stay for observation, stay at emergency room or treatment on an out -patient basis do not constitute a hospitalisation. However, medical judgement must always be exercised and when in doubt the case should be considered serious (i.e., if case fulfils the criterion for a medically important event). Hospitalisation s for administrative or social purposes do not constitute an SAE. Hospital admissions and/or surgical operations planned before trial inclusion are not considered adverse events, if the illness or disease existed before the subject was enrolled in the tria l, provided that the condition did not deteriorate during the trial. results in persistent or significant disability/incapacity Disability/incapacity means a substantial disruption of a personâ€™s ability to conduct normal life functions. In doubt, the deci sion should be left to medical judgement by the investigator. is a congenital anomaly/birth defect Congenital anomaly/birth defect observed in any offspring of the subject conceived during treatment with the IMP. is an important medical event Important m edical events are events that may not be immediately life -threatening or result in death or hospitalisation but may jeopardise the subject or may require intervention to prevent one of the other outcomes listed in the definition above. Examples of imp ortan t medical events include adverse event s that suggest a significant hazard, contraindication or precaution, occurrence of malignancy or development of drug dependency or drug abuse. Medical and scientific judgement should be exercised in deciding whether ev ents qualify as medically important . Important medical events include any suspected transmission of an infectious agent via a medicinal product. Any organism virus or infectious particle (e.g., prion protein transmitting Transmissible Spongiform Encephalop athy), pathogenic or non - pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings indicating an infection in a subject exposed to a medicinal product."
71,page_71,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 71 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 8.5.2 Collection, Recording and Reporting of Serious Adverse Events SAE Reporting by the Investigator An SAE must be reported immediately to Ferring Global Pharmacovigilance as soon as it becomes known to the investigator and not later than within 24 hours of their knowle dge of the occurrence of an SAE. The investigator is responsible for submitting the completed SAE Report Form with the fullest possible details within 3 calendar days of his/her knowledge of the SAE. The SAE Report Form is included in the eCRF system and mus t be completed . In case the eCRF cannot be accessed and hence the SAE Report Form cannot be filled in within the eCRF system, a paper SAE Report Form available in the investigatorâ€™s file should be used and sent to Ferring Global Pharmacovigilance using the contact details below: Global Pharmacovigilan ce, Ferring Pharmaceuticals A/S E-mail: Fax: eCRF information regarding demographics, a dverse events, medical history and concomitant medication is mandatory for initial reports and for follow -up reports if any changes have been made since the initial report. Additional information relevant to the SAE such as hospital records, results from investigations, e.g. laboratory parameters (that are not already uploaded in the eCRF), invasive procedures, scans and x -rays and autopsy results can be faxed or scanned and e -mailed to Ferring Global Pharmacovigilance using the contact details in the section above. In any case this information must be supplied by the investigator upon r equest from the sponsor . On any copies provided, such details such as subjectâ€™s name, address and hospital ID number should be concealed and instead subject number should be provided. The investigator will supply the sponsor and the IEC/IRB/REB with any additional requested information such as results of post -mortem examinations and hospital records. Expedited Reporting by the Sponsor The sponsor will report all adverse events that are serious, unexpected and with a reasonable possible causality to the IMP (referred to as suspected unexpected serious adverse reactions [SUSARs]) as judged by either the investigator or the sponsor to the relevant parties (i.e., investigators, IECs/IRBs/REBs and regulatory authorities) within the stipulated timeline s. The expectedness is assessed by the sponsor according to the current Investigato râ€™s Brochure for FE 201836. Unblinded SAEs will be assessed using the current relevant reference safety information, which for FE 201836 is in the Investigatorâ€™s Brochure an d for desmopressin in the Decentralised Procedure NOCDURNA Summary of Product Characteristics . SAEs will be considered reportable regardless of whether or not the IMP was used in accordance with the provisions in the protocol and the applicable reference safety information document ."
72,page_72,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 72 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 8.6 Follow -up of Adverse Events and Serious Adverse Events 8.6.1 Follow -up of Adverse Events with Onset during the Trial During the trial, the investigator must follow -up on each adverse event until it is resolved or until the medical condition of the subject is stable. After the subjectâ€™s last visit, the investigator must follow -up on any adverse event classified as serious or considered to have a reasonable possible causality to the IMP until it is resolved or unt il the medical condition of the subject is stable. All such relevant follow -up information must be reported to the sponsor . If the event is a chronic condition , the investigator and the sponsor may agree that further follow -up is not required. 8.6.2 Collection o f Serious Adverse Events with Onset after Last Visit in the Trial If an investigator becomes aware of a n SAE after the subjectâ€™s last visit and he/she assesses the SAE to have a reasonable possible causality to the IMP , the case will have to be reported to the sponsor via the paper SAE Report Form , regardless how long after the end of the trial this takes place."
73,page_73,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 73 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 9 STATISTICAL METHODS The Global Biometrics Department at Ferring Pharmaceuticals A/S will be responsible for data management, the Statistical Analysis P lan (SAP) and the statistical analyses, production of tables, listings and figures. This section outlines the planned statistical analysis of the primary endpoint and the planned statistical analyse s for the secondary endpoints. All analyses and further description of the statistical methodology for primary as well as secondary endpoints will be detailed in the SAP . The SAP will be available before the first interim analysis. The analysis concerning the psychometric validation of the NI Diary is p rovided in a separate PAP. 9.1 Operating Characteristics The operating characteristics and associated power are estimated for different dose -response scenarios by computer simulations using the Fixed and Adaptive Clinical Tria l Simulator (FACTS) version 5.6. The five sigmoidal dose-response profiles that were used to simulate trial data are illustrated in Figure 9-1. Further details on the dose -response model an d the associated primary analy sis are given in Section 9.7.2 and Appendix 2 . Figure 9-1 Dose -Response S cenarios"
74,page_74,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 74 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL The longitudinal data profile used in the simulations is based on pooled data from desmopressin clinical trials FE 992026 CS40 and FE 992026 CS41 (planned treatment group ). The following estimates and assumptions were used : â€¢ Dose -response standard deviation ğœ= 0.95 voids â€¢ A between to total variance (Ïƒ2) ratio of 0.90 and a true underlying Ïƒ of 0.95 â€¢ Response fractions of 0.8142, 0.9328 and 0.9874 at Weeks 1, 4 and 8, respectively , as compared to the averaged dose -response at Week 12 â€¢ Varian ce fractions of 0.8481, 0.8329 and 0.8900 at Weeks 1, 4 and 8, respectively, as compared to the averaged dose -respo nse at Week 12 Further design specifications were: â€¢ During the initial 17 weeks the recruitment rate will increase linearly from 0 to 8.2 subjects per week â€¢ After 17 weeks, when all trial sites have been initiated, the recruitment rate is assumed to remain c onstant at 8.2 subjects per week â€¢ Constant dropout rate of 15% during the randomised treatment period â€¢ First interim analysis when 125 subjects are randomised , thereafter interim analyses every 8 weeks â€¢ Up to the first interim analysis the allocation ratio is 2:2:1 for placebo, 500 Âµg FE 201836 and desmopressin â€¢ After the first interim analysis the allocation ratios are 2:7 :1, for placebo, 50 -500 Âµg FE 201836 and desmopressin o Subjects randomised to FE 201836 will be dynamically allotted to 50 Âµg FE 201836, 100 Âµg FE 201836, 150 Âµg FE 201836, 250 Âµg FE 201836, 350 Âµg FE 201836 or 500 Âµg FE 201836 using response -adaptive allocation as outlined in Section 9.11. â€¢ Maximum of 300 randomised subjects These settings were shared for all treatment groups . The average number of subject s and probabilities for futility and success are presented in Table 9-1."
75,page_75,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 75 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Table 9-1 Operati ng Characteristics Dose -Response Scenario Maximum response (ğ›¼2) ED 50 (ğ›¼3) Average Number of Subjects Futility Stopping at First Interim Total Futility stopping Power (Total Success) Null 0 0 Âµg 200 75.8% 97.0% 3.0% I -0.3 150 Âµg 277 15.7% 47.9% 52.1% II -0.4 200 Âµg 288 7.9% 25.1% 74.9% III -0.5 200 Âµg 296 2.8% 9.6% 90.4% IV -0.5 350 Âµg 295 3.4% 15.4% 84.6% V -0.6 300 Âµg 298 1.4% 2.7% 97.3% For each dose -response scenario, 1 ,000 trials were simulated in order to estimate the operating characteristics presented in Table 9-1. The simulations under the null -hypothesis (no effect) demonstrate t hat assuming a maximum reduction versus placebo of 0.5 voids , the power (probability of success) reaches approximately 85 to 90%, while the probability of making a false positive conclusion is 3.0%. 9.2 Protocol Deviations Protocol deviations will be rated as either minor or major. Protocol deviations deemed to impact the primary endpoint and possibly affect the conclusions of the trial will be rated as major. Major protocol deviations will lead to exclusion of data from the Per Protocol (PP) analysis set (Section 9.3.5 ). Data up to the point where the violation occurs wi ll be used in the evaluations. Major protocol deviations include, but are no t restricted to, the following: â€¢ <2 nocturnal voids (average over 3 diaries) prior to Visit 2 or Visit 4 â€¢ NPi â‰¤33% prior to Visit 2 â€¢ <20% decrease in nocturnal diuresis rate (mL/min) from during active run -in (Visit 2 to Visit 3) â€¢ Maximum voided volume <2 00 mL prior to Visit 2 â€¢ Actual treatment not in accordance with randomised treatment â€¢ Significant non -compliant treatment administration and e-Diary completion Serious unforeseen deviations deemed to impact the primary endpoint of the trial may additionally be rated as major protocol deviations by the sponsor on the basis of a blinded review of data befor e declaration of clean -file and lock of database. The list of major protocol deviations will be detailed and documented in the clean file document prior to database release to the trial statistician ."
76,page_76,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 76 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 9.3 Analysis Sets 9.3.1 Intention -to-Treat Analysis Set for the En richment (ITT -ENR) Period The I ntention -to-Treat analysis set for the e nrichment period (ITT-ENR) will be comprised of all subjects found to be eligible to enter the enrichment p eriod (1 week active run -in and 1 week washout) at Visit 2. All analyse s will be conducted with respect to the planned treatment allocation. 9.3.2 Safety Analysis Set for the Enrichment P eriod The safety analysis set for the enrichment period wil l be comprised of a ll subjects who received at least one dose of IMP after Visit 2 i.e., during the 1 week active run -in and 1 week washout . The safety analysis set also includes any subject who was found not eligible at Visit 2, but who had at least one administration of IMP after Visit 2. All analyse s will be with respect to actual treatm ent received . 9.3.3 Intention -to-Treat (ITT) Analysis Set for the Randomised Treatment Period The Intention -to-Treat (ITT) analysis set for the randomised treatment period will be comprised of all subjects randomised at Visit 4. All analyse s will be conducted with respect to the planned treatment allocation . 9.3.4 Full Analysis Set (FAS) The Full Analysis Set (FAS) will be comprised of all subjects in the ITT analysis set with at least one post -baseline record of the number of nocturnal voids (pr imary endpoint). All analyses will be conducted with respect to the planned treatment allocation. 9.3.5 Per Protocol (PP) Analysis Set The PP analysis set will be defined as all subjects included in the FAS except those for whom all data are excluded as a result of major protocol deviations as described in Section 9.2. 9.3.6 Safety Analysis Set for the Randomised Treatment Period The safety analysis set for the randomised treatment period will be comprised of a ll subjects who have received at least one dose of IMP (placebo, FE 201836, or desmopressin) and have had at lea st one safety assessment after r andomi sation (Visit 4). This also includes any subject who wa s found not eligible at Visit 4, but who had at least one dose of IMP after Visit 4. All analysis will be conducted with respect to the actual treatment received . 9.4 Subject Disposition Subject disposition with respect to the number of subject s screened, ITT -ENR and ITT analysis sets (Section 9.3.1 and 9.3.3 ) will be tabulated by treatment group for all subjects. Reasons for not being randomised at Visit 4 will be categoris ed and summarised for the ITT -ENR analysis se t. Subject disposition, with respect to the number of subjects in the safety analysis sets ( Section 9.3.2 and 9.3.6 ), will be presented separate ly."
77,page_77,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 77 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 1-Kaplan â€“Meier (1 -KM) plots of time to early discontinuation per treatment group will be displayed for the ITT analysis set and the treatment group difference will be tested using the Log-Rank test . In addition, time to early discontinuation by reason for discontinuation and treatment group will be presented using cumulative incidence functions. All premature discontinuations will be s ummarised and listed by time of and reason for, discontinuation. Presentations of subject d ispositions will be produced for the overall trial population and by gender. 9.5 Enrichment P eriod Assessments and Analysis Sets Descriptive statistics for demographics and other pre -baseline characteristics (e.g. , number of nocturnal voids, NPi, serum sodium levels, etc.) obtained at Visit 2 (latest) will be summarised for the ITT -ENR and the safety analysis set defined for the enrichment p eriod . Continuous variables will be presented with number of subjects, mean, standard deviation, median, minimum and maximum. Categorical variables will be presented with number and percentage of subjects within each specific category. Treatment compliance, efficacy and s afety pertaining to the enrichment p eriod (Visits 2 through 4) will be summarised by visit for the ITT -ENR and Safety Analysis Set (as defined for the Enrichment p eriod ). Tables will be produced for the overall trial population and by gender. Analyses of hyponatraemia during the enrichment p eriod are further described in Section 9.10.3 . 9.6 Trial Population Descriptive statistics for demographics and other baseline characteristics obtained at Visit 4 (latest) will be summaris ed for the ITT and safety analysis s et as outlined above. All data will be listed per subject for the ITT analysis set. Gender specific tabulations will be provided. 9.6.1 Medical Histor y, Concomitant Medication and Other Safety Evaluations Medical history will be coded using Medical Dictionary for Regulatory Activities (MedDRA ). The version of MedDRA will be documented. Medical history will be listed by subject and summarised by System Organ Class (SOC) and preferred term. Prior and concomitant medication will be summarised by Anatomical Therapeutic Chemical Classification Syste m (ATC) classification first level (alphabetically), ATC classification second level (in decreasing order of frequency) and treatment group. 9.7 Endpoint Assessments 9.7.1 General Considerations Unless stated otherwise the efficacy analysis will be presented for th e ITT analysis set. Continuous variables will be presented with number of subjects, mean, standard deviation, median, inter-quartile range, minimum and maximum. Categorical variables will be presented with number and percentage of subjects within each spe cific category."
78,page_78,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 78 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL For endpoints obtained in the e -Diary prior to a visit, the 3-day e-Diary data will be averaged and interpreted as the observation of the endpoint in question. If nothing else is stated the Bayesian dose -response analyses are conducted with respect to the time - averaged treatment effect. The posterior means estimates, 95% credib ility interval of the estimates and posterior probabilities of quantities of interest will be reported. Frequentist inferences will rely on the appropriate choice of model and report p-values corresponding to the statistical test of the hypothesis of â€œequal effectâ€ against the alternative of â€œdifferent effectâ€. The level of significance is set at 5% (two -sided). Treatment comparison refers to the pair -wise comparison between active doses and placebo. There are no planned adjustments for multiplicity when pair -wise testing any active dose of FE 201836 versus placebo. Desmopressin is included as a benchmark treatment only. None of the primary, secondary or explorative an alyses will include desmopressin . Explorative benchmarking analyses are furher described in Section 9.8. 9.7.2 Primary Analysi s The o bjectives of the primary analysi s are to establish Proof -of-Concept of FE 201836 and to estimate the dose -response profile of FE 201836. The dose -response is the averag e reduction from baseline in nocturnal voids during the randomised period . Proof -of-concept will be evaluated by the posterior probability that FE 201836 has superior efficacy as compared to placebo. Similarly, interim analysis futility criteria will be ev aluated by pre -defined quantities of interest. This section provides a brief background on the statistical Bayesian model that is utili sed. 9.7.2.1 Statistical Dose -Response Model Let ğ‘¥ğ‘¡,ğ‘– denote the observed cross -sectional change from baseline in nocturnal voids (averaged across three consecutive nights) and let ğ‘¦ğ‘¡,ğ‘– denote the time -averaged change from baseline for subject ğ‘– up to time ğ‘¡: ğ‘¦ğ‘¡,ğ‘–=âˆ‘ ğ‘¥ğ‘˜,ğ‘– ğ‘¡ ğ‘˜=1 ğ‘¡, ğ‘¡=1,2,3,4, where ğ‘¡ denotes the nominal post -baseline time -point reflecting data observed at Weeks 1, 4, 8 and 12 (Visits 5, 6, 7 and 8, respectively). The final endpoint, ğ‘¦4,ğ‘–, is modelled as being an observation of ğ‘Œ4,ğ‘–~ğ‘(ğœ‡ğ‘‘,ğ‘–,ğœ2) where the dose -response at dose ğ‘‘ for subject ğ‘– is adjusted for the number of baseline voids ( ğ‘¥0,ğ‘–) and assumed to follow a sigmoidal model: ğœ‡ğ‘‘,ğ‘–=ğ›½ğ‘¥0,ğ‘–+ğ›¼1+(ğ›¼2âˆ’ğ›¼1)ğ‘‘ğ›¼4 ğ‘‘ğ›¼4+ğ›¼3ğ‘4=ğ›½ğ‘¥0,ğ‘–+ğœ‡ğ‘‘,"
79,page_79,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 79 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL and ğœ2 represents the (total error) variance of the dose -response . The interpretation of the parameters are: ğ›¼1 is the placebo response; ğ›¼2 is the maximum response; ğ›¼3 is the dose (ED 50) at which 50% of the maximum effect is obtained; ğ›¼4 is the slope parameter. The longitudinal aspect of the average change from baseline is captured by the following model : ğ‘Œğ‘¡,ğ‘–~ğ‘(ğ‘’ğ›¾ğ‘¡(ğœ‡ğ‘‘,ğ‘–+ğ›¿ğ‘–),ğœ†ğ‘¡2), where the per -subject offset from the mean dose -response is ğ›¿ğ‘–~ğ‘(0,ğœ2) and ğœ†ğ‘¡2 represents the within subject variance . The model is constrained such that ğ›¼4=0 and the intermediate values of ğ‘¦. can thus be thought of as being fractions of final value. Missing data (missing due to drop -out or final visit has not occurred yet) will be imputed using the longitudinal model, assuming missing at random. This implies that als o data from subjects who have not yet been observed at Week 12 are used in the primary efficacy analysis, as described in Appendix 2 . All parameters i n the models are given sufficiently non -informative prior distributions as specified in Appendix 2 . By application of Bayesâ€™ theorem and Markov chain Monte Carlo sampling techniques the posterior probabilities (or the quantities of interest) given in Table 9-2 can be estimated. Table 9-2 Quantities of Interest Quantity of Interest Probability Within the Trial That: Objective Pr(ğœ‡ğ‘€ğ´ğ‘‹ <ğœ‡ğ‘ƒğ‘™ğ‘) the dose with the maximum effect (i.e. the dose that is most likely to have the maximum effect) is superior to placebo Proof -of-Concept Pr(ğœ‡ğ‘€ğ´ğ‘‹ âˆ’ğœ‡ğ‘ƒğ‘™ğ‘<âˆ’0.3) the dose with the maximum effect (i.e. the dose that is most likely to have the maximum effect) has >0.3 voids reduction in nocturnal voids as compared to placebo Futility Pr(dose d is MED) dose d is the minimum dose that has >0.3 voids reduction in nocturnal voids as compared to placebo Establish the MED Pr (dose ğ‘‘ is ğ¸ğ· 85) dose d is the minimum dose that has > 85% of the treatment effect of the maximum effective dose Establish ED 85"
80,page_80,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 80 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL The final two quantit ies are also used to characteris e the dose -response curve (as they are calculated for each dose d) and to assign weights for the adaptive dose allocation. 9.7.2.2 Overall Trial Outcome The overall trial outcome will be presented in terms of the quantities of intere st in Table 9-3. Tabulated are also their criteria against which the overall trial success will be judged. Table 9-3 Overall Trial Criteria Quantity of Interest Criteria At the First Interim Analysis At Intermediate Interim Analyses At the Final Analysis Futility Pr(ğœ‡ğ‘€ğ´ğ‘‹ âˆ’ğœ‡ğ‘ƒğ‘™ğ‘<âˆ’0.3) <10% <5% Success Pr(ğœ‡ğ‘€ğ´ğ‘‹ <ğœ‡ğ‘ƒğ‘™ğ‘) >97.5% 9.7.2.3 Dose -Response The dose -response will be characterised by the posterior estimates of the mean dose -response at each dose, ğœ‡ğ‘‘ and the mean dose -response contrast versus placebo, their associated 95% credibility intervals and the posterior probability Pr(ğœ‡ğ‘‘<ğœ‡ğ‘ƒğ‘™ğ‘) will be tabulated. A ssociated with these, the following (posterior) probabilities will also be tabulated: Pr(ğœ‡ğ‘‘âˆ’ğœ‡ğ‘ƒğ‘™ğ‘<âˆ’0.3), Pr(dose ğ‘‘ is MED ), Pr (dose ğ‘‘ is ğ¸ğ· 85) and Pr (dose d achieves ğœ‡ğ‘€ğ´ğ‘‹ ). The mean dose -response will also be presented gr aphically with its 95% c redible interval. 9.7.2.4 Sensitivity Analyse s The following sensitivity analyses will be conducted: â€¢ The primary analys is will be carried out using the PP analysis sets. â€¢ A completer analysis will be run testing the sensitivity of the imputation method applied in the primary analysis. â€¢ The primary analys is using different priors specified in the SAP. â€¢ Repeated measures Analysis of Covariance (ANCOVA ) using a Missing Not At Random (MNAR) placebo -based pattern mixture model (Ratitch, 2011). 9.7.2.5 Descriptive Analysis The raw average and raw average change from baseline at each dose will be tabulated together with 95% confidence intervals. No imputations will be done for this analysis which will be based on the obser ved cases only."
81,page_81,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 81 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 9.7.3 Secondary and Explorative Analyses The following m ain categories of inferential analyse s will be performed for the secondary endpoints: â€¢ Bayesian estimation of the Sigmoidal dose -response curve will follow the analysis described in Section 9.7.2.3 . Prior distributions for primary analysis are specified in Appendix 2 , while prior distributions for secondary analyses will be specified in the SAP. The dose -response model for the 50% responder rates will also be further detailed in the SAP. â€¢ Continuous treatment effect s at a certain visit will be analysed using SAS PROC MIXED assuming a repeated measures ANCOVA. (A non -parametric dose -response curve is assumed.) The changes from baseline per visit will be regressed upon the baseline observation as covariate and treatment, vi sit and treatment -by-visit interaction as factors. An unstructured covariance structure will be used for the random subject effect. Least square mean estimates of the changes from baseline and the treatment contrasts (with associated 95% confidence interva ls) versus placebo will be tabulated and the changes from baseline will be graphically illustrated. Should only one post -baseline visit be obtained for an endpoint , an ANCOVA will be performed without the visit and treatment -by-visit interaction terms . â€¢ Correlation between endpoints will be reported using Pearson correlation coefficients and partial correlation where applicable. â€¢ Binary endpoints such as â€œresponder status â€ at a certain visit will be analysed using SAS PROC GENMOD with the logit as link functi on for the responder probability. An unstructured covariance matrix will be assumed for the repeated responder status which will be adjusted for baseline value as covariate and treatment, visit and treatment -by-visit interaction as factors. (Associated wit h e.g. , responder analysis in terms of reduction in number of voids, cumulative distritubtion function plots of percentage change from baseline by treatment may be produced.) Table 9-4 presents the planned analys es. Illustration of the therapeutic window is described separately in Section 9.7.3.1 and safety related endpoints are further described in Section 9.10. Explorati ve gender analyses are planned for all endpoints . For these the following are noted: â€¢ Estimates of the gender specific dose -response during 12 weeks of treatment will follow the analysis described in Section 9.7.2.3 by conducting separate analysis for each gender. Possible differences between the gender specific models will be investigated. â€¢ Regression models will include gender and gender -by-treatment as factors. (Possible differences between the treatment effects on gender will be evaluated by the interaction term gender -by-treatment.) Correlation analyses will be done separately for each gender."
82,page_82,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 82 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Table 9-4 Analysis of Endpoints Efficacy Endpoint Analysis category Bayesian Estimation of Dose - response Curve Repeated measures ANCOVA Correlation Analysis Repeated logistic regression (Generalized Estimating Equation [GEE]) ANCOVA Change from baseline in number of nocturnal voids a Primary Secondary e Responder rate defined as 50% reduction in nocturnal voids from baseline a Secondary Secondary Change from baseline in NI Diary Total Score a Secondary Secondary Percentage of nights during treatment period with at most one nocturnal void i Secondary Percentage of nights during treatment period with complete response i Secondary Change from baseline in NI Diary Overall Impact Score a Secondary Secondary PGI-I urinary symptoms score a,b Secondary Change from baseline in PGI -S score a Secondary Change from baseline in Bother as measured by the Hsu 5-point Likert Bother Scale a Secondary Change from baseline in ISI f Secondary Change from baseline in FUSP a Secondary Secondary Explorative h Change from baseline in nocturnal diuresis rate (hourly) c Secondary Change from baseline in NUV c Secondary Secondary Responder rates defined as 33%, 60%, 70%, 80%, 90% and 100% reduction from baseline in number of nocturnal voids a Explorative Responder rates defined as 1, 2, and 3 voids reduction from baseline in number of nocturnal voids a Explorative Copeptin levels at Visit 2 Explorative g Change from baseline in copeptin levels d Explorative Change from baseline in total sleep time per night a Explorative Change from baseline in NPi c Explorative Safety Endpoints Change from baseline in mean 24 -hour urine volume c Safety Incidence and severity of Adverse Events Section 9.10.2 Adverse Event of Special Interest: Hyponatraemia Episodes Section 9.10.3 Clinic ally significant changes in vital signs and laboratory values Sections 9.10.1 and 9.10.4 a. Endpoint assessed at Weeks 1, 4, 8 and 12 weeks of treatment. b. This questionnaire is retrospective and raw scores will be used in the analysis (not changes f rom baseline) and the ANCOVA model will not be adjusted f or baseline value. c. Endpoint assessed at Week 1 and 12 weeks of treatment. d. Endpoint assessed at 12 weeks of treatment. e. Sensitivity analysis placebo pattern -mixture models. f. Endpoint assessed at Week 4, 8 and 12. g. Correlation with NPi at Visit 2. h. Correlation between changes in FUSP and total sleep time at Visits 1, 4, 8 and 12. i. Endpoints are derived using all diary data collected during the treatment period ."
83,page_83,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 83 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 9.7.3.1 Therapeutic Window The estimated dose -response curve (left -sided y -axis) will be illustrated together with the (3 month) incidences of serum sodium <130 mmol/L and â‰¤125 mmol/L (both on right -sided y -axis). The horizontal x -axis will represent the dose range of FE201836. The therapeutic window is defined as the dose range where FE 20183 6 is deemed efficacio us while the incidence of hyponatraemia is acceptable. Corresponding efficacy and safety of desmopressin will be illustrated in a side panel for comparison. Two illustrations will be made, one using the ITT and one using the Safety Ana lysis Set. The gender -specific therapeutic windows will also be illustrated similarly. The therapeutic window of nocturnal volume will be presented similarly. 9.8 Explorative Benchmarking Analysis The explorative benchmarking analysis will descriptively summa rise the changes from baseline and percentage changes from baseline in number of nocturnal voids by all treatment groups, including desmopressin. Tables and figures will be produced as appropriate. This analysis will also be repeated by gender 9.9 Extent of Ex posure and Treatment Compliance Treatment compliance will be summarised by treatment group and visit period for the ITT and safety a nalysis set. 9.10 Safety 9.10.1 General Considerations Safety analyses with respect to the enrichment period will be based on the Safety Analysis Set defined for the enrichment period , while analysis with respect to the randomised period will be performed using the safety analysis s et. Safety will be assessed by analysis of adverse events, vital signs, clinical chemistry, haematology, urinalysis and physical examination. Missing values will be treated as missing, except for causality, intensity, seriousness and outcome of adverse events. A worst -case approach will be used: if causality is missing, the adverse eve nt will be regarded as related to the IMP; if the intensity of an adverse event is missing, the adverse event will be regarded as severe; if seriousness is missing the adverse event will be regarded as serious; if onset date is missing it will be assumed t o be the first day of dosing; if outcome is missing and no date of outcome is present the outcome is regarded as â€˜ongoing â€™. Data will be presented in summary tables and listings. Categorical data will be summarised by treatment group using the number and p ercentage of subjects in each category. For calculation of percentages, the denominator will be the total number of subjects in the respective treatment group"
84,page_84,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 84 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL in the safety analysis set. Continuous data will be summarised by treatment group using number of subjects, mean, standard deviation, median, minimum and maximum. All individual subject data will be listed per subject and treatment as observed including any derived values. 9.10.2 Adverse Events Adverse events will be summarised overall and tabulated by SOC a nd preferred term using MedDRA. The version of MedDRA will be documented. The total number of subjects reporting an adverse event , the percentage of subjects (%) with an adverse event and the number of events reported will be presented. Tables will be prep ared for the enrichment period and randomised treatment period as outlined in Table 9-5. Table 9-5 Tabulations of Adverse E vents E nrichment Period Enrichment period -emergent Adverse Event s (Safety Analysis Set Defined for the Enrichment Period ) Randomised Period Treatment -emergent Adverse Events (Safety Analysis Data Set) Gender -Specific Tabulations Overview of Adverse Events X X Both Adverse Events by causality (related/unrelated) X X X Adverse Events leading to death X X Both Adverse Events by intensity X X SAEs X X Both Adverse Events leading to discontinuation X X Both Adverse Events with an incidence of at least 5% in any treatment group X X Non-serious Adverse Events with an incidence of at least 5% in any treatment group X X 9.10.3 Adverse Events of Special Interest: Hyponatraemia Episodes Observed serum sodium levels and the change from baseline will be tabulated by (planned) visit and treatment group. Similar tables wi ll be produced for both trial period s (enrichment and randomised) . The pre valence of worst -case hyponatraemic episodes, as defined in Table 9-6 will be presented by treatment group and visit for the randomised treatment period. During the enrichment period (active run -in and washout) hyponatraemic episodes will be presented in the same ranges, but here the definition requires only one observatio n below the upper limit (â‰¥135 mmol/L) to yield a hyponatraemic episode."
85,page_85,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 85 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Table 9-6 Definition of Hyponatraemic Episodes by Serum Sodium Range during the Randomised Treatment Period Serum Sodium Range (mmol/L) Number of Serum Sodium Observations â‰¥135 Not applicable (normal serum sodium level) â‰¥130 to <135 3 Consecutive Observations a >125 to <130 2 Consecutive Observations a â‰¤125 1 Observation a Below upper threshold All subjects with a serum sodium value <130 mmol/L will be listed by treatment group , including all serum sodium assessments by time -point and including respective demographic al data. Prese ntations will be done for the overall trial population and by gender. 9.10.3.1 Hyponatr aemia during the Randomi sed Treatment Period These analyses are restricted to the Safety Analysis Set only. The incidence of the post-baseline worst -case hyponataemia episode for each subject will be summaris ed as described in Table 9-6. Graphs will plot the serum sodium levels by treatment group and the profiles of the subject s who at any time (Visit 1 and onwards) ha ve a serum sodium level <135 mmol/L will be highlighted. Kaplan -Meier plots of time from randomi sation (Visit 4) to hyponatraemic serum sodium levels (<135, <130 and â‰¤ 125 mmol/L ) per treatment group will be produced. For the thresholds <135 and <130 mmol/L at least 3 and 2 consecutive observations, respectively, have to be below the threshold to yield a hyponatraemic event (Table 9-6). For both cases the time is from randomisation until first observation bel ow the respective limit that counts. The associated relative hazards of treatment and gender will be analysed using Cox proportional hazards model adjusting for baseline serum sodium and age (<65, â‰¥65 years ). Possible heterogeneity between the genders in the relative treatment hazards will be explored by the inclusion of a treatment -by-gender interaction term. 9.10.4 Safety Laboratory Variables Laboratory test results and their change from baseline to end -of-trial will be summarised by treatment group for the Saf ety Analysis Set . The number and percent of subjects with clinically significant laboratory abnormalities will be presented. Shift tables f rom baseline to end -of-trial visit (categoris ed as low, normal and high) will be presented by treatment group. 9.11 Interi m Analyses Two kind s of interim analyse s are planned in the trial. One is safety -oriented and concerns the monitoring of the serum sodium levels observed during the active run -in period . As described in"
86,page_86,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 86 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Section 3.4, a DMC will be established for the trial and make recommendations based on review of safety data , e.g., increase d rates of clinically significant serums sodium levels observed during the active run -in period , as described in Section 9.11.1 . The second kind concerns the pre -planned efficacy analyse s upon which the trial may be stopp ed due to fu tility, or alloc ation probabilities to FE201836 doses may be adjusted based on estimated dose -response curve , as described in Section 9.11.2 . 9.11.1 Serum Sodium Monitoring during the Active Run -In Period The risk of subjec ts developing hyponatraemia will be mitigated by a serum sodium monitoring plan (Section 7.1.3.1 ), including a 1 -week active run -in period to identify subjects at increased risk for developing acute hyponatraemia prior to randomisation. If the incidence of serum sodium levels <130 mmol/L is statistically significantly >10% during the active run -in, the DMC (Section 3.4) will be notified and further action will be discussed, e.g., the DMC may recommend that the highest dose of FE 201836 ma y be replaced by a lower dose. The number of cases of serum sodium lev els <130 mmol/L resulting in an estimated rate that is statistically significantly >10% depends on the number of subjects who have completed the active run-in, examples are presented in Table 9-7. Table 9-7 Examples of Incidence Rates that are Statistically Significantly >10% Number of S ubjects who have C ompleted 1 -week Active -run in Number of Cases Observed with Serum Sodium levels <130 mmol/L E stimate of Incidence Rate Lower Limit of 95% Confidence Interval 10 4 40% 12.2% 20 6 30% 11.9% 50 10 20% 10.0% 100 17 17% 10.2% 200 30 15% 10.4% Thus, t he present trial has been designed with the option to decrease the maximal dose of FE 201836 from 500 Âµg to 350 Âµg if recommended by the DMC. If this decision is made, randomisation to the 500 Âµg FE 201836 treatment group will be closed, the trial will continue with 350 Âµg FE 201836 as the highest dose fo r the active run -in and the highest dose of FE 201836 that any subject can be randomised to. In the case where subjects have already been randomised to 500 Âµg FE 201836 and have not completed the trial the DMC will recommend whether or not, these subjects may be permitted to remain on 500 Âµg FE 201836 treatment for the remainder of the trial. If the decision to close randomisation to 500 Âµg FE 201836 occurs p rior to the first interim analysis (when the first 125 subjects are randomised) the remaining subjec ts will be randomised to the following treatment groups: placebo, desmopressin (25 Âµg for females and 50 Âµg for males) or 350 Âµg FE 201836. After the interim analysis subjects may be randomised to one of 7 treatment groups: placebo, 50 Âµg FE 201836, 100 Âµg FE 201836, 150 Âµg FE 201836, 250 Âµg FE 201836, 350 Âµg FE 201836, or desmopressin (25 Âµg for females and 50 Âµg for males)."
87,page_87,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 87 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL The dose -response model will be fitted across all doses, i.e., 0 -500 Âµg, but inference will be made only on the doses that remain op en to randomisation e.g., 0 -350 Âµg. That is, the MED and ED 85 doses and the inferences with regards to proof -of-concept and futility will be limited to the dose range (i.e., with a maximum dose of 350 Âµg FE 201836). 9.11.2 Interim Efficacy Analyses The planned interim analys es will be conducted by an internal DMC (Section 3.4) according to a separate DMC charte r, which will be established before the first interim analysis . The interim analyses will use unblinded efficacy data to infer whet her to stop early for futility or to continue the trial as planned . At the first interim analysis the trial may be stopped due to futility if there is a low probability (less than 10%) that 500 Âµg FE 201836 is at least 0.3 voids more efficacious than placebo: Pr(ğœ‡ğ‘€ğ´ğ‘‹ âˆ’ğœ‡ğ‘ƒğ‘™ğ‘<âˆ’0.3)<10% . Up to the first interim analysi s (conducted when 125 subject s have been randomised ) the allocation ratio is 2:2:1 for placebo, 500 Âµg FE 201836 and desmopressin. Should the trial continue, the allocation ratios will be changed to 2:7:1 , where all doses of FE 201836 ( 50-500 Âµg ) are opene d for response -adaptive allocation. The randomisation probabilities for each dose of FE 201836 will be proportional to the average of I(dose is MED) and I(dose is ED 85), where I(target) is the square root of the probability that â€œdose is targetâ€ scaled by the standard error at that dose. The remaining interim analyses are planned to occur every 8 weeks as depicted in the decision tree (Figure 9-2). These interim analyses will re -iterate the (overall) futility criteria at the 5% threshold: Pr(ğœ‡ğ‘€ğ´ğ‘‹ âˆ’ğœ‡ğ‘ƒğ‘™ğ‘<âˆ’0.3)<5% (see Table 9-2 for interpretation). At the final analysis (when all subject s have had their 12 -week visit, or discontinued prior to this visit) Proof -of-Concept is established if Pr(ğœ‡ğ‘€ğ´ğ‘‹ <ğœ‡ğ‘ƒğ‘™ğ‘)>97.5%."
88,page_88,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 88 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Figure 9-2 Interim Analysis Decision Tree ( 2nd Interim Analysis and Onwards)
89,page_89,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 89 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 10 DATA HANDLING 10.1 Source Data and Source Documents Source Data â€“ International Conference on Harmonisation ( ICH ) Definition Source data are defined as all information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data ar e contained in source documents (original records or certified copies). Source Documents - ICH Definition Source documents are defi ned as original documents, data and records (e.g. , hospital records, clinical and office charts, labora tory notes, memoranda, subject diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, microfiches, photographic negatives, microfilm or magnetic med ia, x-rays, subject files and records kept at the pharmacy, at the laboratories and at medico -technical departments involved in the clinical trial). Trial -specific Source Data Requirements - The Sponsor No specific protocol data can be recorded directly in the e -CRF without a prior written or electronic record. The data entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The e -Diary data is part of a process where the subject uses the e -Diary to transmit data to the service providerâ€™s database, hence the service provide râ€™s database is considered to be the source data. The investigator may need to request previous medic al records or transfer records, current me dical records must also be available. For each subject e nrolled, the investigator must document in the subjectâ€™s medical record, that the subject participate s in this trial and at least the following information must be recorded : â€¢ Documentation of signed a nd dated informed consent â€¢ Subjectâ€™s name and date of birth â€¢ Confirmation of participation in the trial (trial identification, screening/randomisation [subject] number) â€¢ Eligibility of participation in the trial (inclusion/exclusion) â€¢ Relevant medical history â€¢ Nocturia medical history or subject -reported nocturia symptoms â€¢ Visit Dates â€¢ Results of any examinations/tests and assessment performed â€¢ Details of any concomitant medication/therapy"
90,page_90,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 90 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL â€¢ Details of any adverse events/SAEs (including description and duration) â€¢ Date IMP is dispensed and returned â€¢ Reason for discontinuation/withdrawal, if applicable â€¢ Event of unblinding, including the reason for unblinding, if applicable The following documents collected during the trial should be stored and archived together with the subjectâ€™s hospital/medical records or in the investigator file as agreed upon prior to the trial start: â€¢ Laboratory print -outs from central laboratory (and local laboratory, if used) â€“ evaluated, signed and dated by the investigator â€¢ ECG print -outs/reports - evaluated, signed and dated by the investigator â€¢ Subject dispensing logs of IMP â€¢ Relevant records for collection of laboratory samples â€¢ Evaluations of physical examinations â€¢ Demographics 10.2 Electronic Case Report Form An eCRF system provided by an independent third -party Contract Research Organisation (CRO) will be used for data capture. The system is validated and access at all levels to the system is granted/revoked following sponsor and vendor procedures, in accordance with regulatory and system requirements. Trial data should be entered into the eCRF in a t imely manner preferably within 3 working days after the subject visit. The investigator will approve/authorise the eCRF entries for each subject with an electronic signature which is equivalen t to a handwritten signature. The eCRF system and the database will be hosted at . After the trial database is declared clean and released to the statistician, a final copy of the database will be stored at the sponsor . The investigator will also receive a copy of the trial siteâ€™s final and locked data (including audit trail, electronic signature and queries) as write -protected PDF -files produced by . The PDF -files will be stored electronically and will be provided by to the investigator before access to the eCRF is revoked. Entry errors occurring in the eCRF will be corrected electronically. Such corrections/modifications will be automatically tracked by an audit trail detailing the date and time of the correction, t he name of the person making the correction and the reason for the correction . 10.3 Use of Patient Reported Outcome s The PRO questionnaires to be used in the trial are described in Section 7.1.1.3 ."
91,page_91,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 91 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL All PROs will be captured in the 3-day e-Diary and completed by the subject , either at the trial site (ISI, Bother) or at home just prior to the trial visit (PGI -I, PGI -S), as outlined in Figure 3-2 and Figure 3-3. For PROs completed at home, subjects will be reminded in due time. The 3-day e-Diary, including the PROs will be reviewed for completeness (via the web -portal) by the trial site personnel throughout the trial ( Section 6). In case of missing ISI and Bother assessments, the reason (s) should be recorded by the trial personnel in the eCRF , e.g., subject refusal, lack of time from subject or functional li mitation from subject to complete the questionnaire. Handling of missing assessments and missing data will be detailed in the SAP. 10.3.1 Validation of the Nocturia Impact Diary 10.3.1.1 Psychometric V alidation In connection with this trial, the NI Diary will be further tested and validated through anchor -based analyses including the PRO questionnaires PGI -I and PGI-S (Section 7.1.1.3.1 ) and subjects â€™ perception o f change in NI Diary Total Score as captured in exit interviews (Section 10.3.1.2 ). Details of these analyses are described in a separate PAP . The order of these three e-Diary assessments , all completed at home, should therefore be NI Diary first, PGI -S second and PGI -I last, as described in Section 7.1.1.3 . 10.3.1.2 Validation through Exit Interviews A sample of subjects (from trial sites in the US A) who have completed the trial will be invited to participate in a n exit interview within 14 days of attending the end -of-trial visit (Visit 8). Signed informed consent must have been obtained through the ICF for the trial, as appropriate, before participation in the exit interview. The exact size of the sample will depend on when saturation has been reached. The subjects included will be proportionate to t he clinical trial sample distribution with respect to demographic and clinical characteristics. The investigator at the trial site will be asked to complete a Case Report Form that includes specific requirements for recruiting subjects to ensure the correc t mix of subjects. The exit interview is designed to examine the impact of living with nocturia and to assess what a meaningful positive change would be from the subjectâ€™s perspective in terms of this impact . In the exit interviews, subject sâ€™ ratings and perceptions of changes will be collected using qualitative and quantitative methods. These data will be used to aid in understanding what is, from a subjectâ€™s perspective , a meaningful change threshold for indicating positive improvement in the impact of nocturia on a subjectâ€™s lif e, as measured by the NI Diary. A detailed description of the exit interview is provided in the Exit Interview Protocol, en closed in Appendix 1 . All exit interviews will be conducted over the telephone by a trained interviewer from ."
92,page_92,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 92 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 10.4 Data Management A data management plan will be prepared under the responsibility of the Global Biometrics Department at Ferring Pharmaceuticals A/S. The data management plan will be issued before data collection begins and will describe all f unctions, processes and specifications for data collection, cleaning a nd validation. 10.5 Provision of Additional Information On request, the investigator will provide the sponsor with additional data relating to the trial, duly anonymised and protected in accordanc e with applicable requirements."
93,page_93,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 93 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 11 MONITORING PROCEDURES 11.1 Periodic Monitoring The monitor will contact and visit the investigator periodically to ensure adherence to the protocol, International Conference of Harmonisation -Good Clinical Practice (ICH -GCP), standard operating procedures and applicable regulatory requirement s, maintenance of trial -related source records, completeness, ac curacy and verifiability of eCRF entries compared to source data, verification of drug accountability and compliance to safety reporting instructions. The investigator will permit the monitor direct access to all source data, including electronic medical records and/or documents in order to facilitate data verification. The investigator will co - operate with the monitor to ensure that any discrepancies that may be identified are resolved. The investigator is expected to be able to meet the monitor during these visits. Risk based monitoring will be applied for this trial. The frequency of the on -site monitoring visits will be adapted depending on the risk level of the site and workload. Site ris k is based on multiple factors including, but not limited to, the quantity of data generated, quality of the source documents, unreported adverse events or SAEs and number of protocol deviations. The risk -based monitoring and adaptive monitoring strategy, source data verification process and definition of key variables to be monitored will be described in detail in the Monitoring Plan for the trial. 11.2 Audit and Inspection The investigator will make all the trial -related source data and records available at a ny time to quality assurance auditor(s) mandated by the sponsor , or to domestic/foreign regulatory inspectors or representatives from IECs/IRBs /REBs who may audit/inspect the trial. The main purposes of an audit or inspection are to assess compliance with the trial protocol and the principles of ICH -GCP including the Declaration of Helsinki (World Medical Association Declaration of Helsinki, 2013 ) and all other relevant regu lations. The subjects must be informed by the investigator and in the Informed Consent Documents that authorised sponsor representatives and representatives from regulatory authorities and IECs/IRBs /REBs may wish to inspect their medical records. During audits/insp ections the auditors/inspectors may copy relevant parts of the medical records. No personal identification apart from the screening/randomisation number will appear on these copies. The investigator should notify the sponsor without any delay of any inspec tion by a regulatory authority or IEC/IRB /REB ."
94,page_94,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 94 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 11.3 Confidentiality of Subject Data The investigator will ensure that the confidentiality of the subjectsâ€™ data will be preserved. In the eCRF or any other documents submitted to the sponsor , the subjects will not be identified by their names, but by an identification system, which consists of an assigned number in the trial. Documents that are not for submission to the sponsor , e.g. , the confidential subject identification code and the signed Informed Consent Docu ments, will be maintained by the investigator in strict confidence. 11.4 Centralised Statistical Monitoring Centralised statistical monitoring will be conducted on (but not limited to) the following key aspects of the trial: â€¢ The incidence rate of hyponatr aemia throughout the trial â€¢ Key inclusion criteria (number of voids, voided volumes, NI Diary and B other) â€¢ The number of voids and NI Diary data as collected in the e -Diary throughout the trial â€¢ Monitoring at trial site level will focus on the accumulated trial site data and comparisons across trial sites will be performed"
95,page_95,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 95 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 12 CHANGES IN THE CONDUCT OF THE TRIAL 12.1 Protocol Amendments Any change to this protocol will be documented in a protocol amendment, issued by the sponsor and agreed upon by the investigator and the sponsor prior to its implementation. Amendments may be submitted for consideration to the approving IEC s/IRBs /REBs and regulatory authorities, in accordance with local regulations. Changes to the protoco l to eliminate immediate hazard s to trial subjects may be implemented prior to IECs/IRBs /REBs approval/favourable opinion. 12.2 Deviations from the Protocol Deviations from the protocol should not occur. If deviations occur, the investigator must inform the monitor and the implications of the deviation must be reviewed and discussed. Any deviation must be documented, either as answer to a query in the eCRF, in a protocol deviation report or a combination of both. A log of protocol deviation reports will be maintained by the sponsor . Deviation reports and supporting documentation must be kept in the Investigatorâ€™s File and in the Trial Master File. 12.3 Premature Trial Termination Both the investigator (with regard to his/her participation) and the sponsor reserve the right to terminate the trial at any time. Sh ould this become necessary, the procedures will be agreed upon after consultation between the two parties. In terminating the trial, the sponsor and the investigator will ensure that adequate consideration is given to the protection of the best interests o f the subjects. Regulatory authorities and IECs/IRBs /REBs will be informed . In addition, the sponsor reserves the right to terminate the participation of individual trial sites. Conditions that may warrant termination include, but are not limited to, insuf ficient adherence to protocol requirements and failure to enter subjects at an acceptable rate."
96,page_96,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 96 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 13 REPORTING AND PUBLICATION 13.1 Clinical Trial Report The data and information collected during this trial will be reported in a clinical trial report prepared by the sponsor and submitted for comments and signature to the signatory investigator s. 13.2 Confidentiality and Ownership of Trial Data Any confidential information relating to the IMP or the trial, including any data and results from the trial will be the exclusive property of the sponsor . The investigator and any other persons involved in the trial will protect the confidentiality of this proprietary information belonging to the sponsor . 13.3 Publications and Public Disclosure 13.3.1 Publication Policy At the end of the trial, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and the sponsor . In a multi -site trial based on the collaboration of many sites, any publication of results must acknowledge all sites. Results from multi -site trials must be reported in entirety in a responsible and coherent manner and results from subsets should not be published in advance or without clear reference to the primary publication of the entire trial. Authorship is gra nted based on the International Committee of Medical Journal Editors ( ICMJE ) criteria (see current official version: http://www.icmje .org). The total number of authors is based on the guideline from the relevant journal or congress. In the event of any disagreement in the content of a publication, both the investigatorâ€™s and the sponsor â€™s opinion will be fairly and sufficiently represented in the publication. Any external C RO or laboratory involved in the conduct of this trial has no publication rights regarding this trial. If the investigator wishes to independently publish/present any results from the trial, the draft manuscript/presentati on must be submitted in writing to the sponsor for comment s prior to submission. Comments will be given within 4 weeks from receipt of the draft manuscript. This statement does not give the sponsor any editorial rights over the content of a publication, ot her than to restrict the disclosure of the sponsor â€™s intellectual property. If the matter considered for publication is deemed patentable by the sponsor , scientific publication will not be allowed until after a filed patent application is published. Under such conditions the publication will be modified or delayed at the investigatorâ€™s discretion, to allow sufficient time for the sponsor to seek patent protection of the invention."
97,page_97,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 97 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 13.3.2 Public Disclosure Policy ICMJE member journals have adopted a trials -registr ation policy as a condition for publication. This policy requires that all clinical trials be registered in a public, clinical trials registry. Thus, it is the responsibility of the sponsor to register the trial in an appropriate public registry, i.e. www. ClinicalTrials.gov ; a website maintained by the National Library of Medicine (NLM) at the U.S. National Institutes of Health (NIH ). The trial will also be made publicly available at the European Union (EU) Clinical Trials Register at www.clinicaltrialsregister.eu . Trial registration may occur in other registries in accordance with local regulatory requirements. A summary of the trial results is made publicly available in accordance with applicable regulatory requirements."
98,page_98,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 98 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 14 ETHICAL AND R EGULATORY ASPECTS 14.1 Independent Ethics Committee / Institutional Review Board / Research Ethics Board An IEC /IRB/REB will review the protocol and any amendments and advertisements used for recruitmen t. The IEC/IRB /REB will review the subject information shee t and the ICF, their updates (if any) and any written materials given to the subjects. A list of all IECs/IRBs /REBs to which the protocol has been submitted and the name of the committee ch airmen will be included in the clinical trial r eport. 14.2 Regulatory Authorit ies Approval The regulatory permission to perform the trial will be obtained in accordance with applicable regulatory requirements. All ethical and regulatory approvals must be available before a subject is exposed to any trial -related procedure, i ncluding screening tests for eligibility. 14.3 End-of-Trial and End -of-Trial Notification The end of this trial is defined as the date of the last visit (Visit 8) of the last subject undergoing the trial. An end -of-trial declaration will be prepared when the tr ial has ended and will be submitted to the IEC s/IRB s/REBs and regulatory authorities . 14.4 Ethical Conduct of the Trial This trial will be conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki (World Medical Association Declaration of Helsinki, 2013 ), in c ompliance with the approved protocol, ICH -GCP and applicable regulatory requirements. 14.5 Subject Information and Consent The investigator (or the person delegated by the investigator) will obtain a freely given written consent from each subject after an appropriate explanation of the aims, methods, sources of funding, any possible conflicts of interest, anticipated benefits, potential risks of the trial and the discomfort it may entail, post -trial provisions and any other aspects of the trial which are relevant to the subjectâ€™s decision to participate. The trial subject must be given ample time to consider participation in the trial, before the consent is obtained. The Informed Consent Documents must be signed and dated by the subject and the investigator who has provided information to the subject regarding the trial before the subject is exposed to any trial -related procedure, including screening tests fo r eligibility. Subjects must be given the option of being informed about the general outcome and the results of the trial. The investigator (or the person delegated by the investigator) will explain that the subject is completely free to refuse to enter th e trial or to withdraw from it at any time, without any consequences for his/her further care and without the need to justify his/her decision. The subject will receive a copy of the subject i nformation and his/her signed ICF."
99,page_99,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 99 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL If new information becomes av ailable that may be relevant to the trial subjectâ€™s willingness to continue par ticipation in the trial, a new subject i nformation and ICF will be forwarded to the IECs/IRBs /REBs (and regulatory authorities, if required). The trial subjects will be informed about this new information and re -consent will be obtained. Each subject will be informed that the monitor(s), quality assurance auditor(s) mandated by the sponsor , IRB/IEC /REB representatives or regulatory authority inspector(s), in accordance with applicable regulatory requirements, may review his/her source records and data. Data protection will be handled in compliance with national/local regulations. 14.6 Subject Participation Card The subject will be provided with a Subject Participation Card bearing the following information: â€¢ That he/she is participating in a clinical trial â€¢ That he/she is treated with FE 201836 / Desmopressin / Placebo â€¢ The name and phone number of the investigator â€¢ The name, address and phone number of the sponsor The subject will be asked to keep the Subject Participation Card in their possession at all times during the trial and to return it at the last trial visit, if applicable. Each subjectâ€™s primary care physician will be notified of their participation in the trial by the investigato r, if the subject agrees and if applicable. 14.7 Compliance Reference Documents The Declaration of Helsi nki (World Medical Association Declaration of Helsinki, 2013 ), the consolidated ICH -GCP, the EU Clinical Trial s Directive and other national laws in the countries where the trial takes place shall constitute the main reference guidelines for ethical and regulatory conduct."
100,page_100,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 100 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 15 LIABILITIES AND INSURANCE 15.1 ICH -GCP Responsibilities The responsibilities of the sponsor , the monitor and the investigator are defined in the ICH-GCP consolidated guideline and applicable regula tory requirements in the countries where the trial takes place. The investigator is responsible for adhering to the ICH -GCP responsibilities of invest igators, for dispensing the IMP in accordance with the approved protocol or an appro ved amendment and for its secure storage and safe handling throughout the trial. 15.2 Liabilities and Insurance Ferring Pharmaceuticals A/S is, as sponsor, responsible for ensur ing appropriate general/product liability insurance and, as required in accordance with applicable laws and regulations, country - specific liability insurance coverage for claims made by a trial subject for injury arising from the subjectâ€™s participation in the trial ."
101,page_101,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 101 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 16 ARCHIVING 16.1 Investigator File The investigator is responsible for maintaining all the records, which enable the conduct of the trial at the site to be fully understood, in compliance with ICH -GCP. The trial documentation including all the relevan t correspondence should be kept by the inv estigator for at least 15 years after the completion or discontinuation of the trial, if no further instructions are given by the sponsor . The investigator is responsible for the completion and maintenance of the c onfidential subject identification code which provides the sole link between named subject source records and anonymous eCRF data for the sponsor . The investigator must arr ange for the retention of this subject identification log and signed informed consen t documents for at least 15 years after the completion or discontinuation of the trial. No trial site document may be destroyed without prior written agreement between the investigator and the sponsor . Should the investigator elect to assign the trial documents to another party, or move them to another location, the sponsor must be notified in advance . If the investigator retires and the documents can no longer be archived by the site , the sponsor can arrange having the Investigator File archived at an external archive. 16.2 Trial Master File The sponsor will archive the Trial Master File in accordance with ICH -GCP and applicable regulatory requirements."
102,page_102,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 102 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 17 REFERENCES Abrams P, Feneley R, Torrens M. Urodynamics . New York: Springer -Verlag Berlin Heidelberg;1983. Chapter 2; Patient assessment; p.6 -27. Abrams P, Mattiasson A, Lose GR, Robertson GL . The role of desmopressin in the treatment of adult nocturia. BJU Int. 2002; 90(suppl 3):32 -36. Ancoli -Israe l S, Bliw ise DL, NÃ¸rgaard JP. The effect of nocturia on sleep. Sleep Med Rev. 2011 Apr;15(2):91 -7. Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med. 1991 Feb;229(2):131 -4. Asplund R. Nocturia: consequences for sleep and daytime activiti es and associated risks. Eur Urol Suppl . 2005;3(6):24 -32. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297 -307. Bliwise DL , Dijk DJ, Juul KV. Nocturia is associated with loss of deep sleep independent ly from sleep apnea. Neurourol Urodyn. 2015;34: 392. Bosch JL, Weiss JP. The Prevalence and Causes of Nocturia. J Urol. 2010;184(2):440 -6. Brunell E, Goessaert AS, Denys MA, Vande Walle J, Juul KV, Rittig S, NÃ¸rgaard JP, Everaert K. Copeptin in nocturics: A posthoc explorative analysis. Eur Urol Suppl 2016; 15: e539. Chartier -Kastler E, Tubaro A. The measurement of nocturia and its impact on quality of sleep and quality of li fe in LUTS/BPH. Eur Urol Suppl . 2006; 5:3-11. Dmochowski RR, Sanders SW, Appell RA, Nitti VW, Davila GW. Bladder health diaries: an assessment of 3 -day vs 7 day entries. BJU Int . 2005;96:1049 -54. U.S. Department of Health and Human Services Food and Drug Administration (FDA). Guidance for Industry, Patient -Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims [Internet] . 2009 [cited 2016 Nov 30]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ et al. Diagnosis and treatment of overactive bladder (non -neurogenic) in adults: AUA/SUFU guideline [Internet]. 2014 [cited 2016 Nov 30]. Available from: https://www.auanet.org/common/pdf/e ducation/clinical - guidance/Overactive -Bladder.pdf Holm -Larsen T, Klein B, Weiss J. Correlation between voiding/sleep diaries, and nocturia and"
103,page_103,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 103 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL sleep quality of life questionnaires. J Urol . 2009;181 (suppl 4):538 -539. Holm -Larsen T , Andersson F, van der Meulen E, Yankov V, Rosen RC, NÃ¸rgaard JP. The nocturia impact diary: a self -reported impact measure to comple ment the voiding diary. Value Health. 2014 Sept;17(6):696 -706. Hsu A, Nakagawa S, Walter LC, Van Den Eeden SK, Brown JS, Thom DH, et al. The Burden of Nocturia Among Middle -Aged and Older Women. Obstet Gynecol. 2015;125(1):35 -43. Juul KV, Malmberg A, van der Meulen E, Walle JV, NÃ¸rgaard JP. Low-dose desmopressin combined with serum sodium monitoring can preve nt clinically significant hyponatraemia in patients treated for nocturia. BJU Int. 2016 Nov 15. [Epub ahead of print] Lose G, Lalos O, Freeman RM, van Kerrebroeck P; Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double -blind placebo -controlled study in wome n. Am J Obstet Gynecol. 2003 Oct ;189(4):1106 -13. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011 May;185(5): 1793 - 803.doi: 10.1016/j.juro.2011.01.074. Mattiasson A. Efficacy of desmopressin in the treatment of nocturia: a double -blind placebo - controlled study in men. BJU Int. 2002;89(9): 855-62. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity -- establishing and reporting the evidence in newly developed patient -reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2 -assessing respondent understanding. Value Health. 2011;14(8):978 -88. Ratitch B, Oâ€™Kelly M. Implementation of Pattern -Mixture Models Using Standard SAS/STAT Procedures. Proceedings of PharmaSUG 2011 (Pharmaceutical Industry SAS Users Group), SP04, Nashville. Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF et al. ISOQOL recommends minimum standards for patient -reported outcome measures used in patient -centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22(8):1889 -905. Tikkinen KA, Johnson TM 2nd, Tammela TL, Sintonen H, Haukka J, Huhtala H, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population -based study in Finland. Eur Urol. 2010;57(3):488 -96. van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub -committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):179 -83."
104,page_104,"Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 104 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL van Kerrebroeck P. Desmopressin in the Treatment of Nocturia: A Double -Blind, Placebo - Controlled Study. Eur Urol. 2007;52(1): 221â€“229. Verbalis JG , Goldsmith SR, Greenberg A , Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013 Oct;126(10 Suppl 1): 1-42. Viktrup L, Hayes RP, Wang P, Shen W. Construct validation of patient global impression of severity (PGI -S) and improvement (PGI -I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to ben ign prostatic hyperplasia. BMC Urology. 2012;12(1):1 -8. Wein A, Lose GR, Fonda D. Nocturia in men, women and the elderly: a practical approach. BJU Int. 2002 Dec;90 (Suppl 3 ):28-31. Weiss JP, Blaivas JG, Blanker MH, Bliwise DL, Dmochowski RR, Drake M, et al. The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy. BJU Int. 2013 May;111(5):700 -16. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Hum an Subjects. 64th WMA General Assembly, Fortaleza, Brazil, October 2013 . Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189(1):98 -101. Yamaguchi O, Nishizawa O, Juul KV, NÃ¸rgaard JP. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with 4 different doses of desmopressin orally disintegrating tablet in a randomized, placebo -controlled trial. BJU Int. 2013 Mar;111(3):474 -84."
105,page_105,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 105 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL 18 APPENDI CES Appendix 1 Exit Interview Protocol
106,page_106,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 106 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
107,page_107,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 107 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
108,page_108,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 108 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
109,page_109,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 109 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
110,page_110,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 110 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
111,page_111,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 111 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
112,page_112,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 112 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
113,page_113,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 113 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
114,page_114,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 114 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
115,page_115,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 115 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
116,page_116,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 116 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
117,page_117,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 117 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
118,page_118,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 118 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
119,page_119,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 119 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
120,page_120,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 120 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
121,page_121,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 121 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
122,page_122,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 122 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
123,page_123,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 123 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
124,page_124,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 124 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
125,page_125,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 125 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
126,page_126,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 126 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
127,page_127,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 127 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
128,page_128,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 128 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
129,page_129,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 129 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
130,page_130,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 130 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
131,page_131,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 131 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
132,page_132,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 132 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
133,page_133,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 133 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
134,page_134,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 134 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
135,page_135,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 135 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
136,page_136,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 136 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
137,page_137,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 137 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
138,page_138,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 138 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
139,page_139,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 139 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
140,page_140,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 140 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL Appendix 2 Statistical Design and Operating Characteristics
141,page_141,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 141 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
142,page_142,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 142 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
143,page_143,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 143 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
144,page_144,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 144 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
145,page_145,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 145 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
146,page_146,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 146 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
147,page_147,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 147 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
148,page_148,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 148 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
149,page_149,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 149 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
150,page_150,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 150 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
151,page_151,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 151 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
152,page_152,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 152 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
153,page_153,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 153 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
154,page_154,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 154 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
155,page_155,Date: 05 Jul 2018 E-Study Protocol -20516; Ver. 5.0 Supersedes: 4.0 Page 155 of 155 FE 201836 Trial C ode: 000233 Oral Solution Clinical Trial Protocol Ferring Pharmaceuticals CONFIDE NTIAL
